Вы находитесь на странице: 1из 104

2009

Report
M E D I C I N E S I N D E V E L O P M E N T F O R

Cancer
P R E S E N T E D B Y A M E R I C A ’ S P H A R M A C E U T I C A L R E S E A R C H C O M P A N I E S

More Than 800 Medicines and Vaccines in Testing


Offer Hope in the Fight Against Cancer

F
ew things cause patients more fear and uncertainty MEDICINES IN DEVELOPMENT FOR CANCER*
than a cancer diagnosis. But today—because of a
Bladder Cancer 23
steady stream of new and improved medicines and Brain Cancer 61
Breast Cancer 106
treatments—cancer increasingly can be managed and even Cervical Cancer 13
Colorectal Cancer 70
beaten. President Obama has called for a cancer cure in Head/Neck Cancer 34
our lifetime, patients and their families are looking for more Kidney Cancer 44
Leukemia 129
and better treatments, and America’s pharmaceutical Liver Cancer 35
Lung Cancer 122
research and biotechnology companies are responding. Lymphoma 99
Multiple Myeloma 52
Pharmaceutical researchers are now working on Ovarian Cancer 63
Pancreatic Cancer 54
861 medicines for cancer. Many are high-tech weapons Prostate Cancer 103
Sarcoma 27
to fight the disease, while some involve innovative Skin Cancer 67
Solid Tumors
research on using existing medicines in new ways. Stomach Cancer 27
203

Cancer-Related Conditions 51
The medicines in development—all in either clinical Other Cancers 55
Unspecified Cancers 74
trials or under Food and Drug Administration review—
include 122 for lung cancer, the leading cause of cancer *Some medicines are listed in more than one category.

death in the United States; 106 for breast cancer, which is


expected to strike more than 180,000 American women • A potential first-line treatment (meaning it’s given to
each year; 103 for prostate cancer, which is expected to patients before any other treatment) and first-in-class
kill more than 28,000 American men each year; and medicine designed to target specific cancer cells and
70 for colorectal cancer, the third most common cancer kill them, then activate the patient’s general immune
in both men and women in this country. Additional system to destroy any remaining cancer cells.
medicines target brain cancer, kidney cancer, leukemia, • One therapy in development uses new nanotech-
ovarian cancer, pancreatic cancer, skin cancer, and nology that enhances the delivery of medicine to
others. In addition, companies are working on medicines the patient, overcoming obstacles in existing
to improve the quality of life for cancer patients. treatments.
This commitment to patients and research is at the core Despite progress, cancer remains the second leading
of the remarkable progress made in the past decade fighting cause of death by disease in the United States, exceeded
cancer that has led to declines in both cancer cases and only by heart disease. In 2008, some 565,650 Americans
cancer deaths. Death rates for eight of the top 10 cancers were expected to die of cancer—more than 1,500 people
remained level or declined during the 1990s, according a day. The hundreds of new medicines to treat cancer
to a Journal of the National Cancer Institute report. now being developed by the pharmaceutical research
America’s pharmaceutical research companies are industry demonstrate our commitment to meeting patient
working on many new cutting edge approaches to fight needs. They are our best hope for stemming the toll of
cancer. They include: cancer-related deaths.

• A medicine that inhibits production of a protein that


may interfere with the effectiveness of chemotherapy.
• A drug that delivers a synthetic version of a substance
derived from scorpions directly to brain tumor cells. Billy Tauzin
President and CEO
• A medicine designed to induce a powerful immune PhRMA
response to melanoma.
Medicines in Development for Cancer
BLADDER CANCER
Product Name Sponsor Indication Development Status*
Advexin® Introgen Therapeutics (see also brain, breast, head/neck, Phase I
contusugene Austin, TX lung, ovarian, prostate, stomach) (512) 708-9310
ladenovec
BC-819 BioCancell Therapeutics Phase II
Jerusalem, Israel
belinostat Topo Target USA combination therapy Phase II
Rockaway, NJ (see also colorectal, leukemia, (973) 895-6900
liver, lung, lymphoma, ovarian)
CDX-1307 Celldex Therapeutics (see also breast, colorectal, ovarian, Phase I
Needham, MA pancreatic) (781) 433-0771
Celebrex® Pfizer (see also prostate) Phase III
celecoxib New York, NY (860) 732-5156
CG0070 Cell Genesys Phase I
South San Francisco, CA (650) 266-3000
Novartis Pharmaceuticals (888) 669-6682
East Hanover, NJ
Chemophase™ Halozyme Therapeutics superficial bladder cancer Phase I/II
hyaluronidase San Diego, CA (858) 794-8889
EOquin® Spectrum Pharmaceuticals Phase III
apaziquone Irvine, CA (949) 788-6700
Erbitux® Bristol-Myers Squibb (see also colorectal, head/neck, Phase II
cetuximab Princeton, NJ lung, prostate, stomach) (212) 546-4000
Eli Lilly (800) 545-5979
Indianapolis, IN (212) 645-1405
ImClone Systems
New York, NY
Hexvix® GE Healthcare diagnostic imaging of application submitted
hexyl Waukesha, WI bladder cancer
aminolevulinate
Iressa® AstraZeneca (see also brain) Phase II
gefitinib Wilmington, DE (800) 236-9933
larotaxel sanofi-aventis (see also pancreatic) Phase III
(XRP9881) Bridgewater, NJ (800) 633-1810
Levulan® PD DUSA Pharmaceuticals (see also cervical, colorectal, lung, Phase I/II
aminolevulinic acid Wilmington, MA stomach) (978) 657-7500
MCC/HA Bioniche Life Sciences second-line therapy Phase III
Belleville, Canada (800) 265-5464
OGX-427 Oncogenex (see also breast, lung, ovarian, Phase I
Pharmaceuticals prostate) (425) 686-1500
Bothell, WA

* For more information about a specific medicine in this report, please call the telephone number listed.

2 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
BLADDER CANCER
Product Name Sponsor Indication Development Status
polyphenon E Polyphenon Pharma superficial bladder cancer Phase II
New York, NY (see also leukemia, prostate) (212) 661-0578
pralatrexate Allos Therapeutics (see also lung, lymphoma) Phase II
(PDX) Westminster, CO (303) 426-6262
SCH-58500 Schering-Plough (see also head/neck, liver, Phase I
(p53 gene therapy) Kenilworth, NJ lung, cancer-related) (908) 298-4000
SCH-721015 Schering-Plough Phase I
Kenilworth, NJ (908) 298-4000
Tarceva® Genentech neoadjuvant therapy Phase II
erlotinib South San Francisco, CA (see also brain, breast, colorectal, (650) 224-1000
OSI Pharmaceuticals head/neck, liver, lung, other) (800) 572-1932
Melville, NY
Valstar® Indevus Pharmaceuticals application submitted
valrubicin Lexington, MA (781) 861-8444
VB-4845 Viventia Biotech (see also head/neck) Phase II
Mississauga, Canada (905) 361-8686
vinflunine Pierre Fabre (see also breast) Phase II
Pharmaceuticals (973) 898-1042
Parsippany, NJ

BRAIN CANCER
Product Name Sponsor Indication Development Status
3F8 mAb United Therapeutics neuroblastoma, leptomeningeal Phase II
Silver Spring, MD cancer (301) 608-9292
(see also other)
8H9 mAb United Therapeutics Phase I
Silver Spring, MD (301) 608-9292
Advexin® Introgen Therapeutics glioblastoma Phase I
contusugene Austin, TX (see also bladder, breast, head/neck, (512) 708-9310
ladenovec lung, ovarian, prostate, stomach)
AEE788 Novartis Pharmaceuticals glioblastoma multiforme Phase I
East Hanover, NJ (see also solid tumors) (888) 669-6682
AMG 102 Amgen glioma Phase II
Thousand Oaks, CA (see also colorectal, kidney, lung, (805) 447-1000
stomach)
ANG-1005 AngioChem metastatic brain cancer, Phase I
Montreal, Canada metastatic glioblastoma (514) 788-7800
Armala™ GlaxoSmithKline glioma Phase II
pazopanib Rsch. Triangle Park, NC (see also breast, cervical, kidney, (888) 825-5249
liver, lung, ovarian, sarcoma, other)

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 3
BRAIN CANCER
Product Name Sponsor Indication Development Status
Avastin® Genentech glioblastoma application submitted
bevacizumab South San Francisco, CA (see also colorectal, head/neck, (650) 225-1000
kidney, liver, lung, lymphoma,
multiple myeloma, ovarian,
pancreatic, prostate, stomach, other)
-------------------------------------------------------------------------------------------
metastatic brain cancer from Phase II
NSCLC (650) 225-1000
Azedra™ Molecular Insight neuroblastoma in children Phase II
iodine-labeled Pharmaceuticals (see also other) (617) 492-5554
metaiodobenzyl- Cambridge, MA
guanidine
Azixa™ Myriad Pharmaceuticals glioblastoma, metastatic brain cancer Phase II
(MPC-6827) Salt Lake City, UT (see also skin) (801) 584-3600
banoxantrone Transcept Pharmaceuticals glioblastoma Phase I/II
Pt. Richmond, CA (510) 215-3500
berubicin Reata Pharmaceuticals brain metastases, recurrent primary Phase II
(Orphan Drug) Dallas, TX brain cancer (972) 865-2200
--------------------------------------------------------------------------------------
glioma Phase I
(972) 865-2200
BIBW 2992 Boehringer Ingelheim glioblastoma Phase I/II
Pharmaceuticals (see also breast, head/neck, lung) (800) 243-0127
Ridgefield, CT
BMS-844203 Bristol-Myers Squibb glioblastoma Phase II
(VEGF inhibitor- Princeton, NJ (see also solid tumors) (212) 546-4000
adnectin)
BSI-201 BiPar Sciences glioblastoma Phase I/II
Brisbane, CA (see also breast, ovarian, other) (650) 635-6050
CC-8490 Celgene glioblastoma Phase II
Summit, NJ (908) 673-9000
CDX-110 Celldex Therapeutics newly diagnosed glioblastoma Phase II/III
(Orphan Drug) Needham, MA (see also solid tumors) (781) 433-0771
Pfizer (860) 732-5156
New York, NY
cilengitide EMD Serono newly diagnosed and recurrent Phase II
(Orphan Drug) Rockland, MA glioblastoma (800) 283-8088
(see also lymphoma, prostate,
solid tumors)
cintredekin NeoPharm glioblastoma Phase III
besudotox Lake Bluff, IL (847) 887-0800
Cotara™ Peregrine Pharmaceuticals glioblastoma Phase I
mAb TNT-1 Tustin, CA (714) 508-6000
(Orphan Drug)
DCVax®-Brain® Northwest Biotherapeutics glioblastoma Phase II
brain cancer Bothell, WA (425) 608-3000
vaccine
(Orphan Drug)

4 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
BRAIN CANCER
Product Name Sponsor Indication Development Status
EMD 273063 EMD Serono neuroblastoma Phase II
Rockland, MA (see also skin) (800) 283-8088
enzastaurin Eli Lilly glioblastoma (combination therapy) Phase II
(LY317615) Indianapolis, IN (see also breast, colorectal, (800) 545-5979
lymphoma, multiple myeloma,
ovarian, prostate)
G 207 MediGene glioma Phase I
(Orphan Drug) San Diego, CA (858) 586-2240
gimatecan Novartis Pharmaceuticals glioma Phase I/II
(Orphan Drug) East Hanover, NJ (see also leukemia) (888) 669-6682
GliAtak™ Advantagene Phase I/II
gene therapy Boston, MA (617) 916-5445
San Diego, CA (760) 943-8981
ICT-107 ImmunoCellular glioblastoma Phase I
(cancer vaccine) Therapeutics (818) 992-2907
Woodland Hills, CA
Iressa® AstraZeneca glioblastoma Phase II
gefitinib Wilmington, DE (see also bladder) (800) 236-9933
Karenitecin® BioNumerik (see also lung, ovarian, skin) Phase II completed
cositecan Pharmaceuticals (210) 614-1701
San Antonio, TX
KRX-0402 Keryx Biopharmaceuticals brain cancer, glioblastoma Phase II
New York, NY (combination therapy), (212) 531-5965
glioma (combination therapy)
(see also colorectal, kidney,
multiple myeloma, sarcoma)
laromustine Vion Pharmaceuticals glioma (combination therapy) Phase II
(VNP 40101M) New Haven, CT (see also leukemia) (203) 498-4210
Lucanix® NovaRx glioma Phase I
belagenpumatucel-L San Diego, CA (see also lung) (858) 552-8600
lucanthone Spectrum Pharmaceuticals glioma (combination therapy) Phase I
Irvine, CA (949) 788-6700
MLN8237 Millennium neuroblastoma Phase I/II
Pharmaceuticals (see also leukemia, lymphoma, (800) 390-5663
Cambridge, MA solid tumors)
Neuradiab™ Bradmer Pharmaceuticals glioblastoma Phase III
anti-tenascin Louisville, KY (502) 657-6038
mAb 81C6-I-131
(Orphan Drug)
OncoGel® Protherics glioblastoma Phase I/II
Brentwood, TN (see also pancreatic, stomach) (615) 327-1027
Oncophage® Antigenics glioma Phase II
vitespan New York, NY (see also colorectal, kidney, (866) 805-8994
pancreatic, skin, stomach)
panobinostat Novartis Pharmaceuticals glioma Phase I/II
East Hanover, NJ (see also breast, leukemia, (888) 669-6682
lymphoma, prostate)

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 5
BRAIN CANCER
Product Name Sponsor Indication Development Status
patupilone Novartis Pharmaceuticals (see also breast, colorectal, liver, Phase II
(EPO906) East Hanover, NJ lung, ovarian) (888) 669-6682
perifosine AEterna Zentaris glioma Phase II
Montreal, Canada (see also head/neck, kidney, (212) 531-5965
Keryx Biopharmaceuticals lymphoma, multiple myeloma,
New York, NY ovarian, sarcoma)
PRX-321 Protox Therapeutics glioblastoma Phase II
(Orphan Drug) Vancouver, Canada (see also solid tumors) (604) 688-0199
Reolysin® Oncolytics Biotech glioma Phase I/II
reovirus Calgary, Canada (see also head/neck, lung, sarcoma, (403) 670-7377
skin)
sagopilone Bayer HealthCare (see also breast, ovarian, prostate) Phase II
Pharmaceuticals (888) 842-2937
Wayne, NJ
SBG Biotec Pharmacon neuroblastoma (pediatric) Phase I/II
Tromso, Norway (combination therapy) www.biotec.no
systemic hedgehog Genentech (see also colorectal, ovarian, skin) Phase I
antagonist South San Francisco, CA (650) 224-1000
talampanel Teva Pharmaceuticals newly diagnosed glioblastoma Phase II
North Wales, PA (215) 591-3000
tandutinib Millennium glioma Phase II
(MLN0518) Pharmaceuticals (see also prostate) (800) 390-5663
Cambridge, MA --------------------------------------------------------------------------------------
gliobastoma Phase I/II
(800) 390-5663
Tarceva® Genentech glioblastoma Phase II
erlotinib South San Francisco, CA (see also bladder, breast, colorectal, (650) 225-1000
(Orphan Drug) OSI Pharmaceuticals head/neck, liver, lung, other) (800) 572-1932
Melville, NY
terameprocol Erimos Pharmaceuticals glioma Phase I/II
Houston, TX (see also cervical, head/neck) (713) 541-2000
TheraCIM™ YM Biosciences glioma (pediatric) Phase II
nimotuzumab Wayne, PA (see also breast, prostate, stomach) (610) 560-0600
(Orphan Drug)
TM-601 TransMolecular recurrent high-grade glioma Phase I
(Orphan Drug) Cambridge, MA (617) 995-3050
TM-601-I-131 TransMolecular glioma (intracranial) Phase II
(Orphan Drug) Cambridge, MA (see also skin) (617) 995-3050
--------------------------------------------------------------------------------------
glioma (intravenous) Phase I/II
(617) 995-3050
Trisenox® Cephalon glioma Phase I
arsenic trioxide Frazer, PA (see also leukemia, multiple myeloma) (610) 344-0200
Tykerb® GlaxoSmithKline brain metastases from breast cancer Phase III
lapatinib Rsch. Triangle Park, NC (see also head/neck, stomach) (888) 825-5249

6 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
BRAIN CANCER
Product Name Sponsor Indication Development Status
VP101 Access Pharmaceuticals glioblastoma Phase II
(Orphan Drug) Dallas, TX (see also colorectal, leukemia, (214) 905-5100
prostate)
Xcytrin® Pharmacyclics brain metastases from non-small-cell application submitted
motexafin Sunnyvale, CA lung cancer (408) 774-0330
gadolinium (see also kidney, leukemia, lung,
lymphoma)
--------------------------------------------------------------------------------------
glioma (combination therapy) Phase II
(408) 774-0330
--------------------------------------------------------------------------------------
glioblastoma (combination therapy) Phase I
(408) 774-0330
Xerecept® Celtic Pharma peritumoral brain edema Phase III
corticorelin Hamilton, Bermuda (441) 299-7440
(Orphan Drug)
XL-184 Bristol-Myers Squibb glioblastoma in clinical trials
Princeton, NJ (see also other) (212) 546-4000
Exelixis
South San Francisco, CA
XL-765 Exelixis glioma Phase I
South San Francisco, CA (see also solid tumors) (650) 837-7000
Zactima® AstraZeneca glioma Phase I
vandetanib Wilmington, DE (see also breast, lung, other) (800) 236-9933
Zolinza® Merck glioblastoma Phase II
vorinostat Whitehouse Station, NJ (see also breast, colorectal, (800) 672-6372
kidney, leukemia, lung, lymphoma,
multiple myeloma)

BREAST CANCER
Product Name Sponsor Indication Development Status
ABI-008 Abraxis BioScience metastatic breast cancer Phase I/II
Los Angeles, CA (see also prostate) (310) 883-1300
ABT-751 Abbott Laboratories (see also colorectal, kidney, lung) Phase II
Abbott Park, IL (847) 937-6100
ABT-869 Abbott Laboratories combination therapy Phase II
Abbott Park, IL (see also kidney, liver, lung) (847) 937-6100
Genentech (650) 225-1000
South San Francisco, CA
aderbasib Incyte combination therapy Phase II
(INCB7839) Wilmington, DE (302) 498-6700
Advexin® Introgen Therapeutics combination therapy Phase II
contusugene Austin, TX (see also bladder, brain, head/neck, (512) 708-9310
ladenovec lung, ovarian, prostate, stomach)

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 7
BREAST CANCER
Product Name Sponsor Indication Development Status
AE-37 Antigen Express (see also ovarian) Phase II
Worcester, MA (508) 852-8783
AG-14699 Pfizer (see also ovarian) Phase II
New York, NY (860) 732-5156
Alimta® Eli Lilly (see also head/neck, lung, ovarian) Phase II
pemetrexed Indianapolis, IN (800) 545-5979
AMG 386 Amgen (see also kidney, ovarian, Phase II
Thousand Oaks, CA stomach, other) (805) 447-1000
AMG 479 Amgen (see also colorectal, lung, Phase II
Thousand Oaks, CA pancreatic, sarcoma) (805) 447-1000
Amplimexon® AmpliMed (see also lung, multiple myeloma, Phase I
imexon Tucson, AZ pancreatic, prostate, skin) (520) 529-1000
anti-CD3 TransTarget metastatic breast cancer Phase I
activated T-cells Hillsborough, CA
anti-MUC1 mAb Paladin Labs (see also multiple myeloma, Phase I completed
St. Laurent, Canada pancreatic) (888) 376-7830
anti-PEM mAb Access Pharmaceuticals Phase I/II
Dallas, TX (214) 905-5100
Armala™ GlaxoSmithKline combination therapy Phase III
pazopanib Rsch. Triangle Park, NC (see also brain, cervical, kidney, (888) 825-5249
liver, lung, ovarian, sarcoma, other)
Aromasin® Pfizer breast cancer prevention Phase III
exemestane New York, NY (860) 732-5156
ARRY-543 Array BioPharma combination therapy Phase I/II
Boulder, CO (303) 381-6600
arzoxifene Eli Lilly invasive breast cancer risk reduction Phase III
Indianapolis, IN (800) 545-5979
AS-1402 Antisoma Phase II
Cambridge, MA (617) 225-0522
AVE1642 sanofi-aventis hormonal-sensitive breast cancer Phase II
(anti-IGF-1R mAb) Bridgewater, NJ (800) 633-1810
AZD2281 AstraZeneca monotherapy Phase II
Wilmington, DE (see also ovarian) (800) 236-9933
--------------------------------------------------------------------------------------
combination therapy Phase I/II
(800) 236-9933
AZD4992 AstraZeneca Phase I
Wilmington, DE (800) 236-9933
BIBW 2992 Boehringer Ingelheim second-line therapy Phase II
Pharmaceuticals (see also brain, head/neck, lung) (800) 243-0127
Ridgefield, CT
bleomycin Inovio Biomedical (see also head/neck) Phase I
(electrical San Diego, CA (858) 597-6006
pulse delivery)
bosutinib Wyeth Pharmaceuticals (see also leukemia, solid tumors) Phase II
Collegeville, PA (800) 934-5556

8 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
BREAST CANCER
Product Name Sponsor Indication Development Status
breast cancer Quantum Immunologics Phase I/II
vaccine Tampa, FL (866) 213-4594
BSI-201 BiPar Sciences (see also brain, ovarian, other) Phase II
Brisbane, CA (650) 635-6050
BTSCAN Molecular Targeting diagnosis of breast cancer Phase I
Technologies (610) 738-7938
West Chester, PA
BZL-101 Bionovo Phase II
Emeryville, CA (510) 601-2000
cancer vaccine MabVax Therapeutics (see also sarcoma) Phase I
San Diego, CA (858) 259-9405
Capoxigem® Tragara Pharmaceuticals combination therapy Phase II
apricoxib San Diego, CA (see also lung, pancreatic) (858) 350-6900
CDX-1307 Celldex Therapeutics (see also bladder, colorectal, Phase I
Needham, MA ovarian, pancreatic) (781) 433-0771
cediranib AstraZeneca (see also kidney, leukemia) Phase II
Wilmington, DE (800) 236-9933
CNF-2024 Biogen Idec (see also leukemia, solid tumors, Phase I
Cambridge, MA stomach) (617) 679-2000
CP-751871 Pfizer combination therapy Phase II
New York, NY (see also colorectal, lung, multiple (860) 732-5156
myeloma, prostate, sarcoma)
CR011-vcMMAE CurGen (see also skin) Phase II
Branford, CT (888) 436-6642
deforolimus ARIAD Pharmaceuticals combination therapy Phase II
(MK-8669) Cambridge, MA (see also lung, prostate, sarcoma, (617) 494-0400
Merck other) (800) 672-6372
Whitehouse Station, NJ
Doxil® Ortho Biotech combination therapy application submitted
doxorubicin Bridgewater, NJ (908) 541-4000
liposome
injection
doxorubicin Sopherion Therapeutics combination therapy Phase III
liposomal Princeton, NJ (609) 986-2021
enzastaurin Eli Lilly combination therapy Phase II
(LY317615) Indianapolis, IN (see also brain, colorectal, (800) 545-5979
lymphoma, multiple myeloma,
ovarian, prostate)
eribulin mesylate Eisai metastatic breast cancer Phase III
(E7389) Woodcliff Lake, NJ (see also head/neck, lung, ovarian, (888) 422-4743
prostate, sarcoma, solid tumors)
--------------------------------------------------------------------------------------
advanced breast cancer Phase II
(888) 422-4743
Genasense® Genta (see also leukemia, lung, lymphoma, Phase II completed
oblimersen Berkeley Heights, NJ skin, solid tumors) (908) 286-9800

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 9
BREAST CANCER
Product Name Sponsor Indication Development Status
glufosfamide Threshold Pharmaceuticals (see also lung, pancreatic, Phase II
Redwood City, CA sarcoma) (650) 474-8200
GRN-163L Geron combination therapy Phase I/II
Menlo Park, CA (see also leukemia, lung, (650) 473-7700
multiple myeloma)
HER2-antigen- Genentech Phase II
specific cancer South San Francisco, CA (650) 224-1000
immunotherapeutic
HER2/neu GlaxoSmithKline Phase I/II
peptide vaccine Rsch. Triangle Park, NC (888) 825-5249
Hycamtin® GlaxoSmithKline (see also colorectal, head/neck, Phase II
topotecan Rsch. Triangle Park, NC kidney, leukemia, lung, lymphoma, (888) 825-5249
multiple myeloma, ovarian,
pancreatic, prostate, stomach, other)
IMC-1121B Eli Lilly (see also colorectal, kidney, liver, Phase III
Indianapolis, IN lung, ovarian, prostate, skin) (800) 545-5979
ImClone Systems (212) 645-1405
New York, NY
IMC-A12 Eli Lilly (see also colorectal, head/neck, Phase II
Indianapolis, IN liver, lung, pancreatic, prostate, (800) 545-5979
ImClone Systems sarcoma, solid tumors) (212) 645-1045
New York, NY
IMT-1012 ImmunoVaccine (see also ovarian) Phase I
Technologies (902) 492-1819
Halifax, Canada
INGN 225 Introgen Therapeutics (see also lung) Phase I/II
(p53 vaccine) Austin, TX (512) 708-9310
ispinesib CytoKinetics (see also colorectal, kidney, Phase II
South San Francisco, CA leukemia) (650) 624-3000
Ixempra™ Bristol-Myers Squibb early breast cancer in clinical trials
ixabepilone Princeton, NJ (see also lung, pancreatic, prostate) (212) 546-4000
lapuleucel-T Dendreon (see also colorectal, ovarian) Phase I completed
Seattle, WA (206) 256-4545
LEP-ETU NeoPharm Phase II
Lake Bluff, IL (847) 887-0800
LOR-2040 Lorus Therapeutics metastatic breast cancer Phase II
Toronto, Canada (see also colorectal, kidney, (416) 798-1200
leukemia)
Lymphoseek™ Neoprobe diagnosis of breast cancer Phase III
Dublin, OH (see also skin) (800) 793-0079
milataxel Taxolog (see also colorectal, lung) Phase II
Fairfield, NJ (877) 829-6564
MK-0646 Merck (see also lung, pancreatic, other) Phase I
Whitehouse Station, NJ (800) 672-6372

10 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
BREAST CANCER
Product Name Sponsor Indication Development Status
MK-0752 Merck (see also leukemia) Phase I
Whitehouse Station, NJ (800) 672-6372
MKC 1 EntreMed metastatic breast cancer Phase II completed
Rockville, MD (see also leukemia, lung, pancreatic) (240) 864-2600
motesanib Amgen combination therapy Phase II
Thousand Oaks, CA (see also colorectal, lung, other) (805) 447-1000
Millennium (800) 390-5663
Pharmaceuticals
Cambridge, MA
NBI-42902 Neurocrine Biosciences (see also prostate, other) Phase I
San Diego, CA (858) 617-7600
neratinib Wyeth Pharmaceuticals monotherapy Phase III
(HKI272) Collegeville, PA (see also lung) (800) 934-5556
--------------------------------------------------------------------------------------
combination therapy Phase I/II
(800) 934-5556
NeuVax™ Apthera (see also prostate) Phase II
E75 cancer Scottsdale, AZ (480) 882-8841
vaccine
Nexavar® Bayer HealthCare combination therapy Phase II
sorafenib Pharmaceuticals (see also lung, skin) (888) 842-2937
Wayne, NJ (510) 597-6500
Onyx Pharmaceuticals
Emeryville, CA
NOV-002 Novelos Therapeutics early-stage breast cancer Phase II
Newton, MA (see also lung, ovarian) (617) 244-1616
OBP-301 Oncolys Biopharma (see also head/neck, lung) Phase I
Tokyo, Japan www.oncolys.com
OGX-427 Oncogenex (see also bladder, lung, ovarian, Phase I
Pharmaceuticals prostate) (425) 686-1500
Bothell, WA
OPT-22 Optimer Pharmaceuticals Phase I
San Diego, CA (858) 909-0736
panobinostat Novartis Pharmaceuticals (see also brain, leukemia, Phase I/II
East Hanover, NJ lymphoma, prostate) (888) 669-6682
patupilone Novartis Pharmaceuticals (see also brain, colorectal, liver, Phase II
(EPO906) East Hanover, NJ lung, ovarian) (888) 669-6682
PD-332991 Pfizer combination therapy, Phase I/II
New York, NY first-line therapy (860) 732-5156
(see also lymphoma,
multiple myeloma)
pertuzumab Genentech first-line therapy, metastatic Phase III
South San Francisco, CA breast cancer (650) 224-1000
(see also ovarian)
PTC-299 PTC Therapeutics (see also skin) Phase I/II
South Plainfield, NJ (908) 222-7000

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 11
BREAST CANCER
Product Name Sponsor Indication Development Status
PX-1032 BN ImmunoTherapeutics Phase I/II
(HER2 breast Mountain View, CA (650) 681-4660
cancer vaccine) Pharmexa
Horsholm, Denmark
Quinamed® ChemGenex (see also ovarian, prostate) Phase II
amonafide Pharmaceuticals (650) 474-9800
Menlo Park, CA
R1507 Roche combination therapy Phase II
Nutley, NJ (see also lung, lymphoma, sarcoma) (973) 235-5000
retaspimycin Infinity Pharmaceuticals (see also lung, stomach) Phase II
(IPI 504) Cambridge, MA (617) 453-1000
Reximmune-C™ Epeius Biotechnologies Phase I/II
San Marino, CA (626) 441-6695
Rexin-G™ Epeius Biotechnologies recurrent, refractory metastatic Phase I/II
tumor-targeted San Marino, CA breast cancer (626) 441-6695
gene therapy (see also pancreatic, sarcoma)
sagopilone Bayer HealthCare (see also brain, ovarian, prostate) Phase II
Pharmaceuticals (888) 842-2937
Wayne, NJ
Sarasar™ Schering-Plough (see also leukemia, pancreatic) Phase II
lonafarnib Kenilworth, NJ (908) 298-4000
satraplatin Spectrum Pharmaceuticals metastatic breast cancer, Phase II completed
Irvine, CA second-line therapy (949) 788-6700
(see also lung, prostate)
SCH-727965 Schering-Plough (see also leukemia, lung) Phase II
Kenilworth, NJ (908) 298-4000
SF1 SonneMed advanced breast cancer Phase I/II
Boston, MA
SNDX-275 Syndax Pharmaceuticals (see also lung) Phase II
Waltham, MA (781) 839-7301
SU-14813 Pfizer Phase II
New York, NY (860) 732-5156
Sutent® Pfizer (see also colorectal, liver, lung, Phase III
sunitinib New York, NY pancreatic, prostate, sarcoma, (860) 732-5156
stomach)
TamoGel™ ASCEND Therapeutics Phase II
afimoxifene Herndon, VA (703) 471-4744
Tarceva® Genentech (see also bladder, brain, colorectal, Phase II
erlotinib South San Francisco, CA head/neck, liver, lung, other) (650) 224-1000
OSI Pharmaceuticals (800) 572-1932
Melville, NY
TAS-108 Taiho Pharma USA Phase II
Princeton, NJ (609) 750-5300
Telcyta™ Telik (see also colorectal, lung, ovarian) Phase II completed
canfosfamide Palo Alto, CA (650) 845-7700

12 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
BREAST CANCER
Product Name Sponsor Indication Development Status
tesmilifene YM BioSciences (see also prostate) Phase III
Wayne, PA (610) 560-0600
TheraCIM™ YM Biosciences adjunctive treatment Phase I
nimotuzumab Wayne, PA (see also brain, prostate, stomach) (610) 560-0600
Thermodox™ Celsion locally recurrent breast cancer Phase I/II
LTSDEL Columbia, MD (see also liver) (410) 290-5390
trastuzumab-DM1 Genentech metastatic breast cancer Phase III
South San Francisco, CA (second-line therapy) (650) 225-1000
ImmunoGen (781) 895-0600
Waltham, MA --------------------------------------------------------------------------------------
metastatic breast cancer Phase II
(first-line therapy, third-line therapy) (650) 225-1000
(781) 895-0600
Trelstar® Watson Pharmaceuticals Phase III
triptorelin Corona, CA (951) 493-5300
tremelimumab Pfizer (see also colorectal, kidney, lung, Phase I
New York, NY prostate, skin) (860) 732-5156
trilostane Genzyme (see also prostate) in clinical trials
Cambridge, MA (617) 252-7500
vinflunine Pierre Fabre advanced breast cancer Phase III
Pharmaceuticals (see also bladder) (973) 898-1042
Parsippany, NJ
WX-671 Wilex Phase II
Munich, Germany www.wilex.com
Yondelis® Johnson & Johnson (see also ovarian, prostate, Phase II
trabectedin Pharmaceutical Research sarcoma, other) (800) 817-5286
& Development
Raritan, NJ
Zactima® AstraZeneca (see also brain, lung, other) Phase II
vandetanib Wilmington, DE (800) 236-9933
Zolinza® Merck (see also brain, colorectal, kidney, Phase II
vorinostat Whitehouse Station, NJ leukemia, lung, lymphoma, (800) 672-6372
multiple myeloma)
ZYC300 Eisai (see also colorectal, kidney, Phase I
Woodcliff Lake, NJ ovarian, prostate) (888) 422-4743

CERVICAL CANCER
Product Name Sponsor Indication Development Status
A-007 Tigris Pharmaceuticals cervical intraepithelial neoplasia Phase II completed
Bonita Springs, FL (see also colorectal) (239) 444-5400
Armala™ GlaxoSmithKline (see also brain, breast, kidney, Phase II
pazopanib Rsch. Triangle Park, NC liver, lung, ovarian, sarcoma, other) (888) 825-5249
Camptosar® Pfizer (see also lung, pancreatic, prostate) application submitted
irinotecan New York, NY (860) 732-5156

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 13
CERVICAL CANCER
Product Name Sponsor Indication Development Status
HspE7 Nventa Biopharmaceuticals cervical intraepithelial neoplasia Phase I completed
(verpasep caltespen) San Diego, CA (858) 202-4900
Levulan® PD DUSA Pharmaceuticals cervical intraepithelial neoplasia Phase II
aminolevulinic acid Wilmington, DE (see also bladder, colorectal, lung, (978) 657-7500
stomach)
Multikine® CEL-SCI cervical cancer, cervical dysplasia Phase I/II completed
leukocyte interleukin Vienna, VA (see also head/neck) (703) 506-9460
PV701 Wellstat Biologics (see also colorectal) Phase II
Gaithersburg, MD (240) 631-2500
R3484 Roche cervical intraepithelial neoplasia Phase II
(MVA-HPV-IL2 Nutley, NJ (973) 235-5000
vaccine)
TAK-851 Millennium cervical dysplasia Phase II
Pharmaceuticals (800) 390-5663
Cambridge, MA
terameprocol Erimos Pharmaceuticals cervical intraepithelial neoplasia Phase II
Houston, TX (see also brain, head/neck) (713) 541-2000
tirapazamine SRI International Phase III
Menlo Park, CA (650) 859-2000
V503 Merck cervical cancer prevention Phase III
Whitehouse Station, NJ (see also other) (800) 672-6372
V505 Merck Phase III
Whitehouse Station, NJ (800) 672-6372

COLORECTAL CANCER
Product Name Sponsor Indication Development Status
1018 ISS Dynavax Technologies (see also lymphoma) Phase I
Berkeley, CA (510) 848-5100
A-007 Tigris Pharmaceuticals anal intraepithelial neoplasia Phase I/II
Bonita Springs, FL (see also cervical) (239) 444-5400
ABT-751 Abbott Laboratories (see also breast, kidney, lung) Phase II
Abbott Park, IL (847) 937-6100
aflibercept sanofi-aventis second-line metastatic Phase III
(VEGF-trap) Bridgewater, NJ colorectal cancer (800) 633-1610
Regeneron Pharmaceuticals (combination therapy) (914) 345-7400
Tarrytown, NY (see also lung, pancreatic,
prostate, other)
AMG 102 Amgen (see also brain, kidney, lung, Phase I/II
Thousand Oaks, CA stomach) (805) 447-1000
AMG 479 Amgen (see also breast, lung, pancreatic, Phase II
Thousand Oaks, CA sarcoma) (805) 447-1000

14 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
COLORECTAL CANCER
Product Name Sponsor Indication Development Status
AMG 951 Amgen (see also lymphoma) Phase I
(rhApo2L/TRAIL) Thousand Oaks, CA (805) 447-1000
Genentech (650) 225-1000
South San Francisco, CA
apomab Genentech (see also lung, lymphoma) Phase I
South San Francisco, CA (650) 225-1000
AR-726 Antigenics (see also lymphoma) Phase II
New York, NY (212) 994-8200
Avastin® Genentech adjuvant treatment Phase III
bevacizumab South San Francisco, CA (see also brain, head/neck, kidney, (650) 225-1000
liver, lung, lymphoma, multiple
myeloma, ovarian, pancreatic,
prostate, stomach, other)
AVX701 AlphaVax colorectal cancer prevention Phase I/II
Rsch. Triangle Park, NC (919) 595-0400
axitinib Pfizer combination first-line therapy Phase II
New York, NY (see also kidney, lung, solid tumors, (860) 732-5156
other)
--------------------------------------------------------------------------------------
metastatic colorectal cancer Phase II
(combination second-line therapy) (860) 732-5156
belinostat TopoTarget USA (see also bladder, leukemia, Phase I
Rockaway, NJ liver, lung, lymphoma, ovarian) (973) 895-6900
brivanib Bristol-Myers Squibb metastatic colorectal cancer Phase III
(VEGFR/FGFR Princeton, NJ (combination with cetuximab) (212) 546-4000
kinase inhibitor) (see also liver)
CDX-1307 Celldex Therapeutics (see also bladder, breast, ovarian, Phase I
Needham, MA pancreatic) (781) 433-0771
conatumumab Amgen (see also lung, pancreatic, sarcoma) Phase II
Thousand Oaks, CA (805) 447-1000
CP-751871 Pfizer (see also breast, lung, multiple Phase II
New York, NY myeloma, prostate, sarcoma) (860) 732-5156
CPX-1 Celator Pharmaceuticals Phase II
Princeton, NJ (609) 243-0123
Davanat™ Pro-Pharmaceuticals (see also solid tumors) Phase II
galactomannan C Newton, MA (617) 559-0033
denenicokin ZymoGenetics combination therapy Phase I
(IL-21) Seattle, WA (see also kidney, lymphoma, (206) 442-6600
ovarian, skin)
edotecarin Pfizer Phase III
New York, NY (860) 732-5156
enzastaurin Eli Lilly combination therapy Phase II
(LY317615) Indianapolis, IN (see also brain, breast, lymphoma, (800) 545-5979
multiple myeloma, ovarian,
prostate)

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 15
COLORECTAL CANCER
Product Name Sponsor Indication Development Status
Erbitux® Bristol-Myers Squibb adjuvant, first-line, second-line Phase III
cetuximab Princeton, NJ colorectal cancer (212) 546-4000
Eli Lilly (see also bladder, head/neck, lung, (800) 545-5979
Indianapolis, IN prostate, stomach) (212) 645-1405
ImClone Systems --------------------------------------------------------------------------------------
New York, NY rectal cancer Phase II
(212) 546-4000
(800) 545-5979
(212) 645-1405
Fusilev™ Spectrum Pharmaceuticals (see also sarcoma) application submitted
levoleucovorin Irvine, CA (949) 788-6700
for injection
Herceptin® Genentech (see also ovarian, pancreatic, Phase II
trastuzumab South San Francisco, CA prostate, stomach, other) (650) 225-1000
huA33 Life Science Phase I
Pharmaceuticals (203) 422-6500
Greenwich, CT
Hycamtin® GlaxoSmithKline (see also breast, head/neck, kidney, Phase II
topotecan Rsch. Triangle Park, NC leukemia, lung, lymphoma, multiple (888) 825-5249
myeloma, ovarian, pancreatic,
prostate, stomach, other)
IMC-1121B Eli Lilly (see also breast, kidney, liver, lung, Phase II
Indianapolis, IN ovarian, prostate, skin) (800) 545-5979
ImClone Systems (212) 645-1405
New York, NY
IMC-A12 Eli Lilly (see also breast, head/neck, liver, Phase II
Indianapolis, IN lung, pancreatic, prostate, sarcoma, (800) 545-5979
ImClone Systems solid tumors) (212) 645-1405
New York, NY
IMO-2055 Idera Pharmaceuticals combination therapy Phase I
Cambridge, MA (see also kidney, lung) (617) 679-5500
ispinesib CytoKinetics (see also breast, kidney, leukemia) Phase II
South San Francisco, CA (650) 624-3000
KRN-330 Kirin Pharma USA Phase I
La Jolla, CA (858) 952-7000
KRX-0402 Keryx Biopharmaceuticals (see also brain, kidney, Phase I
New York, NY multiple myeloma, sarcoma) (212) 531-5965
lapuleucel-T Dendreon (see also breast, ovarian) Phase I completed
Seattle, WA (206) 256-4545
LE-SN38 NeoPharm second-line therapy Phase II
Lake Bluff, IL (847) 887-0800
Levulan® PD DUSA Pharmaceuticals (see also bladder, cervical, lung, in clinical trials
aminolevulinic acid Wilmington, MA stomach) (978) 657-7500
Litx™ Light Sciences Oncology metastatic colorectal cancer Phase III
talaporfin Bellevue, WA (425) 957-8900
LOR-2040 Lorus Therapeutics metastatic colorectal cancer Phase II
Toronto, Canada (see also breast, kidney, leukemia) (416) 798-1200

16 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
COLORECTAL CANCER
Product Name Sponsor Indication Development Status
milataxel Taxolog (see also breast, lung) Phase II
Fairfield, NJ (877) 829-6564
motesanib Amgen metastatic colorectal cancer Phase I
Thousand Oaks, CA (combination therapy) (805) 447-1000
Millennium (see also breast, lung, other) (800) 390-5663
Pharmaceuticals
Cambridge, MA
NKTR-102 Nektar Therapeutics combination, second-line therapy Phase II
San Carlos, CA (see also ovarian) (650) 631-3100
Oncophage® Antigenics (see also brain, kidney, pancreatic, Phase II
vitespen New York, NY skin, stomach) (866) 805-8994
OncoVAX® Vaccinogen stage III colorectal cancer Phase II
cancer vaccine Frederick, MD (combination therapy) (301) 668-8400
(see also kidney, skin)
--------------------------------------------------------------------------------------
colorectal cancer Phase I/II
(301) 668-8400
patupilone Novartis Pharmaceuticals (see also brain, breast, liver, lung, Phase I/II
(EPO906) East Hanover, NJ ovarian) (888) 669-6682
pelitinib Wyeth Pharmaceuticals second-line therapy Phase II
(EKB569) Collegeville, PA (see also lung) (800) 934-5556
picoplatin Poniard Pharmaceuticals (see also lung) Phase II
Seattle, WA (206) 281-7001
PN401 Wellstat Therapeutics (see also pancreatic, stomach) Phase I
Gaithersburg, MD (240) 631-2500
PV701 Wellstat Biologics (see also cervical) Phase II
Gaithersburg, MD (240) 631-2500
RIGScan® CR49 Neoprobe diagnosis of colorectal cancer Phase III
radiodiagnostic Dublin, OH (800) 793-0079
agent
RM1812 Royalmount Pharmaceuticals Phase I
Montreal, Canada (514) 340-7849
robatumumab Schering-Plough (see also sarcoma) Phase II
Kenilworth, NJ (908) 298-4000
sibrotuzumab Life Science (see also head/neck, lung) Phase II
Pharmaceuticals (203) 422-6500
Greenwich, CT
Sutent® Pfizer (see also breast, liver, lung, Phase II
sunitinib New York, NY pancreatic, prostate, sarcoma, (860) 732-5156
stomach)
systemic hedgehog Genentech first-line therapy Phase II
antagonist South San Francisco, CA (see also brain, ovarian, skin) (650) 224-1000
Tarceva® Genentech combination therapy Phase II
erlotinib South San Francisco, CA (see also bladder, brain, breast, (650) 224-1000
OSI Pharmaceuticals head/neck, liver, lung, other) (800) 572-1932
Melville, NY

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 17
COLORECTAL CANCER
Product Name Sponsor Indication Development Status
TAS-109 Taiho Pharma USA Phase II
Princeton, NJ (609) 750-5300
tegafur/uracil EMD Serono (see also head/neck) Phase III
combination Rockland, MA (800) 283-8088
Telcyta™ Telik (see also breast, lung, ovarian) Phase II completed
canfosfamide Palo Alto, CA (650) 845-7700
tesetaxel Genta second-line therapy Phase II
Berkeley Heights, NJ (see also stomach) (908) 286-9800
tetrandrine Millenia Hope Phase III
Montreal, Canada (514) 846-5757
Thymitaq® YM BioSciences USA (see also head/neck, liver, lung, Phase II
nolatrexed Wayne, PA pancreatic, prostate) (610) 560-0600
TNFerade™ GenVec (see also head/neck, pancreatic, Phase II
Gaithersburg, MD skin, stomach) (240) 632-0740
Torisel™ Wyeth Pharmaceuticals (see also kidney, lung, lymphoma, Phase II
temsirolimus Collegeville, PA multiple myeloma, prostate) (800) 934-5556
tremelimumab Pfizer (see also breast, kidney, lung, Phase II
New York, NY prostate, skin) (860) 732-5156
tucotuzumab EMD Serono (see also lung, ovarian, prostate) Phase II
celmoleukin Rockland, MA (800) 283-8088
Urso Forte™ Axcan Pharma (see also cancer-related) Phase II
ursodeoxycholic Birmingham, AL (205) 991-8085
acid
VP101 Access Pharmaceuticals (see also brain, leukemia, prostate) Phase II
Dallas, TX (214) 905-5100
Xeloda® Roche first-line metastatic colorectal cancer, application submitted
capecitabine Nutley, NJ second-line metastatic colorectal (973) 235-5000
cancer
(see also stomach)
Zolinza® Merck (see also brain, breast, kidney, Phase I
vorinostat Whitehouse Station, NJ leukemia, lung, lymphoma, (800) 672-6372
multiple myeloma)
ZYC300 Eisai colon cancer Phase I
Woodcliff Lake, NJ (see also breast, kidney, ovarian, (888) 422-4743
prostate)

HEAD/NECK CANCER
Product Name Sponsor Indication Development Status
Abraxane™ Abraxis BioScience (see also lung, ovarian, pancreatic, Phase I/II
albumin-bound Los Angeles, CA prostate, skin) (310) 883-1300
paclitaxel

18 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
HEAD/NECK CANCER
Product Name Sponsor Indication Development Status
Advexin® Introgen Therapeutics (see also bladder, brain, breast, Phase III completed
contusugene Austin, TX lung, ovarian, prostate, stomach) (512) 708-9310
ladenovec
(Orphan Drug)
Alimta® Eli Lilly (see also breast, lung, ovarian) Phase III
pemetrexed Indianapolis, IN (800) 545-5979
AP-5346 Access Pharmaceuticals Phase II
Dallas, TX (214) 905-5100
ARQ-501 ArQule (see also pancreatic, solid tumors, Phase II
(beta lapachone) Woburn, MA other) (781) 994-0300
Avastin® Genentech combination therapy Phase III
bevacizumab South San Francisco, CA (see also brain, colorectal, kidney, (650) 225-1000
liver, lung, lymphoma, multiple
myeloma, ovarian, pancreatic,
prostate, stomach, other)
BIBW 2992 Boehringer Ingelheim second-line therapy Phase II
Pharmaceuticals (see also brain, breast, lung) (800) 243-0127
Ridgefield, CT
bleomycin Inovio Biomedical (see also breast) Phase III
(electrical pulse San Diego, CA (858) 597-6006
delivery)
Erbitux® Bristol-Myers Squibb first-line application submitted
cetuximab Princeton, NJ (see also bladder, colorectal, lung, (212) 546-4000
Eli Lilly prostate, stomach) (800) 545-5979
Indianapolis, IN (212) 645-1405
ImClone Systems
New York, NY
eribulin mesylate Eisai (see also breast, lung, ovarian, Phase II
(E7389) Woodcliff Lake, NJ prostate, sarcoma, solid tumors) (888) 422-4743
Gemzar® Eli Lilly (see also lung, lymphoma, sarcoma) Phase I
gemcitabine Indianapolis, IN (800) 545-5979
Hycamtin® GlaxoSmithKline (see also breast, colorectal, Phase II
topotecan Rsch. Triangle Park, NC kidney, leukemia, lung, lymphoma, (888) 825-5249
multiple myeloma, ovarian,
pancreatic, prostate, stomach, other)
IMC-A12 Eli Lilly (see also breast, colorectal, liver, Phase II
Indianapolis, IN lung, pancreatic, prostate, sarcoma, (800) 545-5979
ImClone Systems solid tumors) (212) 645-1405
New York, NY
ING 234 Colgate-Palmolive orofacial cancer (prevention) Phase II
(mouthwash) New York, NY (512) 708-9310
Introgen Therapeutics
Austin, TX
INGN 241 Introgen Therapeutics combination therapy Phase III
(mda-7) Austin, TX (see also skin) (512) 708-9310
IRX-2 IRX Therapeutics Phase II
New York, NY (212) 582-1199

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 19
HEAD/NECK CANCER
Product Name Sponsor Indication Development Status
Multikine® CEL-SCI (see also cervical) Phase II
leukocyte Vienna, VA (703) 506-9460
interleukin
OBP-301 Oncolys Biopharma (see also breast, lung) Phase I
Tokyo, Japan www.oncolys.com
perifosine AEterna Zentaris (see also brain, kidney, lymphoma, Phase II
Montreal, Canada multiple myeloma, ovarian, (212) 531-5965
Keryx Biopharmaceuticals sarcoma)
New York, NY
Reolysin® Oncolytics Biotech combination therapy Phase II
reovirus Calgary, Canada (see also brain, lung, sarcoma, skin) (403) 670-7377
SCH-58500 Schering-Plough (see also bladder, liver, Phase I
(p53 gene therapy) Kenilworth, NJ lung, cancer-related) (908) 298-4000
sibrotuzumab Life Science (see also colorectal, lung) Phase II
Pharmaceuticals (203) 422-6500
Greenwich, CT
Tarceva® Genentech resected head/neck squamous Phase III
erlotinib South San Francisco, CA cell cancer (650) 224-1000
OSI Pharmaceuticals (see also bladder, brain, breast, (800) 572-1932
Melville, NY colorectal, liver, lung, other)
TAS-106 Taiho Pharma USA Phase II
Princeton, NJ (609) 750-5300
tegafur/uracil EMD Serono (see also colorectal) Phase II
combination Rockland, MA (800) 283-8088
terameprocol Erimos Pharmaceuticals (see also brain, cervical) Phase I
Houston, TX (713) 541-2000
Thymitaq® YM BioSciences (see also colorectal, liver, lung, Phase II
nolatrexed Wayne, PA pancreatic, prostate) (610) 560-0600
TNFerade™ GenVec (see also colorectal, pancreatic, skin, Phase I/II
Gaithersburg, MD stomach) (240) 632-0740
Tykerb® GlaxoSmithKline (see also brain, stomach) Phase III
lapatinib Rsch. Triangle Park, NC (888) 825-5249
VB-4845 Viventia Biotech (see also bladder) Phase II
(Orphan Drug) Mississauga, Canada (905) 361-8686
Vectibix™ Amgen first-line therapy Phase III
panitumumab Thousand Oaks, CA (see also lung) (805) 447-1000
--------------------------------------------------------------------------------------
second-line therapy Phase II
(805) 447-1000
XL-880 Exelixis (see also kidney, stomach) Phase II
South San Francisco, CA (650) 837-7000
GlaxoSmithKline (888) 825-5249
Rsch. Triangle Park, NC
zalutumumab Genmab Phase II
Princeton, NJ (609) 430-2481

20 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
HEAD/NECK CANCER
Product Name Sponsor Indication Development Status
Zybrestat™ OXiGENE (see also lung, ovarian, other) Phase I/II
fosbretabulin Waltham, MA (781) 547-5900

KIDNEY CANCER
Product Name Sponsor Indication Development Status
ABT-751 Abbott Laboratories (see also breast, colorectal, lung) Phase II
Abbott Park, IL (847) 937-6100
ABT-869 Abbott Laboratories (see also breast, liver, lung) Phase II
Abbott Park, IL (847) 937-6100
Genentech (650) 225-1000
South San Francisco, CA
AGS-003 Argos Therapeutics metastatic renal cancer Phase II
Durham, NC (919) 287-6300
AMG 102 Amgen (see also brain, colorectal, Phase II
Thousand Oaks, CA lung, stomach) (805) 447-1000
AMG 386 Amgen (see also breast, ovarian, Phase II
Thousand Oaks, CA stomach, other) (805) 447-1000
Armala™ GlaxoSmithKline late-stage metastatic kidney cancer Phase III
pazopanib Rsch. Triangle Park, NC (see also brain, breast, cervical, (888) 825-5249
liver, lung, ovarian, sarcoma, other)
AS-1411 Antisoma (see also leukemia) Phase II
(Orphan Drug) Cambridge, MA (617) 225-0522
AV-951 AVEO Pharmaceuticals combination therapy Phase I
Cambridge, MA (see also lung, stomach) (617) 299-5000
Avastin® Genentech first-line metastatic renal cell carcinoma application submitted
bevacizumab South San Francisco, CA (see also brain, colorectal, (650) 225-1000
head/neck, liver, lung, lymphoma,
multiple myeloma, ovarian,
pancreatic, prostate, stomach, other)
axitinib Pfizer second-line therapy Phase III
New York, NY (see also colorectal, lung, (860) 732-5156
solid tumors, other)
BAY 73-4506 Bayer HealthCare Phase II
Pharmaceuticals (888) 842-2937
Wayne, NJ
CA9-SCAN Wilex diagnosis of kidney cancer Phase III
Munich, Germany www.wilex.com
cediranib AstraZeneca (see also breast, leukemia) Phase II
Wilmington, DE (800) 236-9933
CNTO 328 Centocor (see also prostate) Phase I
Horsham, PA (610) 651-6000
CYT-107 Cytheris (see also leukemia, skin, Phase I/II
Rockville, MD solid tumors) (301) 231-0450

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 21
KIDNEY CANCER
Product Name Sponsor Indication Development Status
denenicokin ZymoGenetics combination therapy Phase II
(IL-21) Seattle, WA (see also colorectal, lymphoma, (206) 442-6600
ovarian, skin)
dovitinib Novartis Pharmaceuticals (see also skin) Phase I/II
East Hanover, NJ (888) 669-6682
EC-17 Endocyte combination therapy Phase II
West Lafayette, IN (765) 463-7175
everolimus Novartis Pharmaceuticals (see also pancreatic, other) application submitted
East Hanover, NJ (888) 669-6682
GC-1008 Genzyme (see also skin) Phase I
Cambridge, MA (617) 252-7000
Hycamtin® GlaxoSmithKline (see also breast, colorectal, Phase II
topotecan Rsch. Triangle Park, NC head/neck, leukemia, lung, (888) 825-5249
lymphoma, multiple myeloma,
ovarian, pancreatic, prostate,
stomach, other)
IMC-1121B Eli Lilly metastatic kidney cancer Phase II
Indianapolis, IN (see also breast, colorectal, liver, (800) 545-5979
ImClone Systems lung, ovarian, prostate, skin) (212) 645-1405
New York, NY
IMO-2055 Idera Pharmaceuticals (see also colorectal, lung) Phase II completed
Cambridge, MA (617) 679-5500
ispinesib CytoKinetics (see also breast, colorectal, Phase II
South San Francisco, CA leukemia) (650) 624-3000
KRX-0402 Keryx Biopharmaceuticals (see also brain, colorectal, Phase I
New York, NY multiple myeloma, sarcoma) (212) 531-5965
LOR-2040 Lorus Therapeutics metastatic kidney cancer Phase II
(Orphan Drug) Toronto, Canada (see also breast, colorectal, leukemia) (416) 798-1200
MDX-1411 Medarex clear-cell renal cell carcinoma Phase I
Princeton, NJ (609) 430-2880
naptumomab Active Biotech (see also lung, pancreatic) Phase I completed
estafenatox Lund, Sweden www.activebiotech.com
Oncophage® Antigenics (see also brain, colorectal, Phase II
vitespen New York, NY pancreatic, skin, stomach) (866) 805-8994
OncoVAX® Vaccinogen (see also colorectal, skin) Phase I/II
cancer vaccine Frederick, MD (301) 668-8400
ortataxel Spectrum Pharmaceuticals (see also lymphoma) Phase II
Irvine, CA (949) 788-6700
perifosine AEterna Zentaris (see also brain, head/neck, Phase II
Montreal, Canada lymphoma, multiple myeloma, (212) 531-5965
Keryx Biopharmaceuticals ovarian, sarcoma)
New York, NY
Rencarex® Wilex non-metastatic, clear cell renal Phase III
W-G250 Munich, Germany cell carcinoma www.wilex.com
(Orphan Drug)

22 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
KIDNEY CANCER
Product Name Sponsor Indication Development Status
romidepsin Gloucester Pharmaceuticals (see also lymphoma, multiple myeloma, Phase II completed
Cambridge, MA pancreatic, prostate) (617) 583-1300
RX-0201 Rexahn Pharmaceuticals late-stage kidney cancer Phase II
(Orphan Drug) Rockville, MD (240) 268-5300
talactoferrin Agennix (see also lung) Phase II
(Orphan Drug) Houston, TX (713) 552-1091
Torisel™ Wyeth Pharmaceuticals first-line therapy, late-stage kidney Phase III
temsirolimus Collegeville, PA cancer (800) 934-5556
(Orphan Drug) (see also colorectal, lung, lymphoma,
multiple myeloma, prostate)
tremelimumab Pfizer (see also breast, colorectal, lung, Phase I
New York, NY prostate, skin) (860) 732-5156
TroVax® BioMedica Phase III
(SAR109659) San Diego, CA (858) 677-6500
sanofi-aventis (800) 633-1610
Bridgewater, NJ
Xcytrin® Pharmacyclics (see also brain, leukemia, lung, Phase II
motexafin Sunnyvale, CA lymphoma) (408) 774-0330
gadolinium
XL-880 Exelixis (see also head/neck, stomach) Phase II
South San Francisco, CA (650) 837-7000
GlaxoSmithKline (888) 825-5249
Rsch. Triangle Park, NC
Zolinza® Merck (see also brain, breast, colorectal, Phase I/II
vorinostat Whitehouse Station, NJ leukemia, lung, lymphoma, (800) 672-6372
multiple myeloma)
ZRx101 ZelleRx (see also multiple myeloma, skin, Phase I
Chicago, IL cancer-related) (312) 243-5200
ZYC300 Eisai (see also breast, colorectal, Phase I
Woodcliff Lake, NJ ovarian, prostate) (888) 422-4743

LEUKEMIA
Product Name Sponsor Indication Development Status
ABIO05/01 Abiogen Pharma chronic myeloid leukemia (CML) Phase II
(TALL-104) Pisa, Italy (combination therapy)
Ablvax™ Breakthrough Therapeutics CML Phase II
(VAXICO) Greenwich, CT
ABT-263 Abbott Laboratories chronic lymphocytic leukemia (CLL) Phase I/II
Abbott Park, IL (see also lung, lymphoma) (847) 937-6100
Genentech (650) 225-1000
South San Francisco, CA
AC220 Ambit Biosciences acute myeloid leukemia (AML) Phase I
San Diego, CA (858) 334-2100

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 23
LEUKEMIA
Product Name Sponsor Indication Development Status
AEG-35156 Aegera Therapeutics AML Phase II
Montreal, Canada (combination therapy) (514) 288-5532
AEG-41174 Aegera Therapeutics hematological malignancies Phase I
Montreal, Canada (combination therapy) (514) 288-5532
AEW541 Novartis Pharmaceuticals hematological malignancies Phase I
East Hanover, NJ (see also solid tumors) (888) 669-6682
Aezea™ Eleos AML, CLL Phase II
cenersen Omaha, NE (402) 255-5775
AFX-9154 Afecta Pharmaceuticals in clinical trials
Irvine, CA (949) 253-4688
ALD-151 Aldagen adjunctive treatment Phase I
Durham, NC (adolescents and children) (919) 484-2571
alvocidib sanofi-aventis CLL Phase III
Bridgewater, NJ (800) 633-1610
ALXN-6000 Alexion Pharmaceuticals CLL Phase I/II
Cheshire, CT (203) 272-2596
annamycin Callisto Pharmaceuticals acute lymphocytic leukemia (ALL), Phase I/II
liposomal New York, NY AML (212) 297-0010
(Orphan Drug)
AP24534 ARIAD Pharmaceuticals hematological malignancies Phase I
Cambridge, MA (617) 494-0400
ARRY-520 Array BioPharma AML Phase I/II
Boulder, CO (see also solid tumors) (303) 381-6600
AS-1411 Antisoma AML (combination therapy) Phase II
Cambridge, MA (see also kidney) (617) 225-0522
AS-1413 Antisoma AML (combination therapy) Phase III
(Orphan Drug) Cambridge, MA (617) 225-0522
AT9283 Astex Therapeutics hematological malignancies Phase I/II
Cambridge, United Kingdom (see also solid tumors)
atacicept EMD Serono CLL Phase I
(TACI-Ig) Rockland, MA (see also lymphoma, (800) 283-8088
ZymoGenetics multiple myeloma) (206) 442-6600
Seattle, WA
AVN-944 Avalon Pharmaceuticals hematological malignancies Phase I
Germantown, MD (see also pancreatic) (301) 556-9900
AZD1152 AstraZeneca AML Phase I/II
Wilmington, DE (800) 236-9933
AZD4877 AstraZeneca AML Phase I/II
Wilmington, DE (see also lymphoma) (800) 236-9933
AZD6244 AstraZeneca AML Phase II
Wilmington, DE (see also liver, lung, multiple (800) 236-9933
myeloma, ovarian, pancreatic,
skin, other)
AZM475271 AstraZeneca hematological malignancies Phase II
Wilmington, DE (see also solid tumors) (800) 236-9933

24 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
LEUKEMIA
Product Name Sponsor Indication Development Status
bafetinib CytRx ALL, CML Phase I
(Orphan Drug) Los Angeles, CA (310) 826-5648
belinostat TopoTarget USA AML, myelodysplastic syndromes Phase II
Rockaway, NJ (see also bladder, colorectal, (973) 895-6900
liver, lung, lymphoma, ovarian)
Bexxar® GlaxoSmithKline CLL Phase I
tositumomab Rsch. Triangle Park, NC (see also lymphoma, cancer-related) (888) 825-5249
bosutinib Wyeth Pharmaceuticals CML Phase III
Collegeville, PA (see also breast, solid tumors) (800) 934-5556
--------------------------------------------------------------------------------------
ALL Phase I/II
(800) 934-5556
CAL-101 Calistoga Pharmaceuticals AML, CLL Phase I
Seattle, WA (see also lymphoma) (206) 728-4700
Campath® Bayer HealthCare CLL Phase II
alemtuzumab Pharmaceuticals (888) 842-2937
(subcutaneous) Wayne, NJ
(Orphan Drug)
carfilzomib Proteolix hematological malignancies Phase I
South San Francisco, CA (see also multiple myeloma, (650) 615-7550
solid tumors)
CAT-8015 MedImmune CLL, hairy cell leukemia Phase I
Gaithersburg, MD (see also lymphoma) (301) 398-0000
cediranib AstraZeneca AML in children Phase I
Wilmington, DE (see also breast, kidney) (800) 236-9933
Ceflatonin® ChemGenex CML (second-line therapy) application submitted
omacetaxine Pharmaceuticals (650) 474-9800
mepesuccinate Menlo Park, CA --------------------------------------------------------------------------------------
(Orphan Drug) AML, CML (combination therapy), Phase II
myelodysplastic syndromes (650) 474-9800
cell permeation MaxCyte CLL Phase I/II
therapeutic Gaithersburg, MD (301) 944-1700
Ceplene™ EpiCept AML Phase III completed
histamine Tarrytown, NY (914) 606-3500
dehydrochloride
(Orphan Drug)
Clolar® Genzyme AML application submitted
clofarabine Cambridge, MA (see also lymphoma) (617) 252-7500
--------------------------------------------------------------------------------------
CLL, myelodysplastic syndromes Phase II
(617) 252-7500
CNF-2024 Biogen Idec CLL Phase I
Cambridge, MA (see also breast, solid tumors, (617) 679-2000
stomach)
CPX-351 Celator Pharmaceuticals AML Phase II
Princeton, NJ (609) 243-0123

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 25
LEUKEMIA
Product Name Sponsor Indication Development Status
CYT-107 Cytheris myeloid leukemia Phase I
Rockville, MD (see also kidney, skin, solid tumors) (301) 231-0450
dacetuzumab Genentech CLL Phase I/II
(anti-CD40) South San Francisco, CA (see also lymphoma, (650) 225-1000
(Orphan Drug) Seattle Genetics multiple myeloma) (425) 527-4000
Bothell, WA
darinaparsin ZIOPHARM Oncology hematological malignancies Phase II
(ZIO-101) New York, NY (see also liver, multiple myeloma, (646) 214-0700
solid tumors)
DCC-2036 Deciphera Pharmaceuticals ALL, CML Phase I/II
Lawrence, KS (785) 838-3767
Elacyt™ Clavis Pharma AML Phase II
elacytarabine Oslo, Norway (see also ovarian, skin) www.clavispharma.com
(Orphan Drug)
Fodosine™ BioCryst Pharmaceuticals CLL, leukemia Phase II
forodesine Birmingham, AL (see also lymphoma) (205) 444-4600
GCS-100 Prospect Therapeutics CLL Phase II
Woburn, MA (see also lymphoma, (781) 939-5750
multiple myeloma)
Genasense® Genta CLL application submitted
oblimersen Berkeley Heights, NJ (see also breast, lung, lymphoma, (908) 286-9800
(Orphan Drug) skin, solid tumors)
--------------------------------------------------------------------------------------
AML Phase III
(908) 286-9800
gimatecan Novartis Pharmaceuticals myelodysplastic syndromes Phase I
East Hanover, NJ (see also brain) (888) 669-6682
Gleevec® Novartis Pharmaceuticals AML Phase II
imatinib East Hanover, NJ (see also prostate) (888) 669-6682
GRN-163L Geron CLL Phase I/II
Menlo Park, CA (see also breast, lung, (650) 473-7700
multiple myeloma)
GRNVAC1 Argos Therapeutics AML Phase II
Durham, NC (see also prostate) (919) 287-6300
Geron (650) 473-7700
Menlo Park, CA
GS-9219 Gilead Sciences CLL Phase I/II
Foster City, CA (see also lymphoma) (800) 445-3235
HRC-302 Hemosol BioPharma CML Phase I
Mississauga, Canada (905) 286-6349
Hycamtin® GlaxoSmithKline preleukemia Phase III
topotecan Rsch. Triangle Park, NC (see also breast, colorectal, (888) 825-5249
head/neck, kidney, lung, lymphoma,
multiple myeloma, ovarian,
pancreatic, prostate, stomach, other)
--------------------------------------------------------------------------------------
CML Phase II
(888) 825-5249

26 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
LEUKEMIA
Product Name Sponsor Indication Development Status
INNO-305 CytRx AML, myelodysplastic syndromes Phase I
Los Angeles, CA (see also solid tumors) (310) 826-5648
ISF35 Memgen CLL Phase I
Dallas, TX (214) 731-3141
ispinesib CytoKinetics hematological malignancies Phase I
South San Francisco, CA (see also breast, colorectal, (650) 624-3000
kidney)
JNJ-26481585 Johnson & Johnson refractory metastatic leukemia, Phase I
Pharmaceutical Research refractory metastatic (800) 817-5286
& Development myelodysplastic syndromes
Raritan, NJ
JVRS-100 Juvaris BioTherapeutics Phase I
Burlingame, CA (650) 259-1800
KW-2449 Kyowa Pharmaceutical ALL, AML, CML, Phase I
Princeton, NJ myelodysplastic syndromes (609) 919-1100
laromustine Vion Pharmaceuticals AML (first-line therapy in elderly application submitted
(VNP 40101M) New Haven, CT patients) (203) 498-4210
(Orphan Drug) (see also brain)
--------------------------------------------------------------------------------------
AML (combination second-line Phase III
therapy) (203) 498-4210
--------------------------------------------------------------------------------------
AML (combination therapy in elderly Phase I/II
patients), myelodysplastic syndromes (203) 498-4210
(combination therapy in elderly
patients)
lestaurtinib Cephalon AML Phase II
Frazer, PA (see also multiple myeloma) (610) 344-0200
Leukine® Bayer HealthCare CLL Phase II
sargramostim Pharmaceuticals (see also lymphoma, ovarian, (888) 842-2937
Wayne, NJ prostate, skin)
lintuzumab Facet Biotech AML (combination therapy in Phase II
(SGN-33) Redwood City, CA elderly patients) (650) 454-1000
(Orphan Drug) Seattle Genetics (425) 527-4000
Seattle, WA --------------------------------------------------------------------------------------
myelodysplastic syndromes Phase I
(650) 454-1000
(425) 527-4000
lintuzumab Actinium Pharmaceuticals AML Phase I
Ac-225 Florham Park, NJ (973) 377-0713
LOR-2040 Lorus Therapeutics AML Phase II
(Orphan Drug) Toronto, Canada (see also breast, colorectal, kidney) (416) 798-1200
--------------------------------------------------------------------------------------
CML, myelodysplastic Phase I
syndromes (416) 798-1200
lumilixmab Biogen Idec CLL Phase II/III
(anti-CD23 mAb) Cambridge, MA (617) 679-2000

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 27
LEUKEMIA
Product Name Sponsor Indication Development Status
LY2181308 Eli Lilly AML Phase I/II
Indianapolis, IN (see also solid tumors) (800) 545-5979
Isis Pharmaceuticals (760) 931-9200
Carlsbad, CA
LymphoCide® Immunomedics ALL in children Phase II
epratuzumab Morris Plains, NJ (see also lymphoma) (973) 605-8200
(Orphan Drug)
Marqibo™ Hana Biosciences ALL Phase I/II
vincristine South San Francisco, CA (see also skin) (650) 588-6404
liposomal
(Orphan Drug)
masitinib AB Science USA mastocytosis Phase III
Short Hills, NJ (see also pancreatic, stomach) (973) 218-2437
MDX-1342 Medarex CLL Phase I
Princeton, NJ (609) 430-2880
MGCD-0103 MethylGene AML, CLL, myelodysplastic syndromes Phase II
Montreal, Canada (see also lymphoma, solid tumors) (514) 337-3333
midostaurin Novartis Pharmaceuticals AML Phase III
(PKC412) East Hanover, NJ (888) 669-6682
milatuzumab Immunomedics CLL Phase I/II
(IMMU-115) Morris Plains, NJ (see lymphoma, multiple myeloma) (973) 605-8200
MK-0752 Merck hematological malignancies Phase I
Whitehouse Station, NJ (see also breast) (800) 672-6372
MKC 1 EntreMed hematological malignancies Phase I completed
Rockville, MD (see aslo breast, lung, pancreatic) (240) 864-2600
MLN4924 Millennium hematological malignancies Phase I
Pharmaceuticals (see also solid tumors) (800) 390-5663
Cambridge, MA
MLN8237 Millennium AML, myelodysplastic syndromes Phase II
Pharmaceuticals (see also brain, lymphoma, (800) 390-5663
Cambridge, MA solid tumors)
--------------------------------------------------------------------------------------
ALL Phase I/II
(800) 390-5663
MPC-2130 Myriad Pharmaceuticals hematological malignancies Phase I
Salt Lake City, UT (801) 584-3600
Nipent® Hospira CLL Phase III
pentostatin Lake Forest, IL (see also lymphoma, cancer-related) (224) 212-2000
(Orphan Drug)
Nplate™ Amgen myelodysplastic syndromes Phase II
romiplostim Thousand Oaks, CA (see also cancer-related) (805) 447-1000
obatoclax Gemin X Biotechnologies AML in elderly patients, Phase II
Montreal, Canada myelodysplastic syndromes (514) 281-8989
(see also lung, lymphoma)
--------------------------------------------------------------------------------------
CLL Phase I/II completed
(514) 281-8989

28 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
LEUKEMIA
Product Name Sponsor Indication Development Status
ofatumumab GlaxoSmithKline CLL (second-line therapy) application submitted
Rsch. Triangle Park, NC (see also lymphoma) (888) 825-5249
--------------------------------------------------------------------------------------
CLL (first-line therapy) Phase III
(888) 825-5249
ON-01910 Onconova Therapeutics AML, myelodysplastic syndromes Phase I
Princeton, NJ (see also solid tumors) (609) 844-7735
OVI-123 OncoVista TdT-positive leukemia Phase I/II
(Orphan Drug) San Antonio, TX (210) 677-6000
panobinostat Novartis Pharmaceuticals CML Phase II/III completed
East Hanover, NJ (see also brain, breast, lymphoma, (888) 669-6682
prostate)
--------------------------------------------------------------------------------------
AML Phase II
(888) 669-6682
PCI-24781 Pharmacyclics hematological malignancies Phase II
Sunnyvale, CA (see also solid tumors) (408) 774-0330
PEG-Intron A® Schering-Plough CML Phase II
peginterferon Kenilworth, NJ (see also skin) (908) 298-4000
alfa-2b
PHA-739358 Nerviano Medical Sciences CML Phase II
Nerviano, Italy www.nervianoms.com
polyphenon E Polyphenon Pharma CLL Phase I/II
(Orphan Drug) New York, NY (see also bladder, prostate) (212) 661-0578
PR1 cancer Vaccine Company AML Phase III
vaccine South San Francisco, CA (650) 244-4100
--------------------------------------------------------------------------------------
CML, myelodysplastic syndromes Phase II
(650) 244-4100
PRO-131921 Genentech CLL Phase I/II
South San Francisco, CA (see also lymphoma) (650) 224-1000
Proleukin® Novartis Pharmaceuticals AML Phase III
aldesleukin East Hanover, NJ (888) 669-6682
PS-095760 Ligand Pharmaceuticals (see also lung) Phase II
San Diego, CA (858) 550-7500
Schering-Plough (908) 298-4000
Kenilworth, NJ
R7112 Roche hematological malignancies Phase I
Nutley, NJ (see also solid tumors) (973) 235-5000
recombinant Rare Disease Therapeutics ALL Phase I/II
Wolinella Nashville, TN (615) 399-0700
succinogenes
asparaginase (rWS)

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 29
LEUKEMIA
Product Name Sponsor Indication Development Status
Revlimid® Celgene CLL Phase III
lenalidomide Summit, NJ (see also lymphoma, multiple (908) 673-9000
myeloma, prostate, other)
--------------------------------------------------------------------------------------
AML Phase II
(908) 673-9000
Rituxan® Biogen Idec relapsed CLL Phase III
rituxumab Cambridge, MA (617) 679-2000
Genentech (650) 225-1000
South San Francisco, CA
RTA-402 Reata Pharmaceuticals hematological malignancies Phase I
Dallas, TX (see also pancreatic) (972) 865-2200
sapacitabine Cyclacel Pharmaceuticals AML in elderly patients, Phase II
Short Hills, NJ myelodysplastic syndromes in (973) 847-5955
elderly patients
(see also lung, lymphoma)
Sarasar™ Schering-Plough myelodysplastic syndromes Phase III
lonafarnib Kenilworth, NJ (see also breast, pancreatic) (908) 298-4000
--------------------------------------------------------------------------------------
leukemia Phase II
(908) 298-4000
SB-1518 S*Bio (see also lymphoma) Phase I
Redwood City, CA (650) 730-2860
SCH-727965 Schering-Plough (see also breast, lung) Phase II
Kenilworth, NJ (908) 298-4000
SGN-35 Seattle Genetics hematological malignancies Phase I
Bothell, WA (see also lymphoma) (425) 527-4000
SL-401 Stemline Therapeutics AML Phase I/II
New York, NY (212) 831-1111
SNS-595 Sunesis Pharmaceuticals AML in elderly patients Phase II
South San Francisco, CA (see also ovarian) (650) 266-3500
--------------------------------------------------------------------------------------
AML (combination therapy) Phase I/II
(650) 266-3500
--------------------------------------------------------------------------------------
AML (monotherapy) Phase I
(650) 266-3500
SPC-2996 Santaris Pharma CLL Phase I/II completed
Horsholm, Denmark
Sprycel™ Bristol-Myers Squibb first-line CML Phase III
dasatinib Princeton, NJ (see also prostate, solid tumors) (212) 546-4000
--------------------------------------------------------------------------------------
other hematological malignancies in clinical trials
(212) 546-4000
STA-9090 Synta Pharmaceuticals hematological malignancies Phase I/II
Lexington, MA (see also solid tumors) (781) 274-8200

30 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
LEUKEMIA
Product Name Sponsor Indication Development Status
StemEx® Gamida Cell hematological malignancies Phase II/III
hematopoietic Jerusalem, Israel (215) 591-3000
stem cell therapy Teva Pharmaceuticals USA
(Orphan Drug) North Wales, PA
TAK901 Millennium hematological malignancies Phase I
Pharmaceuticals (800) 390-5663
Cambridge, MA
tamibarotene CytRx APL Phase II
(Orphan Drug) Los Angeles, CA (310) 826-5648
Tasigna® Novartis Pharmaceuticals CML (first-line therapy) Phase II
nilotinib East Hanover, NJ (see also stomach) (888) 669-6682
(Orphan Drug)
tasisulam (ASAP) Eli Lilly AML Phase I
Indianapolis, IN (see also ovarian, sarcoma, skin) (800) 545-5979
Telintra® Telik myelodysplastic syndromes Phase II
ezatiostat Palo Alto, CA (see also cancer-related) (650) 845-7700
Temodar® Schering-Plough AML Phase II
temozolomide Kenilworth, NJ (see also lung) (908) 298-4000
Triapine® Vion Pharmaceuticals leukemia Phase II
New Haven, CT (see also lung, pancreatic, prostate) (203) 498-4210
--------------------------------------------------------------------------------------
hematological malignancies Phase I
(203) 498-4210
tricirbine VioQuest Pharmaceuticals hematological malignancies Phase I/II
(VQD-002) Basking Ridge, NJ (see also solid tumors) (908) 766-4400
Trisenox® Cephalon AML in elderly patients Phase III
arsenic trioxide Frazer, PA (combination therapy) (610) 344-0200
(see also brain, multiple myeloma)
TRU-016 Trubion Pharmaceuticals CLL Phase I/II
Seattle, WA (206) 838-0500
Vidaza® Celgene AML, myelodysplastic syndromes Phase I
azacitidine Summit,NJ (see also lymphoma, prostate) (908) 673-9000
(Orphan Drug)
VP101 Access Pharmaceuticals hematological malignancies Phase II
Dallas, TX (see also brain, colorectal, prostate) (214) 905-5100
VP701 Virium Pharmaceuticals Phase I
Princeton, NJ (609) 951-2270
Xcytrin® Pharmacyclics CLL Phase II
motexafin Sunnyvale, CA (see also brain, kidney, lung, (408) 774-0330
gadolinium lymphoma)
XL-228 Exelixis ALL, CML Phase I
South San Francisco, CA (650) 837-7000
Zarnestra™ Johnson & Johnson AML Phase III
tipifarnib Pharmaceutical Research (see also pancreatic) (800) 817-5286
& Development
Raritan, NJ

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 31
LEUKEMIA
Product Name Sponsor Indication Development Status
Zolinza® Merck AML, myelodysplastic syndromes Phase II
vorinostat Whitehouse Station, NJ (see also brain, breast, colorectal, (800) 672-6372
kidney, lung, lymphoma, multiple
myeloma)
zosuquidar Kanisa Pharmaceuticals AML in elderly patients Phase I/II
San Diego, CA (858) 436-1800

LIVER CANCER
Product Name Sponsor Indication Development Status
ABT-869 Abbott Laboratories (see also breast, kidney, lung) Phase II
Abbott Park, IL (847) 937-6100
Genentech (650) 225-1000
South San Francisco, CA
amsilarotene Taiho Pharma USA Phase I/II
Princeton, NJ (609) 750-5300
Armala™ GlaxoSmithKline (see also brain, breast, cervical, Phase I
pazopanib Rsch. Triangle Park, NC kidney, lung, ovarian, sarcoma, other) (888) 825-5249
ARQ-197 ArQule hepatocellular carcinoma Phase I
Woburn, MA (see also lung, pancreatic, (781) 994-0300
Daiichi Sankyo solid tumors) (973) 359-2600
Parsippany, NJ
Avastin® Genentech (see also brain, colorectal, Phase II
bevacizumab South San Francisco, CA head/neck, kidney, lung, lymphoma, (650) 225-1000
multiple myeloma, ovarian,
pancreatic, prostate, stomach, other)
AZD6244 AstraZeneca biliary cancer, liver cancer Phase II
Wilmington, DE (see also leukemia, lung, multiple (800) 236-9933
myeloma, ovarian, pancreatic, skin,
other)
batabulin Amgen Phase III
Thousand Oaks, CA (805) 447-1000
belinostat TopoTarget USA inoperable/unresectable liver cancer Phase I/II
Rockaway, NJ (see also bladder, colorectal, (973) 895-6900
leukemia, lung, lymphoma, ovarian)
brivanib Bristol-Myers Squibb hepatocellular carcinoma Phase III
(VEGFR/FGFR Princeton, NJ (see also colorectal) (212) 546-4000
kinase inhibitor)
CRS-100 Cerus Phase I
Concord, CA (925) 288-6000
darinaparsin ZIOPHARM Oncology (see also leukemia, Phase II completed
(ZIO-101) New York, NY multiple myeloma, solid tumors) (646) 214-0700
DENSPM Genzyme Phase I/II
(Orphan Drug) Cambridge, MA (617) 252-7500

32 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
LIVER CANCER
Product Name Sponsor Indication Development Status
doxorubicin Delcath Systems Phase II
(percutaneous New York, NY (212) 489-2100
hepatic perfusion)
EHC-18 Enzo BioChem Phase I
New York, NY (212) 583-0100
eniluracil Adherex Technologies (see also solid tumors) Phase I/II
Durham, NC (919) 484-8484
ferucarbotran Bayer HealthCare liver cancer imaging application submitted
Pharmaceuticals (888) 842-2937
Wayne, NJ
GC-33 Chugai Pharma USA Phase I
Berkeley Heights, NJ (908) 516-1350
IMC-1121B Eli Lilly (see also breast, colorectal, kidney, Phase II
Indianapolis, IN lung, ovarian, prostate, skin) (800) 545-5979
ImClone Systems (212) 645-1405
New York, NY
IMC-A12 Eli Lilly (see also breast, colorectal, Phase II
Indianapolis, IN head/neck, lung, pancreatic, (800) 545-5979
ImClone Systems prostate, sarcoma, solid tumors) (212) 645-1405
New York, NY
irinotecan Biocompatibles metastatic liver cancer from Phase II
eluting beads International colorectal cancer www.biocompatibles.com
Surrey, United Kingdom
JX-594 Jennerex Biotherapeutics (see also solid tumors) Phase II
San Francisco, CA (415) 281-8886
mapatumumab Human Genome Sciences (see also lung, multiple myeloma) Phase I/II
Rockville, MD (301) 309-8504
MB-7133 Metabasis Therapeutics inoperable, unresectable Phase I/II
(Orphan Drug) La Jolla, CA liver cancer (858) 587-2770
melphalan drug Delcath Systems Phase III
delivery system New York, NY (212) 489-2100
NV1020 MediGene Phase I/II
San Diego, CA (858) 586-2240
patupilone Novartis Pharmaceuticals (see also brain, breast, colorectal, Phase II
(EPO906) East Hanover, NJ lung, ovarian) (888) 669-6682
Photofrin® PDT Axcan Pharma cholangiocarcinoma Phase II
porfimer sodium Birmingham, AL (205) 991-8085
PR-104 Proacta Therapeutics (see also lung) Phase I
San Diego, CA (858) 642-0386
SCH-58500 Schering-Plough (see also bladder, head/neck, Phase I
(p53 gene therapy) Kenilworth, NJ lung, cancer-related) (908) 298-4000
Sutent® Pfizer (see also breast, colorectal, lung, Phase III
sunitinib New York, NY pancreatic, prostate, sarcoma, (860) 732-5156
stomach)

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 33
LIVER CANCER
Product Name Sponsor Indication Development Status
tacatuzumab-Y-90 Immunomedics Phase I
(IMMU-105) Morris Plains, NJ (973) 605-8200
Tarceva® Genentech (see also bladder, brain, breast, Phase II
erlotinib South San Francisco, CA colorectal, head/neck, lung, other) (650) 224-1000
OSI Pharmaceuticals (800) 572-1932
Melville, NY
Thermodox™ Celsion inoperable, unresectable liver cancer Phase III
LTSDEL Columbia, MD (see also breast) (410) 290-5390
Thymitaq® YM BioSciences (see also colorectal, head/neck, Phase III
nolatrexed Wayne, PA lung, pancreatic, prostate) (610) 560-0600
(Orphan Drug)
TJ9 Tsumura Phase II
Tokyo, Japan www.tsumura.co.jp

LUNG CANCER
Product Name Sponsor Indication Development Status
1572932A GlaxoSmithKline non-small-cell lung cancer (NSCLC) Phase III
Rsch. Triangle Park, NC (888) 825-5249
Abraxane™ Abraxis BioScience NSCLC Phase III
albumin-bound Los Angeles, CA (see also head/neck, ovarian, (310) 883-1300
paclitaxel pancreatic, prostate, skin)
ABT-263 Abbott Laboratories small-cell-lung cancer (SCLC) Phase I/II
Abbott Park, IL (see also leukemia, lymphoma) (847) 937-6100
Genentech (650) 225-1000
South San Francisco, CA
ABT-751 Abbott Laboratories NSCLC Phase II
Abbott Park, IL (see also breast, colorectal, kidney) (847) 937-6100
ABT-869 Abbott Laboratories NSCLC Phase II
Abbott Park, IL (see also breast, kidney, liver) (847) 937-6100
Genentech (650) 225-1000
South San Francisco, CA
Actimid™ Celgene SCLC (combination therapy) Phase I/II
pomalidomide Summit, NJ (see also multiple myeloma, (908) 673-9000
pancreatic, prostate, sarcoma)
Advexin® Introgen Therapeutics NSCLC (combination therapy) Phase II
contusugene Austin, TX (see also bladder, brain, breast, (512) 708-9310
ladenovec head/neck, ovarian, prostate,
stomach)
--------------------------------------------------------------------------------------
bronchioloalveolar adenocarcinoma Phase I
(512) 708-9310
aflibercept sanofi-aventis second-line NSCLC Phase III
(VEGF-trap) Bridgewater, NJ (combination therapy) (800) 633-1610
Regeneron Pharmaceuticals (see also colorectal, pancreatic, (914) 345-7400
Tarrytown, NY prostate, other)

34 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
LUNG CANCER
Product Name Sponsor Indication Development Status
Alimta® Eli Lilly NSCLC (maintenance therapy) Phase III
pemetrexed Indianapolis, IN (see also breast, head/neck, ovarian) (800) 545-5979
AMG 102 Amgen SCLC Phase I/II
Thousand Oaks, CA (see also brain, colorectal, (805) 447-1000
kidney, stomach)
AMG 479 Amgen (see also breast, colorectal, Phase II
Thousand Oaks, CA pancreatic, sarcoma) (805) 447-1000
Amplimexon® AmpliMed (see also breast, multiple myeloma, Phase I
imexon Tucson, AZ pancreatic, prostate, skin) (520) 529-1000
amrubicin Celgene SCLC (second-line therapy) Phase III
(Orphan Drug) Summit, NJ (908) 673-9000
ANZ-207 Anza Therapeutics mesothelioma, NSCLC Phase I
Concord, CA (see also ovarian, pancreatic) (925) 288-6000
apomab Genentech NSCLC (combination therapy) Phase II
South San Francisco, CA (see also colorectal, lymphoma) (650) 225-1000
Armala™ GlaxoSmithKline NSCLC Phase II
pazopanib Rsch. Triangle Park, NC (see also brain, breast, cervical, (888) 825-5249
kidney, liver, ovarian, sarcoma,
other)
ARQ-197 ArQule NSCLC Phase I/II
Woburn, MA (see also liver, pancreatic, (781) 994-0300
Daiichi Sankyo solid tumors) (973) 359-2600
Parsippany, NJ
AT-101 Ascenta Therapeutics NSCLC, SCLC Phase II
San Diego, CA (see also lymphoma, prostate) (858) 436-1200
AV-951 AVEO Pharmaceuticals NSCLC Phase I/II
Cambridge, MA (see also kidney, stomach) (617) 299-5000
Avastin® Genentech SCLC Phase II
bevacizumab South San Francisco, CA (see also brain, colorectal, (650) 225-1000
head/neck, kidney, liver, lymphoma,
multiple myeloma, ovarian,
pancreatic, prostate, stomach, other)
axitinib Pfizer NSCLC (first-line therapy) Phase II
New York, NY (see also colorectal, kidney, (860) 732-5156
solid tumors, other)
AZD6244 AstraZeneca NSCLC Phase II
Wilmington, DE (see also leukemia, liver, (800) 236-9933
multiple myeloma, ovarian,
pancreatic, skin, other)
belinostat TopoTarget USA mesothelioma Phase II
Rockaway, NJ (see also bladder, colorectal, (973) 895-6900
leukemia, liver, lymphoma,
ovarian, stomach)
BIBF 1120 Boehringer Ingelheim NSCLC Phase III
Pharmaceuticals (see also solid tumors) (800) 243-0127
Ridgefield, CT

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 35
LUNG CANCER
Product Name Sponsor Indication Development Status
BIBW 2992 Boehringer Ingelheim NSCLC (second-line therapy) Phase II/III
Pharmaceuticals (see also brain, breast, head/neck) (800) 243-0127
Ridgefield, CT
BMS-690514 Bristol-Myers Squibb (see also solid tumors) in clinical trials
(ErbB/VEGF Princeton, NJ (212) 546-4000
receptor inhibitor)
Camptosar® Pfizer (see also cervical, pancreatic, application submitted
irinotecan New York, NY prostate) (860) 732-5156
canertinib Pfizer NSCLC Phase II
New York, NY (860) 732-5156
Capoxigem® Tragara Pharmaceuticals NSCLC (combination therapy) Phase II
apricoxib San Diego, CA (see also breast, pancreatic) (858) 350-6900
CBP501 Millennium mesothelioma (combination therapy) Phase II
Pharmaceuticals (see also solid tumors) (800) 390-5663
Cambridge, MA
cisplatin Transave Phase II
liposomal Monmouth Junction, NJ (732) 438-9434
conatumumab Amgen NSCLC Phase I/II
Thousand Oaks, CA (see also colorectal, pancreatic, (805) 447-1000
sarcoma)
CP-751871 Pfizer NSCLC (combination therapy), Phase III
New York, NY metastatic disease (860) 732-5156
(see also breast, colorectal, multiple
myeloma, prostate, sarcoma)
--------------------------------------------------------------------------------------
NSCLC (combination first-line Phase I/II
therapy) (860) 732-5156
CS-1017 Daiichi Sankyo NSCLC Phase II
Parsippany, NJ (see also other) (973) 359-2600
deforolimus ARIAD Pharmaceuticals NSCLC Phase II
(MK-8669) Cambridge, MA (see also breast, prostate, sarcoma, (617) 494-0400
Merck other) (800) 672-6372
Whitehouse Station, NJ
diflomotecan Biomeasure (Ipsen) SCLC Phase II
Milford, MA (508) 478-0144
DMXAA Antisoma NSCLC (first-line therapy) Phase III
Cambridge, MA (see also prostate) (617) 225-0522
Novartis Pharmaceuticals (888) 669-6682
East Hanover, NJ
doxorubicin Zivena Phase II
inhaled Columbus, OH (614) 340-2370
EC-145 Endocyte late-stage NSCLC Phase II
West Lafayette, IN (see also ovarian, other) (765) 463-7175

36 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
LUNG CANCER
Product Name Sponsor Indication Development Status
Erbitux® Bristol-Myers Squibb advanced NSCLC, Phase III
cetuximab Princeton, NJ locally advanced NSCLC, (212) 546-4000
Eli Lilly first-line, second-line (800) 545-5979
Indianapolis, IN (see also bladder, colorectal, (212) 645-1405
ImClone Systems head/neck, prostate, stomach)
New York, NY
eribulin mesylate Eisai NSCLC Phase II
(E7389) Woodcliff Lake, NJ (see also breast, head/neck, ovarian, (888) 422-4743
prostate, sarcoma, solid tumors)
Gemzar® Eli Lilly metastatic SCLC Phase II
gemcitabine Indianapolis, IN (see also head/neck, lymphoma, (800) 545-5979
sarcoma)
Genasense® Genta NSCLC Phase II/III
oblimersen Berkeley Heights, NJ (see also breast, leukemia, (908) 286-9800
lymphoma, skin, solid tumors)
GI-4000 GlobeImmune NSCLC Phase II
Louisville, CO (see also pancreatic) (303) 625-2700
glufosfamide Threshold Pharmaceuticals SCLC Phase II
Redwood City, CA (see also breast, pancreatic, sarcoma) (650) 474-8200
GRN-163L Geron NSCLC (combination therapy) Phase I
Menlo Park, CA (see also breast, leukemia, (650) 473-7700
multiple myeloma)
Hycamtin® GlaxoSmithKline NSCLC Phase III
topotecan Rsch. Triangle Park, NC (see also breast, colorectal, (888) 825-5249
head/neck, kidney, leukemia,
lymphoma, multiple myeloma,
ovarian, pancreatic, prostate,
stomach, other)
HyperAcute® Lung NewLink Genetics NSCLC Phase I/II
lung cancer Ames, IA (515) 296-5555
vaccine
IMC-1121B Eli Lilly NSCLC Phase II
Indianapolis, IN (see also breast, colorectal, kidney, (800) 545-5979
ImClone Systems liver, ovarian, prostate, skin) (212) 645-1405
New York, NY
IMC-A12 Eli Lilly NSCLC (combination therapy) Phase II
Indianapolis, IN (see also breast, colorectal, (800) 545-5979
ImClone Systems head/neck, liver, pancreatic, (212) 645-1405
New York, NY prostate, sarcoma, solid tumors)
IMGN-901 ImmunoGen SCLC Phase II
Cambridge, MA (see also multiple myeloma) (617) 995-2500
IMO-2055 Idera Pharmaceuticals NSCLC (second-line therapy) Phase I
Cambridge, MA (see also colorectal, kidney) (617) 679-5500
INGN 225 Introgen Therapeutics SCLC Phase II
(p53 vaccine) Austin, TX (see also breast) (512) 708-9310
INGN 401 Introgen Therapeutics NSCLC Phase I
(nano-FUS-1) Austin, TX (512) 708-9310

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 37
LUNG CANCER
Product Name Sponsor Indication Development Status
Ixempra™ Bristol-Myers Squibb NSCLC in clinical trials
ixabepilone Princeton, NJ (see also breast, pancreatic, prostate) (212) 546-4000
JNJ-26854165 Johnson & Johnson NSCLC Phase I
Pharmaceutical Research (see also prostate) (800) 817-5286
& Development
Raritan, NJ
Karenitecin® BioNumerik NSCLC (intravenous) Phase II
cositecan Pharmaceuticals (see also brain, ovarian, skin) (210) 614-1701
San Antonio, TX --------------------------------------------------------------------------------------
NSCLC (oral) Phase I/II
(210) 614-1701
Levulan® PD DUSA Pharmaceuticals (see also bladder, cervical, in clinical trials
aminolevulinic acid Wilmington, MA colorectal, stomach) (978) 657-7500
Lucanix® NovaRx NSCLC Phase III
belagenpumatucel-L San Diego, CA (see also brain) (858) 552-8600
lung cancer AVAX Technologies NSCLC Phase I/II
vaccine Philadelphia, PA (215) 241-9760
lung cancer Pfizer NSCLC Phase I
vaccine New York, NY (860) 732-5156
(NY-ESO-1)
mapatumumab Human Genome Sciences NSCLC Phase II
Rockville, MD (see also liver, multiple myeloma) (301) 309-8504
milataxel Taxolog NSCLC Phase II
Fairfield, NJ (see also breast, colorectal) (877) 829-6564
MK-0646 Merck NSCLC Phase I/II
Whitehouse Station, NJ (see also breast, pancreatic, other) (800) 672-6372
MKC 1 EntreMed NSCLC Phase II
Rockville, MD (see also breast, leukemia, pancreatic) (240) 864-2600
MORAb-009 Eisai mesothelioma Phase II
Woodcliff Lake, NJ (see also ovarian, pancreatic) (888) 422-4743
--------------------------------------------------------------------------------------
NSCLC Phase I
(888) 422-4743
motesanib Amgen NSCLC (combination therapy) Phase III
Thousand Oaks, CA (see also breast, colorectal, other) (805) 447-1000
Millennium (800) 390-5663
Pharmaceuticals
Cambridge, MA
naptumomab Active Biotech NSCLC Phase I completed
estafenatox Lund, Sweden (see also kidney, pancreatic) www.activebiotech.com
neratinib Wyeth Pharmaceuticals NSCLC Phase II
(HKI272) Collegeville, PA (see also breast) (800) 934-5556

38 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
LUNG CANCER
Product Name Sponsor Indication Development Status
Nexavar® Bayer HealthCare NSCLC (combination therapy) Phase III
sorafenib Pharmaceuticals (see also breast, skin) (888) 842-2837
Wayne, NJ (510) 597-6500
Onyx Pharmaceuticals --------------------------------------------------------------------------------------
Emeryville, CA SCLC Phase II
(888) 842-2837
(510) 597-6500
NOV-002 Novelos Therapeutics NSCLC Phase III
Newton, MA (combination first-line therapy) (617) 244-1616
(see also breast, ovarian)
NPI-2358 Nereus Pharmaceuticals NSCLC Phase I
San Diego, CA (see also lymphoma) (858) 587-4090
obatoclax Gemin X Biotechnologies NSCLC, SCLC (combination therapy) Phase I/II
Montreal, Canada (see also leukemia, lymphoma) (514) 281-8989
OBP-301 Oncolys Biopharma mesothelioma Phase I
Tokyo, Japan (see also breast, head/neck) www.oncolys.com
OGX-011 Isis Pharmaceuticals NSCLC Phase I/II
(ISIS-112989) Carlsbad, CA (760) 931-9200
Oncogenex (425) 686-1500
Pharmaceuticals
Bothell, WA
OGX-427 Oncogenex NSCLC Phase I
Pharmaceuticals (see also bladder, breast, ovarian, (425) 686-1500
Bothell, WA prostate)
Onconase® Alfacell mesothelioma Phase III
ranpirnase Bloomfield, NJ (combination therapy) (973) 748-8082
(Orphan Drug) Strativa Pharmaceuticals --------------------------------------------------------------------------------------
Woodcliff Lake, NJ NSCLC Phase I/II
(973) 748-8082
Opaxio™ Cell Therapeutics NSCLC Phase III
paclitaxel Seattle, WA (see also ovarian, stomach, other) (800) 215-2355
poliglumex Novartis Pharmaceuticals (888) 669-6682
East Hanover, NJ
P-2045 Antisoma NSCLC, SCLC Phase I
Cambridge, MA (617) 225-0522
patupilone Novartis Pharmaceuticals NSCLC Phase II
(EPO906) East Hanover, NJ (see also brain, breast, colorectal, (888) 669-6682
liver, ovarian)
pelitinib Wyeth Pharmaceuticals NSCLC (second-line therapy) Phase II
(EKB569) Collegeville, PA (see also colorectal) (800) 934-5556
PF-299804 Pfizer NSCLC Phase II
New York, NY (860) 732-5156
picoplatin Poniard Pharmaceuticals SCLC Phase II
(Orphan Drug) Seattle, WA (see also colorectal) (206) 281-7001
plitidepsin PharmaMar USA SCLC Phase II
Cambridge, MA (see also multiple myeloma, prostate) (617) 868-3797

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 39
LUNG CANCER
Product Name Sponsor Indication Development Status
PR-104 Proacta Therapeutics NSCLC, SCLC Phase II
San Diego, CA (see also liver) (858) 642-0386
pralatrexate Allos Therapeutics NSCLC Phase II
(PDX) Westminster, CO (see also bladder, lymphoma) (303) 426-6262
ProMune® Pfizer NSCLC Phase II
agatolimod New York, NY (860) 732-5156
PS-095760 Ligand Pharmaceuticals NSCLC Phase II
San Diego, CA (see also leukemia) (858) 550-7500
Schering-Plough (908) 298-4000
Kenilworth, NJ
R1454 Roche NSCLC Phase I
Nutley, NJ (973) 235-5000
R1507 Roche NSCLC (combination therapy) Phase II
Nutley, NJ (see also breast, lymphoma, sarcoma) (973) 235-5000
Reolysin® Oncolytics Biotech NSCLC (combination therapy) Phase II
reovirus Calgary, Canada (see also brain, head/neck, sarcoma, (403) 670-7377
skin)
retaspimycin Infinity Pharmaceuticals NSCLC Phase II
(IPI 504) Cambridge, MA (see also breast, stomach) (617) 453-1000
S-1 Taiho Pharma USA NSCLC Phase II
Princeton, NJ (609) 750-5300
salirasib Concordia Pharmaceuticals NSCLC Phase II
Ft. Lauderdale, FL (see also pancreatic) www.concordiapharma.com
sapacitabine Cyclacel Pharmaceuticals NSCLC Phase II
Short Hills, NJ (see also leukemia, lymphoma) (973) 847-5955
satraplatin Spectrum Pharmaceuticals NSCLC (combination therapy) Phase II
Irvine, CA (see also breast, prostate) (949) 788-6700
SCH-58500 Schering-Plough NSCLC Phase II
(p53 gene therapy) Kenilworth, NJ (see also bladder, head/neck, (908) 298-4000
liver, cancer-related)
SCH-727965 Schering-Plough NSCLC Phase II
Kenilworth, NJ (see also breast, leukemia)) (908) 298-4000
seliciclib Cyclacel Pharmaceuticals NSCLC Phase II
Short Hills, NJ (see also other) (973) 847-5955
sibrotuzumab Life Science NSCLC Phase II
Pharmaceuticals (see also colorectal, head/neck) (203) 422-6500
Greenwich, CT
SNDX-275 Syndax Pharmaceuticals NSCLC Phase I/II
Waltham, MA (see also breast) (781) 839-7301
Stimuvax® EMD Serono NSCLC Phase III
BLP25 liposomal Rockland, MA (800) 283-8088
cancer vaccine Oncothyreon (425) 450-0370
Bellevue, WA

40 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
LUNG CANCER
Product Name Sponsor Indication Development Status
Sutent® Pfizer NSCLC (combination therapy, Phase III
sunitinib New York, NY second-line therapy) (860) 732-5156
(see also breast, colorectal, liver,
pancreatic, prostate, sarcoma,
stomach)
talactoferrin Agennix NSCLC Phase III
(Orphan Drug) Houston, TX (see also kidney) (713) 552-1091
Tarceva® Genentech NSCLC (combination therapy) Phase III
erlotinib South San Francisco, CA (see also bladder, brain, breast, (650) 225-1000
OSI Pharmaceuticals colorectal, head/neck, liver, (800) 572-1932
Melville, NY other)
Telcyta™ Telik NSCLC (third-line therapy) Phase III
canfosfimide Palo Alto, CA (see also breast, colorectal, (650) 845-7700
ovarian)
Temodar® Schering-Plough SCLC Phase II
temozolomide Kenilworth, NJ (see also leukemia) (908) 298-4000
TG-4010 Transgene Phase I
Kensington, MD (301) 816-5404
Thymitaq® YM BioSciences (see also colorectal, head/neck, liver, Phase II
nolatrexed Wayne, PA pancreatic, prostate) (610) 560-0600
topotecan Hana Biosciences SCLC Phase I
liposomal South San Francisco, CA (see also ovarian) (650) 588-6404
Torisel™ Wyeth Pharmaceuticals NSCLC Phase II
temsirolimus Collegeville, PA (see also colorectal, kidney, (800) 934-5556
lymphoma, multiple myeloma,
prostate)
tremelimumab Pfizer NSCLC Phase II
New York, NY (see also breast, colorectal, kidney, (860) 732-5156
prostate, skin)
Triapine® Vion Pharmaceuticals NSCLC Phase II
New Haven, CT (see also leukemia, pancreatic, (203) 498-4210
prostate)
tucotuzumab EMD Serono NSCLC, SCLC Phase II
celmoleukin Rockland, MA (see also colorectal, ovarian, (800) 283-8088
prostate)
Vectibix™ Amgen NSCLC Phase II
panitumumab Thousand Oaks, CA (see also head/neck) (805) 447-1000
Velcade® Millennium NSCLC (combination therapy, Phase II
bortezomib Pharmaceuticals metastatic disease, monotherapy, (800) 390-5663
Cambridge, MA second-line therapy)
(see also lymphoma, multiple
myeloma, solid tumors)
volociximab Biogen Idec NSCLC Phase II
Cambridge, MA (see also ovarian, pancreatic, skin) (617) 679-2000
Facet Biotech (650) 454-1000
Redwood City, CA

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 41
LUNG CANCER
Product Name Sponsor Indication Development Status
Xcytrin® Pharmacyclics NSCLC Phase II
motexafin Sunnyvale, CA (see also brain, kidney, leukemia, (408) 774-0330
gadolinium lymphoma)
XL-647 Exelixis NSCLC (first-line therapy, Phase II
South San Francisco, CA second-line therapy) (650) 837-7000
Zactima™ AstraZeneca NSCLC Phase III
vandetanib Wilmington, DE (see also brain, breast, other) (800) 236-9933
--------------------------------------------------------------------------------------
SCLC Phase II
(800) 236-9933
Zolinza® Merck mesothelioma Phase III
vorinostat Whitehouse Station, NJ (see also brain, breast, colorectal, (800) 672-6372
kidney, leukemia, lymphoma,
multiple myeloma)
Zybrestat™ OXiGENE NSCLC (first-line therapy) Phase II
fosbretabulin Waltham, MA (see also head/neck, ovarian, other) (781) 547-5900

LYMPHOMA
Product Name Sponsor Indication Development Status
461364 GlaxoSmithKline non-Hodgkin’s lymphoma Phase I
Rsch. Triangle Park, NC (see also solid tumors) (888) 825-5249
690693 GlaxoSmithKline (see also solid tumors) Phase I
Rsch. Triangle Park, NC (888) 825-5249
743921 Cytokinetics non-Hodgkin’s lymphoma Phase I/II
South San Francisco, CA (650) 624-3000
--------------------------------------------------------------------------------------
Hodgkin’s disease Phase I
(650) 624-3000
1018 ISS Dynavax Technologies non-Hodgkin’s lymphoma Phase II
Berkeley, CA (see also colorectal) (510) 848-5100
ABT-263 Abbott Laboratories (see also leukemia, lung) Phase I/II
Abbott Park, IL (847) 937-6100
Genentech (650) 225-1000
South San Francisco, CA
AME-133 Applied Molecular non-Hodgkin’s lymphoma Phase I/II
Evolution (858) 597-4990
San Diego, CA
AMG 951 Amgen non-Hodgkin’s lymphoma Phase II
(rhApo2L/TRAIL) Thousand Oaks, CA (see also colorectal) (805) 447-1000
Genentech (650) 225-1000
South San Francisco, CA
apomab Genentech non-Hodgkin’s lymphoma Phase II
South San Francisco, CA (combination therapy) (650) 225-1000
(see also colorectal, lung)

42 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
LYMPHOMA
Product Name Sponsor Indication Development Status
AR-726 Antigenics non-Hodgkin’s lymphoma Phase I
New York, NY (see also colorectal) (212) 994-8200
AT-101 Ascenta Therapeutics non-Hodgkin’s lymphoma Phase II
San Diego, CA (see also lung, prostate) (858) 436-1200
atacicept EMD Serono non-Hodgkin’s lymphoma Phase I
(TACI-Ig) Rockland, MA (see also leukemia, (800) 283-8088
ZymoGenetics multiple myeloma) (206) 442-6600
Seattle, WA
AV-299 AVEO Pharmaceuticals (see also solid tumors) Phase I
(SCH-90015) Cambridge, MA (617) 299-5000
Schering-Plough
Kenilworth, NJ
Avastin® Genentech diffuse large B-cell lymphoma Phase III
bevacizumab South San Francisco, CA (first-line therapy) (650) 225-1000
(see also brain, colorectal, head/neck,
kidney, liver, lung, multiple myeloma,
ovarian, pancreatic, prostate,
stomach, other)
--------------------------------------------------------------------------------------
non-Hodgkin’s lymphoma Phase II
(650) 225-1000
AZD4877 AstraZeneca (see also leukemia) Phase I
Wilmington, DE (800) 236-9933
bectumomab Immunomedics non-Hodgkin’s lymphoma Phase II
Morris Plains, NJ imaging agent (973) 605-8200
belinostat TopoTarget USA peripheral T-cell lymphoma Phase III
Rockaway, NJ (see also bladder, colorectal, (973) 895-6900
leukemia, liver, lung, ovarian)
--------------------------------------------------------------------------------------
cutaneous T-cell lymphoma, Phase II
non-Hodgkin’s lymphoma, (973) 895-6900
thymoma
Bexxar® GlaxoSmithKline (see also leukemia, cancer-related) Phase II
tositumomab Rsch. Triangle Park, NC (888) 825-5249
BI 2536 Boehringer Ingelheim non-Hodgkin’s lymphoma Phase I
Pharmaceuticals (800) 243-0127
Ridgefield, CT
BiovaxID™ Accentia non-Hodgkin’s lymphoma Phase III
B-cell lymphoma BioPharmaceuticals (813) 864-2554
vaccine Tampa, FL
CAL-101 Calistoga Pharmaceuticals non-Hodgkin’s lymphoma Phase I
Seattle, WA (see also leukemia) (206) 728-4700
CAT-8015 MedImmune non-Hodgkin’s lymphoma Phase I
Gaithersburg, MD (see also leukemia) (301) 398-0000
cilengitide EMD Serono late-stage lymphoma Phase I
Rockland, MA (see also brain, prostate, (800) 283-8088
solid tumors)

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 43
LYMPHOMA
Product Name Sponsor Indication Development Status
Clearazide™ Yaupon Therapeutics cutaneous T-cell lymphoma Phase III
Radnor, PA (610) 975-9290
Clolar® Genzyme B-cell lymphoma, Phase I/II
clofarabine Cambridge, MA non-Hodgkin’s lymphoma (617) 252-7500
(see also leukemia)
crinobulin EpiCept (see also solid tumors) Phase I
Tarrytown, NY (914) 606-3500
CT-011 CureTech B-cell lymphoma Phase II
Yavne, Israel www.curetechbio.com
dacetuzumab Genentech diffuse large B-cell lymphoma Phase II
(anti-CD40) South San Francisco, CA (see also leukemia, (650) 225-1000
Seattle Genetics multiple myeloma) (425) 527-4000
Bothell, WA --------------------------------------------------------------------------------------
non-Hodgkin’s lymphoma Phase I
(650) 225-1000
(425) 527-4000
denenicokin ZymoGenetics non-Hodgkin’s lymphoma Phase I
(IL-21) Seattle, WA (combination therapy) (206) 442-6600
(see also colorectal, kidney,
ovarian, skin)
DI-Leu16-IL2 EMD Serono non-Hodgkin’s lymphoma Phase I
Rockland, MA (800) 283-8088
Provenance (781) 491-9888
Biopharmaceuticals
Waltham, MA
elsamitrucin Spectrum non-Hodgkin’s lymphoma Phase II completed
Pharmaceuticals (949) 788-6700
Irvine, CA
enzastaurin Eli Lilly non-Hodgkin’s lymphoma Phase III
(LY317615) Indianapolis, IN (see also brain, breast, colorectal, (800) 545-5979
multiple myeloma, ovarian, prostate)
EZN-2968 Enzon Pharmaceuticals (see also solid tumors) Phase I
Bridgewater, NJ (866) 792-5172
Fodosine™ BioCryst Pharmaceuticals cutaneous T-cell lymphoma Phase III
forodesine Birmingham, AL (see also leukemia) (205) 444-4600
--------------------------------------------------------------------------------------
T-cell lymphoma Phase II
(205) 444-4600
fostamatinib Rigel Pharmaceuticals B-cell lymphoma, Phase II
South San Francisco, CA T-cell lymphoma (650) 624-1100
GA101 Biogen Idec B-cell lymphoma, Phase II
Cambridge, MA non-Hodgkin’s lymphoma (617) 679-2000
Genentech (650) 225-1000
South San Francisco, CA
galiximab Biogen Idec non-Hodgkin’s lymphoma Phase III
(anti-CD80 mAb) Cambridge, MA (617) 679-2000

44 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
LYMPHOMA
Product Name Sponsor Indication Development Status
GCS-100 Prospect Therapeutics diffuse large B-cell lymphoma Phase I/II
Woburn, MA (combination therapy) (781) 939-5750
(see also leukemia,
multiple myeloma)
Gemzar® Eli Lilly (see also head/neck, lung, sarcoma) Phase II
gemcitabine Indianapolis, IN (800) 545-5979
Genasense® Genta non-Hodgkin’s lymphoma Phase II
oblimersen Berkeley Heights, NJ (see also breast, leukemia, lung, (908) 286-9800
skin, solid tumors)
GMX-1777 Gemin X Biotechnologies (see also skin, solid tumors) Phase I
Montreal, Canada (514) 281-8989
GS-9219 Gilead Sciences non-Hodgkin’s lymphoma Phase I/II
Foster City, CA (see also leukemia) (800) 445-3235
Hycamtin® GlaxoSmithKline non-Hodgkin’s lymphoma Phase II
topotecan Rsch. Triangle Park, NC (see also breast, colorectal, (888) 825-5249
head/neck, kidney, leukemia, lung,
multiple myeloma, ovarian,
pancreatic, prostate, stomach, other)
iboctadekin GlaxoSmithKline non-Hodgkin’s lymphoma Phase I
Rsch. Triangle Park, NC (combination therapy) (888) 825-5249
(see also ovarian)
Idamycin® Pfizer non-Hodgkin’s lymphoma Phase III
idarubicin New York, NY (see also multiple myeloma) (860) 732-5156
inotuzumab UCB non-Hodgkin’s lymphoma, Phase III
ozogamicin Smyrna, GA (combination therapy) (770) 970-7500
Wyeth Pharmaceuticals (800) 934-5556
Collegeville, PA
iratumumab Medarex Hodgkin’s disease, lymphoma, Phase II
(MDX-060) Princeton, NJ non-Hodgkin’s lymphoma (609) 430-2880
(Orphan Drug)
IT-101 Calando Pharmaceuticals (see also ovarian) Phase II
Pasadena, CA (626) 683-7200
Leukine® Bayer HealthCare non-Hodgkin’s lymphoma Phase II
sargramostim Pharmaceuticals (see also leukemia, ovarian, (888) 842-2937
Wayne, NJ prostate, skin)
lucatumumab Novartis Pharmaceuticals (see also multiple myeloma) Phase I/II
East Hanover, NJ (888) 669-6682
XOMA (510) 204-7200
Berkeley, CA
LY2469298 Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
LymphoCide® Immunomedics non-Hodgkin’s lymphoma Phase II
epratuzumab Morris Plains, NJ (see also leukemia) (973) 605-8200
(Orphan Drug)
MDX-1401 Medarex Hodgkin’s disease Phase I
Princeton, NJ (609) 430-2880

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 45
LYMPHOMA
Product Name Sponsor Indication Development Status
MGCD-0103 MethylGene B-cell lymphoma, Phase II
Montreal, Canada Hodgkin’s disease, (514) 337-3333
non-Hodgkin’s lymphoma
(see also leukemia, solid tumors)
milatuzumab Immunomedics non-Hodgkin’s lymphoma Phase I/II
(IMMU-115) Morris Plains, NJ (see also leukemia, multiple (973) 605-8200
myeloma)
MLN8237 Millennium non-Hodgkin’s lymphoma Phase II
Pharmaceuticals (see also brain, leukemia, (800) 390-5663
Cambridge, MA solid tumors)
Nipent® Hospira cutaneous T-cell lymphoma application submitted
pentostatin Lake Forest, IL (see also leukemia, cancer-related) (224) 212-2000
(Orphan Drug) --------------------------------------------------------------------------------------
non-Hodgkin’s lymphoma Phase II
(224) 212-2000

NPI-0052 Nereus Pharmaceuticals (see also multiple myeloma, Phase I


San Diego, CA solid tumors) (858) 587-4090
NPI-2358 Nereus Pharmaceuticals (see also lung) Phase I
San Diego, CA (858) 587-4090
obatoclax Gemin X Biotechnologies follicular lymphoma, Phase II
Montreal, Canada Hodgkin’s disease (514) 281-8989
(see also leukemia, lung)
--------------------------------------------------------------------------------------
mantle-cell lymphoma Phase I
(combination therapy) (514) 281-8989
ofatumumab GlaxoSmithKline non-Hodgkin’s lymphoma Phase III
Rsch. Triangle Park, NC (second-line therapy) (888) 825-5249
(see also leukemia)
--------------------------------------------------------------------------------------
non-Hodgkin’s lymphoma Phase II
(first-line therapy), Waldenström’s (888) 825-5249
macroglobulinemia
Oncaspar® Enzon Pharmaceuticals combination therapy Phase I
pegaspargase Bridgewater, NJ (see also solid tumors) (866) 792-5172
ortatexal Spectrum Pharmaceuticals non-Hodgkin’s lymphoma Phase II
Irvine, CA (see also kidney) (949) 788-6700
P276 Piramal Life Sciences mantle-cell lymphoma Phase II
Mumbai, India (see also multiple myeloma)
panobinostat Novartis Pharmaceuticals cutaneous T-cell lymphoma Phase II/III
East Hanover, NJ (see also brain, breast, leukemia, (888) 669-6682
prostate)
--------------------------------------------------------------------------------------
Hodgkin’s disease Phase II
(888) 669-6682
PCI-32765 Pharmacyclics B-cell lymphoma Phase I
Sunnyvale, CA (408) 774-0330

46 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
LYMPHOMA
Product Name Sponsor Indication Development Status
PD-332991 Pfizer mantle-cell lymphoma Phase I
New York, NY (see also breast, multiple myeloma) (860) 732-5156
perifosine AEterna Zentaris Waldenström’s macroglobulinemia Phase II
Montreal, Canada (see also brain, head/neck, kidney, (212) 531-5965
Keryx Biopharmaceuticals multiple myeloma, ovarian,
New York, NY sarcoma)
pixantrone Cell Therapeutics non-Hodgkin’s lymphoma Phase III
Seattle, WA (800) 215-2355
PM-00104 PharmaMar USA (see also solid tumors) Phase I
Cambridge, MA (617) 868-3797
pralatrexate Allos Therapeutics B-cell lymphoma, Phase II
(PDX) Westminster, CO peripheral T-cell lymphoma (303) 426-6262
(Orphan Drug) (see also bladder, lung)
--------------------------------------------------------------------------------------
Hodgkin’s disease, Phase I/II
non-Hodgkin’s lymphoma (303) 426-6262
--------------------------------------------------------------------------------------
cutaneous T-cell lymphoma Phase I
(303) 426-6262
PRO-131921 Genentech non-Hodgkin’s lymphoma Phase I/II
South San Francisco, CA (see also leukemia) (650) 224-1000
PX-478 Oncothyreon (see also solid tumors) Phase I
Seattle, WA (206) 801-2100
R1507 Roche Hodgkin’s disease, Phase I
Nutley, NJ non-Hodgkin’s lymphoma (973) 235-5000
(see also breast, lung, sarcoma)
Revlimid® Celgene mantle-cell lymphoma, Phase II
lenalidomide Summit, NJ non-Hodgkin’s lymphoma (908) 673-9000
(see also leukemia, multiple
myeloma, prostate, other)
RH-1 Allos Therapeutics non-Hodgkin’s lymphoma Phase I
Westminster, CO (see also solid tumors) (303) 426-6262
romidepsin Gloucester Pharmaceuticals cutaneous T-cell lymphoma, Phase II
(Orphan Drug) Cambridge, MA peripheral T-cell lymphoma (617) 583-1300
(see also kidney, multiple myeloma,
pancreatic, prostate)
sapacitabine Cyclacel Pharmaceuticals cutaneous T-cell lymphoma Phase II
Short Hills, NJ (see also leukemia, lung) (973) 847-5955
SAR3419 sanofi-aventis non-Hodgkin’s lymphoma Phase I
Bridgewater, NJ (800) 633-1610
sardomozide Novartis Pharmaceuticals non-Hodgkin’s lymphoma Phase II
East Hanover, NJ (see also solid tumors) (888) 669-6682
SB-1518 S*Bio (see also leukemia) Phase I
Redwood City, CA (650) 730-2860
SCH-900776 Schering-Plough (see also solid tumors) Phase I
Kenilworth, NJ (908) 298-4000

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 47
LYMPHOMA
Product Name Sponsor Indication Development Status
SGN-30 Seattle Genetics cutaneous T-cell lymphoma, Phase II
(Orphan Drug) Bothell, WA Hodgkin’s disease (425) 527-4000
SGN-35 Seattle Genetics Hodgkin’s disease Phase II
(Orphan Drug) Bothell, WA (see also leukemia) (425) 527-4000
SNS-032 Sunesis Pharmaceuticals B-cell lymphoma Phase I
South San Francisco, CA (see also solid tumors) (650) 266-3500
stem cell therapy Benitec AIDS-related lymphoma Phase I
Melbourne, Australia
City of Hope
Medical Center
Duarte, CA
TG-1042 Transgene cutaneous B-cell lymphoma Phase II
Kensington, MD (301) 816-5404
TNX-650 Genentech refractory metastatic Hodgkin’s Phase I/II
South San Francisco, CA disease (650) 225-1000
Torisel™ Wyeth Pharmaceuticals mantle-cell lymphoma Phase III
temsirolimus Collegeville, PA (see also colorectal, kidney, lung, (800) 934-5556
multiple myeloma, prostate)
UNBS-5162 Drais Pharmaceuticals (see also solid tumors) Phase I
Bridgewater, NJ (908) 895-1200
Velcade® Millennium non-Hodgkin’s lymphoma Phase III
bortezomib Pharmaceuticals (see also lung, multiple myeloma, (800) 390-5663
Cambridge, MA solid tumors)
veltuzumab Immunomedics non-Hodgkin’s lymphoma Phase I/II
(IMMU-106) Morris Plains, NJ (see also cancer-related) (973) 605-8200
Vidaza® Celgene (see also leukemia, prostate) Phase I
azacitidine Summit,NJ (908) 673-9000
vinorelbine Hana Biosciences non-Hodgkin’s lymphoma Phase I
liposomal South San Francisco, CA (see also solid tumors) (650) 588-6404
Xcytrin® Pharmacyclics lymphoma, non-Hodgkin’s lymphoma Phase II
motexafin Sunnyvale, CA (see also brain, kidney, leukemia, (408) 774-0330
gadolinium lung)
XmAb 2513 Xencor Hodgkin’s disease, Phase I
Monrovia, CA T-cell lymphoma (626) 305-5900
YM-155 Astellas Pharma US refractory, metastatic diffuse large Phase II
Deerfield, IL B-cell lymphoma (800) 727-7003
(see also prostate)
ZEN-012 AEterna Zentaris (see also solid tumors) Phase I
Warren, NJ (908) 626-5428
Zevalin® Spectrum Pharmaceuticals non-Hodgkin’s lymphoma application submitted
ibritumomab Irvine, CA (first-line therapy) (949) 788-6700
tiuxetan
Zolinza® Merck B-cell lymphoma, lymphoma Phase II
vorinostat Whitehouse Station, NJ (see also brain, breast, colorectal, (800) 672-6372
kidney, leukemia, lung,
multiple myeloma)

48 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
MULTIPLE MYELOMA
Product Name Sponsor Indication Development Status
Actimid™ Celgene (see also lung, pancreatic, prostate, Phase I/II
pomalidomide Summit, NJ sarcoma) (908) 673-9000
Amplimexon® AmpliMed (see also breast, lung, pancreatic, Phase I/II completed
imexon Tucson, AZ prostate, skin) (520) 529-1000
anti-MUC1 mAb Paladin Labs (see also breast, pancreatic) Phase I completed
St. Laurent, Canada (888) 376-7830
Aredia® Novartis Pharmaceuticals (see also cancer-related) Phase II
pamidronic acid East Hanover, NJ (888) 669-6682
atacicept EMD Serono (see also leukemia, lymphoma) Phase II
(TACI-Ig) Rockland, MA (800) 283-8088
ZymoGenetics (206) 442-6600
Seattle, WA
ATN-224 Attenuon (see also prostate, skin) Phase I/II
San Diego, CA (858) 558-4111
AUY922 Novartis Pharmaceuticals (see also solid tumors) Phase I/II
East Hanover, NJ (888) 669-6682
Avastin® Genentech combination therapy Phase II
bevacizumab South San Francisco, CA (see also brain, colorectal, (650) 225-1000
head/neck, kidney, liver, lung,
lymphoma, ovarian, pancreatic,
prostate, stomach, other)
AZD6244 AstraZeneca (see also leukemia, liver, lung, Phase II
Wilmington, DE ovarian, pancreatic, skin, other) (800) 236-9933
BIW 8962 BioWa Phase I/II
Princeton, NJ (609) 734-3420
carfilzomib Proteolix monotherapy Phase II
(Orphan Drug) South San Francisco, CA (see also leukemia, solid tumors) (650) 615-7550
--------------------------------------------------------------------------------------
combination therapy Phase I
(650) 615-7550
CEP-18770 Cephalon Phase I
Frazer, PA (610) 344-0200
CP-751871 Pfizer (see also breast, colorectal, lung, Phase I completed
New York, NY prostate, sarcoma) (860) 732-5156
CX-4945 Cylene Pharmaceuticals (see also solid tumors, other) Phase I
San Diego, CA (858) 875-5100
dacetuzumab Genentech (see also leukemia, lymphoma) Phase I
(anti-CD40) South San Francisco, CA (650) 225-1000
(Orphan Drug) Seattle Genetics (425) 527-4000
Bothell, WA
darinaparsin Ziopharm Oncology (see also leukemia, liver, Phase II
(ZIO-101) New York, NY solid tumors) (646) 214-0700
denosumab Amgen (see also cancer-related, other) Phase III
(AMG 162) Thousand Oaks, CA (805) 447-1000

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 49
MULTIPLE MYELOMA
Product Name Sponsor Indication Development Status
elotuzumab Bristol-Myers Squibb Phase I
Princeton, NJ (212) 546-4000
Facet Biotech (650) 454-1000
Redwood City, CA
ENMD-2076 EntreMed (see also solid tumors) Phase I
Rockville, MD (240) 864-2600
enzastaurin Eli Lilly (see also brain, breast, colorectal, Phase II
(LY317615) Indianapolis, IN lymphoma, ovarian, prostate) (800) 545-5979
GCS-100 Prospect Therapeutics (see also leukemia, lymphoma) Phase I
Woburn, MA (781) 939-5750
GRN-163L Geron (see also breast, leukemia, lung) Phase I
Menlo Park, CA (650) 473-7700
Hycamtin® GlaxoSmithKline (see also breast, colorectal, in clinical trials
topotecan Rsch. Triangle Park, NC head/neck, kidney, leukemia, lung, (888) 825-5249
lymphoma, ovarian, pancreatic,
prostate, stomach, other)
Idamycin® Pfizer (see also lymphoma) Phase III
idarubicin New York, NY (860) 732-5156
IMGN-901 ImmunoGen (see also lung) Phase I
Cambridge, MA (617) 995-2500
INCB-18424 Incyte (see also prostate) Phase II
Wilmington, DE (302) 498-6700
IPH-2101 Innate Pharma Phase I
Marseille, France www.innate-pharma.com
KRX-0402 Keryx Biopharmaceuticals (see also brain, colorectal, kidney, Phase II
New York, NY sarcoma) (212) 531-5965
lestaurtinib Cephalon (see also leukemia) Phase II
Frazer, PA (610) 344-0200
lucatumumab Novartis Pharmaceuticals (see also lymphoma) Phase I
East Hanover, NJ (888) 669-6682
XOMA (510) 204-7200
Berkeley, CA
LY2127399 Eli Lilly Phase II
Indianapolis, IN (800) 545-5979
mapatumumab Human Genome Sciences (see also liver, lung) Phase II
Rockville, MD (301) 309-8504
milatuzumab Immunomedics (see also leukemia, lymphoma) Phase I/II
(IMMU-115) Morris Plains, NJ (973) 605-8200
natalizumab Biogen Idec Phase I/II
Cambridge, MA (617) 679-2000
noscapine Cougar Biotechnology Phase I/II
Los Angeles, CA (310) 943-8040
NPI-0052 Nereus Pharmaceuticals (see also lymphoma, solid tumors) Phase I
San Diego, CA (858) 587-4090

50 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
MULTIPLE MYELOMA
Product Name Sponsor Indication Development Status
P276 Piramal Life Sciences (see also lymphoma) Phase I
Mumbai, India
PD-332991 Pfizer combination therapy Phase I/II
New York, NY (see also breast, lymphoma) (860) 732-5156
perifosine AEterna Zentaris (see also brain, head/neck, Phase II
Montreal, Canada kidney, lymphoma, ovarian, (212) 531-5965
Keryx Biopharmaceuticals sarcoma)
New York, NY
plitidepsin PharmaMar USA (see also lung, prostate) Phase II
(Orphan Drug) Cambridge, MA (617) 868-3797
Quadramet® Cytogen (see also prostate, sarcoma, Phase I/II
samarium sm-153 Princeton, NJ other) (800) 833-3533
lexidronam
injection
Revlimid® Celgene newly-diagnosed multiple myeloma Phase III
lenalidomide Summit, NJ (see also leukemia, lymphoma, (908) 673-9000
prostate, other)
romidepsin Gloucester Pharmaceuticals (see also kidney, lymphoma, Phase II
Cambridge, MA pancreatic, prostate) (617) 583-1300
SF1126 Semafore Pharmaceuticals (see also solid tumors) Phase I
Indianapolis, IN (317) 876-3075
tanespimycin Bristol-Myers Squibb (see also solid tumors) Phase III
(Hsp90 inhibitor) Princeton, NJ (212) 546-4000
Torisel™ Wyeth Pharmaceuticals (see also colorectal, kidney, lung, Phase I/II
temsirolimus Collegeville, PA lymphoma, prostate) (800) 934-5556
Treanda® Cephalon Phase II
bendamustine Frazer, PA (610) 344-0200
Trisenox® Cephalon combination therapy Phase II
arsenic trioxide Frazer, PA (see also brain, leukemia) (610) 344-0200
VEL-0230 Velcura Therapeutics Phase I completed
Ann Arbor, MI (734) 973-1000
Velcade® Millennium previously untreated multiple Phase III
bortezomib Pharmaceuticals myeloma (800) 390-5663
(subcutaneous) Cambridge, MA (see also lung, lymphoma, solid
tumors)
Zolinza® Merck (see also brain, breast, colorectal, Phase III
vorinostat Whitehouse Station, NJ kidney, leukemia, lung, lymphoma) (800) 672-6372
ZRx101 ZelleRx (see also kidney, skin, Phase I
Chicago, IL cancer-related) (312) 243-5200

O VA R I A N C A N C E R
Product Name Sponsor Indication Development Status
°
A6 Angstrom Pharmaceuticals (see also other) Phase II
Solana Beach, CA (858) 314-2356

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 51
O VA R I A N C A N C E R
Product Name Sponsor Indication Development Status
abagovomab Menarini Phase II/III
(anti-idiotype Florence, Italy www.menarini.com
ovarian cancer
vaccine)
Abraxane™ Abraxis BioScience (see also head/neck, lung, Phase II
albumin-bound Los Angeles, CA pancreatic, prostate, skin) (310) 883-1300
paclitaxel
Advexin® Introgen Therapeutics (see also bladder, brain, breast, Phase I
contusugene Austin, TX head/neck, lung, prostate, stomach) (512) 708-9310
ladenovec
AE-37 Antigen Express combination therapy Phase I
Worcester, MA (see also breast) (508) 852-8783
AG-14699 Pfizer (see also breast) Phase II
New York, NY (860) 732-5156
AGS-8M4 Agensys Phase I
Santa Monica, CA (310) 820-8029
Astellas Pharma US (800) 477-6472
Deerfield, IL
Alimta® Eli Lilly (see also breast, head/neck, lung) Phase II
pemetrexed Indianapolis, IN (800) 545-5979
AMG 386 Amgen (see also breast, kidney, Phase II
Thousand Oaks, CA stomach, other) (805) 447-1000
ANZ-207 Anza Therapeutics (see also lung, pancreatic) Phase I
Concord, CA (925) 288-6000
Armala™ GlaxoSmithKline (see also brain, breast, cervical, Phase II
pazopanib Rsch. Triangle Park, NC kidney, liver, lung, sarcoma, other) (888) 825-5249
Avastin® Genentech (see also brain, colorectal, Phase III
bevacizumab South San Francisco, CA head/neck, kidney, liver, lung, (650) 225-1000
lymphoma, multiple myeloma,
pancreatic, prostate, stomach, other)
AZD2281 AstraZeneca (see also breast) Phase II
Wilmington, DE (800) 236-9933
AZD6244 AstraZeneca (see also leukemia, liver, lung, Phase II
Wilmington, DE multiple myeloma, pancreatic, skin, (800) 236-9933
other)
belinostat TopoTarget USA (see also bladder, colorectal, leukemia, Phase II
Rockaway, NJ liver, lung, lymphoma) (973) 895-6900
BMS-753493 Bristol-Myers Squibb in clinical trials
(epothilone-folate) Princeton, NJ (212) 546-4000
BSI-201 BiPar Sciences combination and monotherapy Phase II
Brisbane, CA (see also brain, breast, other) (650) 635-6050
catumaxomab Fresenius Biotech (see also other) Phase II
North America www.fresenius-biotech.com
Waltham, MA
CDX-1307 Celldex Therapeutics (see also bladder, breast, colorectal, Phase I
Needham, MA pancreatic) (781) 433-0771

52 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
O VA R I A N C A N C E R
Product Name Sponsor Indication Development Status
D4064A Genentech (see also other) Phase I
South San Francisco, CA (650) 224-1000
DCVax®-L Northwest Biotherapeutics Phase I/II
ovarian cancer Bothell, WA (425) 608-3000
vaccine
denenicokin ZymoGenetics (see also colorectal, kidney, Phase I/II
(IL-21) Seattle, WA lymphoma, skin) (206) 442-6600
EC-145 Endocyte (see also lung, other) Phase II
West Lafayette, IN (765) 463-7175
EGEN 001 Expression Genetics recurrent ovarian cancer Phase I
(Orphan Drug) Huntsville, AL (combination therapy) (256) 512-0077
Elacyt™ Clavis Pharma (see also leukemia, skin) Phase II
elacytarabine Oslo, Norway www.clavispharma.com
enzastaurin Eli Lilly combination therapy Phase II
(LY317615) Indianapolis, IN (see also brain, breast, colorectal, (800) 545-5979
lymphoma, multiple myeloma,
prostate)
eribulin mesylate Eisai (see also breast, head/neck, lung, Phase II
(E7389) Woodcliff Lake, NJ prostate, sarcoma, solid tumors) (888) 422-4743
farletuzumab Eisai Phase II/III
(MORAb-003) Woodcliff Lake, NJ (888) 422-4743
Herceptin® Genentech (see also colorectal, pancreatic, Phase II
trastuzumab South San Francisco, CA prostate, stomach, other) (650) 225-1000
Hycamtin® GlaxoSmithKline (see also breast, colorectal, Phase III
topotecan Rsch. Triangle Park, NC head/neck, kidney, leukemia, lung, (888) 825-5249
(oral) lymphoma, multiple myeloma,
pancreatic, prostate, stomach, other)
iboctadekin GlaxoSmithKline combination therapy Phase I
Rsch. Triangle Park, NC (see also lymphoma) (888) 825-5249
idronoxil Marshall Edwards combination therapy Phase III
North Ryde, Australia (see also prostate, other)
IMC-1121B Eli Lilly (see also breast, colorectal, kidney, Phase II
Indianapolis, IN liver, lung, prostate, skin) (800) 545-5979
ImClone Systems (212) 645-1405
New York, NY
IMT-1012 ImmunoVaccine (see also breast) Phase I
Technologies (902) 492-1819
Halifax, Canada
IT-101 Calando Pharmaceuticals (see also lymphoma) Phase II
Pasadena, CA (626) 683-7200
Karenitecin® BioNumerik (see also brain, lung, skin) Phase III
cositecan Pharmaceuticals (210) 614-1701
San Antonio, TX
lapuleucel-T Dendreon (see also breast, colorectal) Phase I completed
Seattle, WA (206) 256-4545

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 53
O VA R I A N C A N C E R
Product Name Sponsor Indication Development Status
Leukine® Bayer HealthCare (see also leukemia, lymphoma, Phase II
sargramostim Pharmaceuticals prostate, skin) (888) 842-2937
Wayne, NJ
MK-4827 Merck Phase I
Whitehouse Station, NJ (800) 672-6372
MORAb-009 Eisai (see also lung, pancreatic) Phase I
Woodcliff Lake, NJ (888) 422-4743
NKTR-102 Nektar Therapeutics metastatic ovarian cancer Phase II
San Carlos, CA (second-line therapy) (650) 631-3100
(see also colorectal)
NOV-002 Novelos Therapeutics combination therapy Phase II completed
Newton, MA (see also breast, lung) (617) 244-1616
oglufanide Implicit Bioscience Phase II
Woodside, CA (650) 851-3133
OGX-427 Oncogenex (see also bladder, breast, lung, Phase I
Pharmaceuticals prostate) (425) 686-1500
Bothell, WA
Opaxio™ Cell Therapeutics (see also lung, stomach, other) Phase III
paclitaxel Seattle, WA (800) 215-2355
poliglumex Novartis Pharmaceuticals (888) 669-6682
East Hanover, NJ
OvaRex® Paladin Labs Phase III
oregovomab St. Laurent, Canada (514) 340-1112
OVax® AVAX Technologies Phase I/II
ovarian cancer Philadelphia, PA (215) 241-9760
vaccine
(Orphan Drug)
patupilone Novartis Pharmaceuticals (see also brain, breast, colorectal, Phase III
(EPO906) East Hanover, NJ liver, lung) (888) 669-6682
perifosine AEterna Zentaris (see also brain, head/neck, kidney, Phase I
Montreal, Canada lymphoma, multiple myeloma, (212) 531-5965
Keryx Biopharmaceuticals sarcoma)
New York, NY
pertuzumab Genentech (see also breast) Phase II completed
South San Francisco, CA (650) 225-1000
plevitrexed BTG International Phase II
(BGC 9331) West Conshohocken, PA (610) 278-1660
(Orphan Drug)
Quinamed® ChemGenex (see also breast, prostate) Phase II
amonafide Pharmaceuticals (650) 474-9800
Menlo Park, CA
sagopilone Bayer HealthCare combination therapy Phase I/II
Pharmaceuticals (see also brain, breast, prostate) (888) 842-2937
Wayne, NJ
SNS-595 Sunesis Pharmaceuticals (see also leukemia) Phase II
South San Francisco, CA (650) 266-3500

54 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
O VA R I A N C A N C E R
Product Name Sponsor Indication Development Status
systemic hedgehog Genentech (see also brain, colorectal, skin) Phase II
antagonist South San Francisco, CA (650) 224-1000
tasisulam (ASAP) Eli Lilly (see also leukemia, sarcoma, skin) Phase II
Indianapolis, IN (800) 545-5979
Telcyta™ Telik (see also breast, colorectal, lung) Phase III
canfosfimide Palo Alto, CA (650) 845-7700
topotecan Hana Biosciences (see also lung) Phase I
liposomal South San Francisco, CA (650) 588-6404
tucotuzumab EMD Serono (see also colorectal, lung, prostate) Phase II
celmoleukin Rockland, MA (800) 283-8088
volociximab Biogen Idec (see also lung, pancreatic, skin) Phase II
Cambridge, MA (617) 679-2000
Facet Biotech (650) 454-1000
Redwood City, CA
Yondelis® Johnson & Johnson combination therapy, application submitted
trabectedin Pharmaceutical Research second-line therapy (800) 817-5286
(Orphan Drug) & Development (see also breast, prostate, sarcoma,
Raritan, NJ other)
Zybrestat™ OXiGENE (see also head/neck, lung, other) Phase II
fosbretabulin Waltham, MA (781) 547-5900
(Orphan Drug)
ZYC300 Eisai (see also breast, colorectal, kidney, Phase I
Woodcliff Lake, NJ prostate) (888) 422-4743

PANCREATIC CANCER
Product Name Sponsor Indication Development Status
Abraxane™ Abraxis BioScience (see also head/neck, lung, Phase I/II
albumin-bound Los Angeles, CA ovarian, prostate, skin) (310) 883-1300
paclitaxel
Actimid™ Celgene combination therapy Phase I/II
pomalidomide Summit, NJ (see also lung, multiple myeloma, (908) 673-9000
prostate, sarcoma)
aflibercept sanofi-aventis first-line metastatic Phase III
(VEGF-trap) Bridgewater, NJ pancreatic cancer (800) 633-1810
Regeneron Pharmaceuticals (combination therapy) (914) 345-7400
Tarrytown, NY (see also colorectal, lung,
prostate, other)
AMG 479 Amgen (see also breast, colorectal, lung, Phase I/II
Thousand Oaks, CA sarcoma) (805) 447-1000
Amplimexon® AmpliMed (see also breast, lung, multiple Phase II
imexon Tucson, AZ myeloma, prostate, skin) (520) 529-1000
anti-MUC1 mAb Paladin Labs (see also breast, multiple myeloma) Phase I completed
St. Laurent, Canada (888) 376-7830

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 55
PANCREATIC CANCER
Product Name Sponsor Indication Development Status
ANZ-207 Anza Therapeutics (see also lung, ovarian) Phase I
Concord, CA (925) 288-6000
ARQ-197 ArQule (see also liver, lung, solid tumors) Phase I/II
Woburn, MA (781) 994-0300
Daiichi Sankyo (973) 359-2600
Parsippany, NJ
ARQ-501 ArQule combination therapy, inoperable/ Phase II
(beta lapachone) Woburn, MA unresectable pancreatic cancer (781) 994-0300
(see also head/neck, solid tumors,
other)
Avastin® Genentech combination first-line therapy Phase III
bevacizumab South San Francisco, CA (see also brain, colorectal, (650) 225-1000
head/neck, kidney, liver, lung,
lymphoma, multiple myeloma,
ovarian, prostate, stomach, other)
--------------------------------------------------------------------------------------
pancreatic cancer Phase II
(650) 225-1000
AVN-944 Avalon Pharmaceuticals combination therapy Phase II
Germantown, MD (see also leukemia) (301) 556-9900
AZD6244 AstraZeneca (see also leukemia, liver, lung, Phase II
Wilmington, DE multiple myeloma, ovarian, (800) 236-9933
skin, other)
Camptosar® Pfizer (see also cervical, lung, prostate) Phase III
irinotecan New York, NY (860) 732-5156
Capoxigem® Tragara Pharmaceuticals combination therapy Phase II
apricoxib San Diego, CA (see also breast, lung) (858) 350-6900
CDX-1307 Celldex Therapeutics (see also bladder, breast, Phase I
Needham, MA colorectal, ovarian) (781) 433-0771
conatumumab Amgen (see also colorectal, lung, sarcoma) Phase I/II
Thousand Oaks, CA (805) 447-1000
everolimus Novartis Pharmaceuticals (see also kidney, other) Phase II
East Hanover, NJ (888) 669-6682
FG-3019 Fibrogen combination therapy Phase I
San Francisco, CA (415) 978-1200
GI-4000 GlobeImmune combination therapy Phase II
Louisville, CO (see also lung) (303) 625-2700
glufosfamide Threshold Pharmaceuticals (see also breast, lung, sarcoma) Phase III
(Orphan Drug) Redwood City, CA (650) 474-8200
Herceptin® Genentech (see also colorectal, ovarian, Phase II
trastuzumab South San Francisco, CA prostate, stomach, other) (650) 225-1000
Hycamtin® GlaxoSmithKline (see also breast, colorectal, Phase II
topotecan Rsch. Triangle Park, NC head/neck, kidney, leukemia, lung, (888) 825-5249
lymphoma, multiple myeloma,
ovarian, prostate, stomach, other)

56 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
PANCREATIC CANCER
Product Name Sponsor Indication Development Status
HyperAcute® NewLink Genetics Phase II
Pancreas Ames, IA (515) 296-5555
pancreatric
cancer vaccine
IMC-A12 Eli Lilly first-line combination therapy Phase I/II
Indianapolis, IN (see also breast, colorectal, (800) 545-5979
ImClone Systems head/neck, liver, lung, prostate, (212) 645-1405
New York, NY sarcoma, solid tumors)
Ixempra™ Bristol-Myers Squibb (see also breast, lung, prostate) in clinical trials
ixabepilone Princeton, NJ (212) 546-4000
larotaxel sanofi-aventis (see also bladder) Phase III
(XRP9881) Bridgewater, NJ (800) 633-1610
masitinib AB Science USA (see also leukemia, stomach) Phase III
Short Hills, NJ (973) 218-2437
MK-0646 Merck (see also breast, lung, other) Phase I/II
Whitehouse Station, NJ (888) 669-6682
MKC 1 EntreMed (see also breast, leukemia, lung) Phase II
Rockville, MD (240) 864-2600
MORAb-009 Eisai (see also lung, ovarian) Phase II
Woodcliff Lake, NJ (888) 422-4743
naptumomab Active Biotech (see also kidney, lung) Phase I completed
estafenatox Lund, Sweden www.activebiotech.com
OncoGel™ Protherics (see also brain, stomach) Phase II
Brentwood, TN (615) 327-1027
Oncophage® Antigenics (see also brain, colorectal, kidney, Phase I/II
vitespen New York, NY skin, stomach) (866) 805-8994
OncoVEX GM-CSF BioVex (see also skin) Phase I
Woburn, MA (781) 376-4900
PancAtak™ Advantagene Phase I
gene therapy Boston, MA (617) 916-5445
San Diego, CA (760) 943-8981
PN401 Wellstat Therapeutics (see also colorectal, stomach) Phase III
Gaithersburg, MD (240) 631-2500
PX-12 Oncothyreon (see also stomach, other) Phase II
Seattle, WA (206) 801-2100
RAV-12 Raven Biotechnologies combination therapy Phase II
South San Francisco, CA (see also other) (650) 624-2600
Rexin-G™ Epeius Biotechnologies recurrent, refractory metastatic Phase I/II
tumor-targeted San Marino, CA pancreatic cancer (626) 441-6695
gene therapy (see also breast, sarcoma)
(Orphan Drug)
romidepsin Gloucester (see also kidney, lymphoma, Phase I/II
Pharmaceuticals multiple myeloma, prostate) (617) 583-1300
Cambridge, MA
RP-101 SciClone Pharmaceuticals Phase II
(Orphan Drug) Foster City, CA (650) 358-3456

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 57
PANCREATIC CANCER
Product Name Sponsor Indication Development Status
RTA-402 Reata Pharmaceuticals combination therapy Phase I/II
Dallas, TX (see also leukemia) (972) 865-2200
salirasib Concordia Pharmaceuticals (see also lung) Phase I/II
(Orphan Drug) Ft. Lauderdale, FL www.concordiapharma.com
Sarasar™ Schering-Plough (see also breast, leukemia) Phase II
lonafarnib Kenilworth, NJ (908) 298-4000
Sutent® Pfizer (see also breast, colorectal, liver, Phase III
sunitinib New York, NY lung, prostate, sarcoma, stomach) (860) 732-5156
Thymitaq® YM BioSciences (see also colorectal, head/neck, Phase II
nolatrexed Wayne, PA liver, lung, prostate) (610) 560-0600
tigatuzumab Daiichi Sankyo Phase II
Parsippany, NJ (973) 359-2600
TNFerade™ GenVec (see also colorectal, head/neck, Phase III
Gaithersburg, MD skin, stomach) (240) 632-0740
TPI-287 Tapestry Pharmaceuticals (see also prostate) Phase II
Boulder, CO (303) 516-8500
Triapine® Vion Pharmaceuticals (see also leukemia, lung, prostate) Phase II
New Haven, CT (203) 498-4210
Virulizin® Lorus Therapeutics Phase III
Toronto, Canada (416) 798-1200
volociximab Biogen Idec (see also lung, ovarian, skin) Phase II
Cambridge, MA (617) 679-2000
Facet Biotech (650) 454-1000
Redwood City, CA
Y-90 hPAM4 Immunomedics metastatic pancreatic cancer Phase I/II
(IMMU-107) Morris Plains, NJ (973) 605-8200
(Orphan Drug)
Zarnestra™ Johnson & Johnson (see also leukemia) Phase III
tipifarnib Pharmaceutical Research (800) 817-5286
& Development
Raritan, NJ

PROSTATE CANCER
Product Name Sponsor Indication Development Status
ABI-008 Abraxis BioScience hormone-refractory prostate cancer Phase I/II
Los Angeles, CA (see also breast) (310) 883-1300
abiraterone acetate Cougar Biotechnology combination therapy, Phase III
(CB7630) Los Angeles, CA second-line therapy (310) 943-8040
ABR-215050 Active Biotech Phase II
Lund, Sweden www.activebiotech.com
Abraxane™ Abraxis BioScience (see also head/neck, lung, ovarian, Phase II
albumin-bound Los Angeles, CA pancreatic, skin) (310) 883-1300
paclitaxel

58 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
PROSTATE CANCER
Product Name Sponsor Indication Development Status
Acapodene® GTx prostatic intraepithelial neoplasia Phase III
toremifene Memphis, TN (prevention) (901) 523-9700
(see also cancer-related)
Actimid™ Celgene (see also lung, multiple myeloma, Phase II
pomalidomide Summit, NJ pancreatic, sarcoma) (908) 673-9000
Advexin® Introgen Therapeutics (see also bladder, brain, breast, Phase I
contusugene Austin, TX head/neck, lung, ovarian, stomach) (512) 708-9310
ladenovec
aflibercept sanofi-aventis first-line metastatic prostate Phase III
(VEGF-trap) Bridgewater, NJ cancer (combination therapy) (800) 633-1610
Regeneron Pharmaceuticals (see also colorectal, lung, (714) 345-7400
Tarrytown, NY pancreatic, other)
AGS-1C4D4 Agensys Phase I completed
Santa Monica, CA (310) 820-8029
Astellas Pharma US (800) 477-6472
Deerfield, IL
Amplimexon® AmpliMed (see also breast, lung, multiple Phase I
imexon Tucson, AZ myeloma, pancreatic, skin) (520) 529-1000
anti-idiotype Onyvax Phase II
cancer vaccine London, England www.onyvax.com
105AD7
AT-101 Ascenta Therapeutics (see also lung, lymphoma) Phase II
San Diego, CA (858) 436-1200
ATN-224 Attenuon (see also multiple myeloma, skin) Phase II
San Diego, CA (858) 558-4111
Avastin® Genentech (see also brain, colorectal, Phase III
bevacizumab South San Francisco, CA head/neck, kidney, liver, lung, (650) 225-1000
lymphoma, multiple myeloma,
ovarian, pancreatic, stomach, other)
Avodart® GlaxoSmithKline prostate cancer prevention, Phase III
dutasteride Rsch. Triangle Park, NC prostatic intraepithelial neoplasia (888) 825-5249
AZD4054 AstraZeneca hormone-refractory, metastatic Phase III
Wilmington, DE prostate cancer (800) 236-9933
BMS-641988 Bristol-Myers Squibb Phase I
(androgen receptor Princeton, NJ (212) 546-4000
antagonist)
cabazitaxel sanofi-aventis Phase III
(XRP6258) Bridgewater, NJ (800) 633-1610
Camptosar® Pfizer (see also cervical, lung, pancreatic) Phase II
irinotecan New York, NY (860) 732-5156
Celebrex® Pfizer (see also bladder) Phase II
celecoxib New York, NY (860) 732-5156
cilengitide EMD Serono (see also brain, lymphoma, Phase II
Rockland, MA solid tumors) (800) 283-8088
CNTO 95 Centocor (see also skin, solid tumors) Phase II completed
Horsham, PA (610) 651-6000

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 59
PROSTATE CANCER
Product Name Sponsor Indication Development Status
CNTO 328 Centocor hormone-refractory prostate cancer Phase II
Horsham, PA (see also kidney) (610) 651-6000
CP-751871 Pfizer combination therapy Phase II
New York, NY (see also breast, colorectal, lung, (860) 732-5156
multiple myeloma, sarcoma)
CYT-500 Cytogen Phase I
Princeton, NJ (800) 833-3533
deforolimus ARIAD Pharmaceuticals (see also breast, lung, sarcoma, Phase II
(MK-8669) Cambridge, MA other) (617) 494-0400
Merck (800) 672-6372
Whitehouse Station, NJ
DMXAA Antisoma (see also lung) Phase II completed
Cambridge, MA (617) 225-0522
Novartis Pharmaceuticals (888) 669-6682
East Hanover, NJ
enzastaurin Eli Lilly (see also brain, breast, colorectal, Phase II
(LY317615) Indianapolis, IN lymphoma, multiple myeloma, (800) 545-5979
ovarian)
Erbitux® Bristol-Myers Squibb (see also bladder, colorectal, Phase III
cetuximab Princeton, NJ head/neck, lung, stomach) (212) 546-4000
Eli Lilly (800) 545-5979
Indianapolis, IN (212) 645-1405
ImClone Systems
New York, NY
eribulin mesylate Eisai hormone-refractory prostate cancer, Phase II
(E7389) Woodcliff Lake, NJ prostate cancer (888) 422-4743
(see also breast, head/neck, lung,
ovarian, sarcoma, solid tumors)
Gleevec® Novartis Pharmaceuticals (see also leukemia) Phase II/III
imatinib East Hanover, NJ (888) 669-6682
GRNVAC1 Argos Therapeutics (see also leukemia) Phase I/II
Durham, NC (919) 287-6300
Geron (650) 473-7700
Menlo Park, CA
GTx-758 GTx Phase I
Memphis, TN (901) 523-9700
HE-3235 Hollis-Eden late-stage prostate cancer Phase I/II
Pharmaceuticals (858) 587-9333
San Diego, CA
Herceptin® Genentech (see also colorectal, ovarian, Phase II
trastuzumab South San Francisco, CA pancreatic, stomach, other) (650) 225-1000
Hycamtin® GlaxoSmithKline (see also breast, colorectal, Phase II
topotecan Rsch. Triangle Park, NC head/neck, kidney, leukemia, lung, (888) 825-5249
(oral) lymphoma, multiple myeloma,
ovarian, pancreatic, stomach, other)

60 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
PROSTATE CANCER
Product Name Sponsor Indication Development Status
HyperAcute® NewLink Genetics Phase I/II
Prostate Ames, IA (515) 296-5555
prostate cancer
vaccine
idronoxil Marshall Edwards (see also ovarian, other) Phase II
North Ryde, Australia
IMC-1121B Eli Lilly (see also breast, colorectal, kidney, Phase II
Indianapolis, IN liver, lung, ovarian, skin) (800) 545-5979
ImClone Systems (212) 645-1405
New York, NY
IMC-A12 Eli Lilly (see also breast, colorectal, Phase II
Indianapolis, IN head/neck, liver, lung, pancreatic, (800) 545-5979
ImClone Systems sarcoma, solid tumors) (212) 645-1045
New York, NY
INCB-18424 Incyte (see also multiple myeloma) Phase II
Wilmington, DE (302) 498-6700
INSM-18 Insmed Phase I/II completed
Glen Allen, VA (804) 565-3000
Ixempra™ Bristol-Myers Squibb (see also breast, lung, pancreatic) in clinical trials
ixabepilone Princeton, NJ (212) 546-4000
JNJ-26854165 Johnson & Johnson (see also lung) Phase I
Pharmaceutical Research (800) 817-5286
& Development
Raritan, NJ
Leukine® Bayer HealthCare (see also leukemia, lymphoma, Phase II
sargramostim Pharmaceuticals ovarian, skin) (888) 842-2937
Wayne, NJ
Leupron Depot® Abbott Pharmaceuticals Phase III
leuprorelin depot Abbott Park, IL (847) 937-6100
(6-month
formulation)
leuprorelin Enzon Pharmaceuticals Phase I
inhalation Bridgewater, NJ (908) 541-8600
Nektar Therapeutics (650) 631-3100
San Carlos, CA
MCS110 Novartis Pharmaceuticals (see also other) Phase I/II
East Hanover, NJ (888) 669-6682
MDV-3100 Medivation hormone-refractory prostate Phase I/II
San Francisco, CA cancer (415) 543-3470
mepacrine Cleveland BioLabs Phase II
Buffalo, NY (716) 849-6810
MER-104 Merrion Pharmaceuticals Phase I/II
Wilmington, NC (910) 799-1847
MIP1072 Molecular Insight diagnosis of prostate cancer Phase I
Pharmaceuticals (617) 492-5554
Cambridge, MA

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 61
PROSTATE CANCER
Product Name Sponsor Indication Development Status
MIP1095 Molecular Insight diagnosis of prostate cancer Phase I
Pharmaceuticals (617) 492-5554
Cambridge, MA
MK-0429 Merck Phase I
Whitehouse Station, NJ (800) 672-6372
MVA-BN®-PRO BN ImmunoTherapeutics Phase I/II
Mountain View, CA (650) 681-4660
NBI-42902 Neurocrine Biosciences (see also breast, other) Phase I
San Diego, CA (858) 617-7600
NeuVax™ Apthera (see also breast) Phase I/II
E75 cancer Scottsdale, AZ (480) 882-8841
vaccine
OGX-427 Oncogenex (see also bladder, breast, lung, Phase I
Pharmaceuticals ovarian) (425) 686-1500
Bothell, WA
Oncolar® Novartis Pharmaceuticals Phase II
octreotide East Hanover, NJ (888) 669-6682
ONY-105 Onyvax Phase II
(cancer vaccine) London, England www.onyvax.com
ONY-P Onyvax Phase II
(prostate cancer London, England www.onyvax.com
vaccine)
ozarelix Spectrum Pharmaceuticals Phase I/II
Irvine, CA (949) 788-6700
panobinostat Novartis Pharmaceuticals (see also brain, breast, leukemia, Phase II
East Hanover, NJ lymphoma) (888) 669-6682
plitidepsin PharmaMar USA (see also lung, multiple myeloma) Phase II
Cambridge, MA (617) 868-3797
polyphenon E Polyphenon Pharma prostatic intraepithelial neoplasia Phase II
New York, NY (see also bladder, leukemia) (212) 661-0578
Proscar® Merck prostate cancer prevention Phase III
finasteride Whitehouse Station, NJ (800) 672-6372
ProstAtak™ Advantagene Phase II
gene therapy Boston, MA (617) 916-5445
San Diego, CA (760) 943-8981
prostate cancer Novartis Pharmaceuticals Phase I/II
vaccine East Hanover, NJ (888) 669-6682
Prostvac®-VF BN ImmunoTherapeutics Phase II
prostate Mountain View, CA (650) 681-4660
cancer vaccine
Provenge® Dendreon hormone-refractory, metastatic application submitted
sipuleucel-T Seattle, WA prostate cancer (206) 256-4545
--------------------------------------------------------------------------------------
non-metastatic androgen-dependent Phase III
prostate cancer (206) 256-4545

62 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
PROSTATE CANCER
Product Name Sponsor Indication Development Status
PRX-302 Protox Therapeutics Phase II
Vancouver, Canada (604) 688-0199
PSMA-ADC Progenics Pharmaceuticals Phase I
Tarrytown, NY (914) 789-2800
PSMA cancer Progenics Pharmaceuticals Phase I
vaccine Tarrytown, NY (914) 789-2800
Quadramet® Cytogen (see also multiple myeloma, Phase II
samarium SM-153 Princeton, NJ sarcoma, other) (800) 833-3533
lexidronam
injection
Quinamed® ChemGenex (see also breast, ovarian) Phase II
amonafide Pharmaceuticals (650) 474-9800
Menlo Park, CA
Revlimid® Celgene (see also leukemia, lymphoma, Phase II
lenalidomide Summit, NJ multiple myeloma, other) (908) 673-4900
romidepsin Gloucester Pharmaceuticals (see also kidney, lymphoma, Phase II completed
Cambridge, MA multiple myeloma, pancreatic) (617) 583-1300
sagopilone Bayer HealthCare combination therapy Phase II
Pharmaceuticals (see also brain, breast, ovarian) (888) 842-2937
Wayne, NJ
satraplatin Spectrum hormone-refractory prostate cancer Phase III
Pharmaceuticals (combination therapy, (949) 788-6700
Irvine, CA second-line therapy)
(see also breast, lung)
seocalcitol Cougar Biotechnology Phase I
(CB1089) Los Angeles, CA (310) 943-8040
Sprycel™ Bristol-Myers Squibb (see also leukemia, solid tumors) in clinical trials
dasatinib Princeton, NJ (212) 546-4000
Sutent® Pfizer hormone-refractory metastatic Phase III
sunitinib New York, NY prostate cancer (860) 732-5156
(see also breast, colorectal, liver,
lung, pancreatic, sarcoma, stomach)
--------------------------------------------------------------------------------------
adjunctive treatment Phase II
(860) 732-5156
TAK683 Millennium Phase I
Pharmaceuticals (800) 390-5663
Cambridge, MA
TAK700 Millennium Phase I/II
Pharmaceuticals (800) 390-5663
Cambridge, MA
tandutinib Millennium (see also brain) Phase II
(MLN0518) Pharmaceuticals (800) 390-5663
Cambridge, MA
tesmilifene YM BioSciences (see also breast) Phase II
Wayne, PA (610) 560-0600

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 63
PROSTATE CANCER
Product Name Sponsor Indication Development Status
TheraCIM™ YM Biosciences hormone-refractory prostate cancer Phase II
nimotuzumab Wayne, PA (see also brain, breast, stomach) (610) 560-0600
Thymitaq® YM BioSciences (see also colorectal, head/neck, Phase II
nolatrexed Wayne, PA liver, lung, pancreatic) (610) 560-0600
tigapotide Ambrilia Biopharma Phase II
Verdun, Canada (514) 751-2003
Torisel™ Wyeth Pharmaceuticals (see also colorectal, kidney, lung, Phase II
temsirolimus Collegeville, PA lymphoma, multiple myeloma) (800) 934-5556
TPI-287 Tapestry Pharmaceuticals hormone-refractory prostate cancer Phase II
Boulder, CO (see also pancreatic) (303) 516-8500
transgenic B Cosmo Bioscience Phase II
lymphocyte San Diego, CA (858) 823-0413
immunotherapy/
cancer vaccine
tremelimumab Pfizer high-risk prostate cancer Phase II completed
New York, NY (see also breast, colorectal, kidney, (860) 732-5156
lung, skin)
--------------------------------------------------------------------------------------
combination therapy Phase I
(860) 732-5156
Triapine® Vion Pharmaceuticals (see also leukemia, lung, pancreatic) Phase II
New Haven, CT (203) 498-4210
trilostane Genzyme (see also breast) Phase II
Cambridge, MA (617) 252-7500
tucotuzumab EMD Serono (see also colorectal, lung, ovarian) Phase II
celmoleukin Rockland, MA (800) 283-8088
VDC2008 Bostwick Laboratories Phase I/II
Glen Allen, VA (804) 967-9225
Vidaza® Celgene (see also leukemia, lymphoma) Phase II
azacitidine Summit,NJ (908) 673-9000
VP101 Access Pharmaceuticals (see also brain, colorectal, leukemia) Phase II
Dallas, TX (214) 905-5100
YM-155 Astellas Pharma US hormone-refractory prostate cancer Phase II
Deerfield, IL (see also lymphoma) (800) 727-7003
YMB2002 YM BioSciences Phase II
(prostate cancer Wayne, PA (610) 560-0600
vaccine)
Yondelis® Johnson & Johnson (see also breast, ovarian, Phase II
trabectedin Pharmaceutical Research sarcoma, other) (800) 817-5286
& Development
Raritan, NJ
ZYC300 Eisai (see also breast, colorectal, kidney, Phase I
Woodcliff Lake, NJ ovarian) (888) 422-4743

64 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
SARCOMA
Product Name Sponsor Indication Development Status
Actimid™ Celgene (see also lung, multiple myeloma, Phase II
pomalidomide Summit, NJ pancreatic, prostate) (908) 673-9000
AMG 479 Amgen (see also breast, colorectal, lung, Phase II
Thousand Oaks, CA pancreatic) (805) 447-1000
Armala™ GlaxoSmithKline (see also brain, breast, cervical, Phase III
pazopanib Rsch. Triangle Park, NC kidney, liver, lung, ovarian, other) (888) 669-6682
AVE8062 sanofi-aventis Phase III
Bridgewater, NJ (800) 633-1610
brostallicin Cell Therapeutics soft tissue sarcoma Phase II
Seattle, WA (see also solid tumors) (800) 215-2355
cancer vaccine MabVax Therapeutics (see also breast) Phase I
San Diego, CA (858) 259-9405
conatumumab Amgen (see also colorectal, lung, Phase I/II
Thousand Oaks, CA pancreatic) (805) 447-1000
CP-751871 Pfizer (see also breast, colorectal, lung, Phase I/II
New York, NY multiple myeloma, prostate) (860) 732-5156
deforolimus ARIAD Pharmaceuticals oral formulation Phase III
(MK-8669) Cambridge, MA (see also breast, lung, prostate, other) (617) 494-0400
(Orphan Drug) Merck (800) 672-6372
Whitehouse Station, NJ --------------------------------------------------------------------------------------
intravenous formulation Phase I/II
(617) 494-0400
(800) 672-6372
eribulin mesylate Eisai (see also breast, head/neck, lung, Phase II
(E7389) Woodcliff Lake, NJ ovarian, prostate, solid tumors) (877) 873-4724
Fusilev™ Spectrum Pharmaceuticals (see also colorectal) application submitted
levoleucovorin Irvine, CA (949) 788-6700
for injection
Gemzar® Eli Lilly (see also head/neck, lung, Phase II
gemcitabine Indianapolis, IN lymphoma) (800) 545-5979
glufosfamide Threshold Pharmaceuticals (see also breast, lung, pancreatic) Phase II
Redwood City, CA (650) 474-8200
IMC-A12 Eli Lilly soft tissue sarcoma Phase II
Indianapolis, IN (see also breast, colorectal, (800) 545-5979
ImClone Systems head/neck, liver, lung, pancreatic, (212) 645-1405
New York, NY prostate, solid tumors)
Junovan™ IDM Pharma osteosarcoma application submitted
mifamurtide Irvine, CA (949) 470-4751
KRX-0402 Keryx Biopharmaceuticals (see also brain, colorectal, kidney, Phase II
New York, NY multiple myeloma) (212) 531-5965
palifosfamide ZIOPHARM Oncology combination therapy Phase II
(ZIO-201) New York, NY (see also solid tumors) (212) 214-0700
(Orphan Drug) --------------------------------------------------------------------------------------
monotherapy Phase I/II
(212) 214-0700

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 65
SARCOMA
Product Name Sponsor Indication Development Status
perifosine AEterna Zentaris (see also brain, head/neck, Phase II
Montreal, Canada kidney, lymphoma, multiple (212) 531-5965
Keryx Biopharmaceuticals myeloma, ovarian)
New York, NY
Quadramet® Cytogen osteosarcoma Phase I/II
samarium sm-153 Princeton, NJ (see also multiple myeloma, (800) 833-3533
lexidronam prostate, other)
injection
R1507 Roche (see also breast, lung, lymphoma) Phase II
Nutley, NJ (973) 235-5000
Reolysin® Oncolytics Biotech (see also brain, head/neck, lung, Phase II
reovirus Calgary, Canada skin) (403) 670-7377
Rexin-G™ Epeius Biotechnologies osteosarcoma Phase II
tumor-targeted San Marino, CA (see also breast, pancreatic) (626) 441-6695
gene therapy --------------------------------------------------------------------------------------
soft tissue sarcoma Phase I/II
(626) 441-6695
robatumumab Schering-Plough osteosarcoma, sarcoma Phase II
Kenilworth, NJ (see also colorectal) (908) 298-4000
Sutent® Pfizer soft tissue sarcoma Phase II
sunitinib New York, NY (see also breast, colorectal, liver, (860) 732-5156
lung, pancreatic, prostate, stomach)
tasisulam (ASAP) Eli Lilly soft tissue sarcoma Phase II
Indianapolis, IN (see also leukemia, ovarian, skin) (800) 545-5979
TH-302 Threshold soft tissue sarcoma Phase I/II
Pharmaceuticals (see also solid tumors) (650) 474-8200
Redwood City, CA
Yondelis® Johnson & Johnson first-line therapy Phase III
trabectedin Pharmaceutical Research (see also breast, ovarian, prostate, (800) 817-5286
(Orphan Drug) & Development other)
Raritan, NJ --------------------------------------------------------------------------------------
in adolescents and children Phase II
(800) 817-5286

SKIN CANCER
Product Name Sponsor Indication Development Status
1203486A GlaxoSmithKline malignant melanoma Phase II
Rsch. Triangle Park, NC (888) 825-5249
2132231A GlaxoSmithKline malignant melanoma Phase III
Rsch. Triangle Park, NC (888) 825-5249
Abraxane™ Abraxis BioScience malignant melanoma Phase II
albumin-bound Los Angeles, CA (see also head/neck, lung, ovarian, (310) 883-1300
paclitaxel pancreatic, prostate)
ABT-888 Abbott Laboratories malignant melanoma Phase II
Abbott Park, IL (see also solid tumors) (847) 937-6100

66 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
SKIN CANCER
Product Name Sponsor Indication Development Status
Allovectin-7® Vical metastatic melanoma Phase III
velimogene San Diego, CA (858) 646-1100
aliplasmid
(immunotherapeutic
vaccine)
(Orphan Drug)
ALS-357 Advanced Life Sciences malignant melanoma Phase I
(betulinic topical) Woodridge, IL (630) 739-6744
Amplimexon® AmpliMed malignant melanoma Phase I/II completed
imexon Tucson, AZ (see also breast, lung, multiple (520) 529-1000
myeloma, pancreatic, prostate)
ATN-224 Attenuon malignant melanoma Phase II
San Diego, CA (see also multiple myeloma, prostate) (858) 720-8797
AZD6244 AstraZeneca malignant melanoma Phase II
Wilmington, DE (see also leukemia, liver, lung, (800) 236-9933
multiple myeloma, ovarian,
pancreatic, other)
Azixa™ Myriad Pharmaceuticals malignant melanoma Phase I/II
(MPC-6827) Salt Lake City, UT (see also brain) (801) 584-3600
BMS-663513 Bristol-Myers Squibb second-line melanoma in clinical trials
(anti-CD137 Princeton, NJ (212) 546-4000
antibody)
Cadi 05 Cadila Pharmaceuticals malignant melanoma Phase I/II
Bhat, India (see also solid tumors) www.cadilapharma.com
CNTO 95 Centocor malignant melonoma Phase I/II
Horsham, PA (see also prostate, solid tumors) (610) 651-6000
CR011-vcMMAE CuraGen malignant melanoma Phase II
Branford, CT (see also breast) (888) 436-6642
CYT-107 Cytheris malignant melanoma Phase I/II
Rockville, MD (see also kidney, leukemia, (301) 231-0450
solid tumors)
denenicokin ZymoGenetics malignant melanoma Phase I/II
(IL-21) Seattle, WA (see also colorectal, kidney, (206) 442-6600
lymphoma, ovarian)
Dimericine® AGI Dermatics Phase II
T4N5 liposome Freeport, NY (516) 868-9026
lotion
dovitinib Novartis Pharmaceuticals malignant melanoma Phase I/II
East Hanover, NJ (see also kidney) (888) 669-6682
ecromeximab Life Sciences malignant melanoma Phase II
Pharmaceuticals (combination therapy) (203) 422-6500
Greenwich, CT
Elacyt™ Clavis Pharma malignant melanoma (combination Phase II
elacytarabine Oslo, Norway therapy), malignant melanoma www.clavispharma.com
(first-line therapy)
(see also leukemia, ovarian)

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 67
SKIN CANCER
Product Name Sponsor Indication Development Status
EMD 273063 EMD Serono malignant melanoma Phase II
Rockland, MA (see also brain) (800) 283-8088
Exherin™ Adherex Technologies malignant melanoma Phase I/II
(ADH-1) Durham, NC (see also solid tumors) (919) 484-8484
GC-1008 Genzyme malignant melanoma Phase I
Cambridge, MA (see also kidney) (617) 252-7000
Genasense® Genta malignant melanoma Phase III
oblimersen Berkeley Heights, NJ (see also breast, leukemia, lung, (908) 286-9800
(Orphan Drug) lymphoma, solid tumors)
GMX-1777 Gemin X Biotechnologies malignant melanoma Phase I/II
Montreal, Canada (combination therapy) (514) 281-8989
(see also lymphoma, solid tumors)
HyperAcute® NewLink Genetics malignant melanoma Phase I/II
Melanoma Ames, IA (515) 296-5555
melanoma vaccine
IMC-1121B Eli Lilly metastatic malignant melanoma Phase II
Indianapolis, IN (see also breast, colorectal, kidney, (800) 545-5979
ImClone Systems liver, lung, ovarian, prostate) (212) 645-1405
New York, NY
INGN 241 Introgen Therapeutics malignant melanoma Phase II
(mda-7) Austin, TX (see also head/neck) (512) 708-9310
interleukin-12 Inovio malignant melanoma Phase I
gene therapy San Diego, CA (877) 446-6846
Karenitecin® BioNumerik malignant melanoma Phase II completed
cositecan Pharmaceuticals (see also brain, lung, ovarian) (201) 614-1710
San Antonio, TX
Leukine® Bayer HealthCare malignant melanoma Phase II
sargramostim Pharmaceuticals (see also leukemia, lymphoma, (888) 842-2937
Wayne, NJ ovarian, prostate)
Lymphoseek™ Neoprobe diagnosis of malignant melanoma Phase III
Dublin, OH (see also breast) (800) 793-0079
Marqibo™ Hana Biosciences malignant melanoma Phase II
vincristine South San Francisco, CA (see also leukemia) (650) 588-6404
liposomal
(Orphan Drug)
MDX-010 Bristol-Myers Squibb adjuvant melanoma, Phase III
(ipilimumab) Princeton, NJ metastatic melanoma (212) 546-4000
Medarex (see also solid tumors)
Princeton, NJ
melanoma Ichor Medical Systems malignant melanoma Phase I
vaccine San Diego, CA (858) 550-2022
melanoma Novavax malignant melanoma Phase I
vaccine Malvern, PA (484) 913-1200
melanoma sanofi-aventis treatment of stage III and Phase II
vaccine Bridgewater, NJ stage IV melanoma (800) 633-1610

68 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
SKIN CANCER
Product Name Sponsor Indication Development Status
Melaxin® Oncolix malignant melanoma Phase II
autologous Greenville, SC
dendritoma
vaccine
Metvixia® PhotoCure basal cell cancer Phase III
methyl Oslo, Norway www.photocure.com
aminolevulinate
MKC 1106-MT MannKind malignant melanoma Phase I
Valencia, CA (661) 775-5300
M-Vax® AVAX Technologies malignant melanoma Phase III
melanoma Philadelphia, PA (215) 241-9760
vaccine
Nexavar® Bayer HealthCare malignant melanoma Phase III
sorafenib Pharmaceuticals (combination therapy) (888) 842-2837
Wayne, NJ (see also breast, lung) (510) 597-6500
Onyx Pharmaceuticals
Emeryville, CA
ODC-0501 ODC Therapy malignant melanoma Phase I/II
Dallas, TX (214) 826-7019
Oncophage® Antigenics malignant melanoma Phase III
vitespen New York, NY (see also brain, colorectal, kidney, (866) 805-8994
pancreatic, stomach)
OncoVAX® Vaccinogen malignant melanoma Phase I/II
cancer vaccine Frederick, MD (see also colorectal, kidney) (301) 668-8400
OncoVEX GM-CSF BioVex malignant melanoma Phase II
Woburn, MA (see also pancreatic) (781) 376-4900
PARP inhibitor Genentech malignant melanoma Phase I
South San Francisco, CA (650) 225-1000
PEG-Intron A® Schering-Plough adjunctive treatment of stage III application submitted
peginterferon Kenilworth, NJ malignant melanoma (908) 298-4000
alfa-2b (see also leukemia)
PEP-005 Peplin basal cell cancer Phase II
Emeryville, CA (510) 653-9700
PHP Curacyte malignant melanoma Phase II
Chapel Hill, NC www.curacyte.com
PI-88 Progen Pharmaceuticals malignant melanoma Phase II
Redwood City, CA (650) 610-7080
PLX-4032 Plexxikon malignant melanoma Phase I
Berkeley, CA (510) 647-4000
Roche (973) 235-5000
Nutley, NJ
PTC-299 PTC Therapeutics Kaposi’s sarcoma Phase I/II
South Plainfield, CT (see also breast) (908) 222-7000
PV-10 Provectus Pharmaceuticals malignant melanoma Phase II
Knoxville, TN (866) 594-5999

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 69
SKIN CANCER
Product Name Sponsor Indication Development Status
RAF265 Novartis Pharmaceuticals malignant melanoma Phase I
East Hanover, NJ (888) 669-6682
Reolysin® Oncolytics Biotech malignant melanoma Phase II
reovirus Calgary, Canada (see also brain, head/neck, lung, (403) 670-7377
sarcoma)
systemic hedgehog Genentech basal cell cancer Phase II
antagonist South San Francisco, CA (see also brain, colorectal, ovarian) (650) 224-1000
tasisulam (ASAP) Eli Lilly malignant melanoma Phase II
Indianapolis, IN (see also leukemia, ovarian, sarcoma) (800) 545-5979
TM-601-I-131 TransMolecular metastatic malignant melanoma Phase I/II
Cambridge, MA (see also brain) (617) 995-3050
TNFerade™ GenVec malignant melanoma Phase II
Gaithersburg, MD (see also colorectal, head/neck, (240) 632-0740
pancreatic, stomach)
tremelimumab Pfizer malignant melanoma Phase II
New York, NY (see also breast, colorectal, kidney, (860) 732-5156
lung, prostate)
VCL-IM01 Vical metastatic malignant melanoma Phase I
San Diego, CA (858) 646-1100
veglin VasGene Therapeutics Kaposi’s sarcoma Phase I
Los Angeles, CA (323) 221-7818
Visudyne® QLT USA malignant melanoma Phase I/II
verteporfin Fort Collins, CO (800) 663-5486
volociximab Biogen Idec malignant melanoma Phase II
Cambridge, MA (see also lung, ovarian, pancreatic) (617) 679-2000
Facet Biotech (650) 454-1000
Redwood City, CA
Zadaxin® SciClone Pharmaceuticals malignant melanoma Phase II
thymalfasin Foster City, CA (650) 358-3456
ZRx101 ZelleRx malignant melanoma Phase I
Chicago, IL (see also kidney, multiple myeloma, (312) 243-5200
cancer-related)

SOLID TUMORS
Product Name Sponsor Indication Development Status
461364 GlaxoSmithKline (see also lymphoma) Phase I
Rsch. Triangle Park, NC (888) 825-5249
690693 GlaxoSmithKline (see also lymphoma) Phase I
Rsch. Triangle Park, NC (888) 825-5249
923295 GlaxoSmithKline refractory metastatic disease Phase I
Rsch. Triangle Park, NC (888) 825-5249
1MT NewLink Genetics Phase I
Ames, IA (515) 296-5555

70 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
SOLID TUMORS
Product Name Sponsor Indication Development Status
2DG Threshold Pharmaceuticals Phase I
(2-deoxy-d-glucose) Redwood City, CA (605) 474-8200
ABI-009 Abraxis BioScience Phase I
Los Angeles, CA (310) 883-1300
ABT-828 Abbott Laboratories Phase I
Abbott Park, IL (847) 937-6100
ABT-888 Abbott Laboratories (see also skin) Phase I
Abbott Park, IL (847) 937-6100
AEE788 Novartis Pharmaceuticals (see also brain) Phase I
East Hanover, NJ (888) 669-6682
AEW541 Novartis Pharmaceuticals (see also leukemia) Phase I
East Hanover, NJ (888) 669-6682
AFP-464 Tigris Pharmaceuticals Phase I
Bonita Springs, FL (239) 444-5400
AI-850 Acusphere Phase I
Watertown, MA (617) 648-8800
Cephalon (610) 344-0200
Frazer, PA
ALB 109564(a) AMRI Phase I
Albany, NY (518) 512-2000
AMG 208 Amgen Phase I
Thousand Oaks, CA (805) 447-1000
AMG 888 Amgen Phase I
(U3-1287) Thousand Oaks, CA (805) 447-1000
Daiichi Sankyo (973) 359-2600
Parsippany, NJ
ANA-773 Anadys Pharmaceuticals Phase I
San Diego, CA (858) 530-3600
angiostatic Angiogen Phase I
cocktail Evanston, IL (847) 866-6700
anti-EGFR Abbott Laboratories Phase I
mAb-806 Abbott Park, IL (847) 937-6100
anti-IGF-1R mAb Genentech Phase I
South San Francisco, CA (650) 225-1000
AR-67 Arno Therapeutics Phase I
Fairfield, NJ (862) 703-7170
ARQ-197 ArQule microphthalmia transcription Phase I/II
Woburn, MA factor tumors (781) 994-0300
Daiichi Sankyo (see also liver, lung, pancreatic) (973) 359-2600
Parsippany, NJ
ARQ-501 ArQule refractory metastatic solid tumors Phase I/II
(beta lapachone) Woburn, MA (combination therapy) (781) 994-0300
(see also head/neck, pancreatic,
other)
ARRY-520 Array BioPharma (see also leukemia) Phase I
Boulder, CO (303) 381-6600

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 71
SOLID TUMORS
Product Name Sponsor Indication Development Status
AT7519 Astex Therapeutics Phase I
Cambridge, United Kingdom
AT9283 Astex Therapeutics (see also leukemia) Phase I
Cambridge, United Kingdom
AT13387 Astex Therapeutics Phase I
Cambridge, United Kingdom
ATN-161 Attenuon Phase I
San Diego, CA (858) 720-8797
AUY922 Novartis Pharmaceuticals (see also multiple myeloma) Phase I/II
East Hanover, NJ (888) 669-6682
AV-299 AVEO Pharmaceuticals advanced solid tumors Phase I
(SCH-90015) Cambridge, MA (see also lymphoma) (617) 299-5000
Schering-Plough
Kenilworth, NJ
AV-412 AVEO Pharmaceuticals Phase I
Cambridge, MA (617) 299-5000
axitinib Pfizer combination therapy, Phase I
New York, NY late-stage disease (860) 732-5156
(see also colorectal, kidney, lung,
other)
AZD4769 AstraZeneca Phase I
Wilmington, DE (800) 236-9933
AZD6918 AstraZeneca Phase I
Wilmington, DE (800) 236-9933
AZD7762 AstraZeneca Phase I
Wilmington, DE (800) 236-9933
AZD8055 AstraZeneca Phase I/II
Wilmington, DE (800) 236-9933
AZD8330 AstraZeneca Phase I
Wilmington, DE (800) 236-9933
AZD8931 AstraZeneca Phase I
Wilmington, DE (800) 236-9933
AZM475271 AstraZeneca (see also leukemia) Phase I
Wilmington, DE (800) 236-9933
BEZ235 Novartis Pharmaceuticals Phase I
East Hanover, NJ (888) 669-6682
BGT226 Novartis Pharmaceuticals Phase I/II
East Hanover, NJ (888) 669-6682
BHQ880 Novartis Pharmaceuticals Phase I
East Hanover, NJ (888) 669-6682
BI 6727 Boehringer Ingelheim Phase I
Pharmaceuticals (800) 243-0127
Ridgefield, CT
BI 831266 Boehringer Ingelheim Phase I
Pharmaceuticals (800) 243-0127
Ridgefield, CT

72 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
SOLID TUMORS
Product Name Sponsor Indication Development Status
BIBF 1120 Boehringer Ingelheim combination therapy Phase I
Pharmaceuticals (see also lung) (800) 243-0127
Ridgefield, CT
BIIB 015 Biogen Idec Phase I
Cambridge, MA (617) 679-2000
BIIB 022 Biogen Idec Phase I
Cambridge, MA (617) 679-2000
BMS-690514 Bristol-Myers Squibb (see also lung) in clinical trials
(ErbB/VEGF Princeton, NJ (212) 546-4000
receptor inhibitor)
BMS-754807 Bristol-Myers Squibb in clinical trials
(IGF-1R antagonist) Princeton, NJ (212) 546-4000
BMS-833923 Bristol-Myers Squibb Phase I
(SMO inhibitor) Princeton, NJ (212) 546-4000
Exelixis
South San Francisco, CA
BMS-844203 Bristol-Myers Squibb (see also brain) in clinical trials
(VEGF inhibitor- Princeton, NJ (212) 546-4000
adnectin)
bosutinib Wyeth Pharmaceuticals (see also breast, leukemia) Phase I
Collegeville, PA (800) 934-5556
BQS481 Novartis Pharmaceuticals Phase I
East Hanover, NJ (888) 669-6682
brostallicin Cell Therapeutics advanced solid tumors Phase II
Seattle, WA (see also sarcoma) (800) 215-2355
--------------------------------------------------------------------------------------
combination therapy Phase I/II
(800) 215-2355
Cadi 05 Cadila Pharmaceuticals (see also skin) Phase I
Bhat, India www.cadilapharma.com
CALAA 01 Calando Pharmaceuticals Phase I
Pasadena, CA (626) 683-7200
carfilzomib Proteolix relapsed solid tumors Phase I/II
South San Francisco, CA (see also leukemia, (650) 615-7550
multiple myeloma)
CBP501 Millennium (see also lung) Phase I
Pharmaceuticals (800) 390-5663
Cambridge, MA
CDX-110 Celldex Therapeutics (see also brain) Phase I
Needham, MA (781) 433-0771
Pfizer (860) 732-5156
New York, NY
CEP-11981 Cephalon Phase I
Frazer, PA (610) 344-0200
cevipabulin Wyeth Pharmaceuticals Phase I
Collegeville, PA (800) 934-5556

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 73
SOLID TUMORS
Product Name Sponsor Indication Development Status
CG-201 CG Therapeutics Phase I
Seattle, WA (206) 336-5604
cilengitide EMD Serono late-stage solid tumors Phase I
Rockland, MA (see also brain, lymphoma, prostate) (800) 283-8088
CNF-2024 Biogen Idec (see also breast, leukemia, stomach) Phase I
Cambridge, MA (617) 679-2000
CNTO 95 Centocor (see also prostate, skin) Phase I completed
Horsham, PA (610) 651-6000
CNTO 888 Centocor Phase I
Horsham, PA (610) 651-6000
CP-870893 Pfizer Phase I
New York, NY (860) 732-5156
crinobulin EpiCept (see also lymphoma) Phase I
Tarrytown, NY (914) 606-3500
CRx-026 CombinatoRx late-stage, metastatic solid tumors Phase I/II
Cambridge, MA (617) 301-7000
CUDC-101 Curis Phase I
Cambridge, MA (617) 503-6500
CX-4945 Cylene Pharmaceuticals (see also multiple myeloma, other) Phase I
San Diego, CA (858) 875-5100
CYC-116 Cyclacel Pharmaceuticals Phase I
Berkeley Heights, NJ (908) 517-7330
CYT-107 Cytheris (see also kidney, leukemia, skin) Phase I
Rockville, MD (301) 231-0450
CYT 6091 CytImmune Sciences Phase I
Rockville, MD (240) 864-2796
darinaparsin ZIOPHARM Oncology (see also leukemia, liver, Phase I
(ZIO-101) New York, NY multiple myeloma) (646) 214-0700
Davanat™ Pro-Pharmaceuticals (see also colorectal) Phase I
galactomannan C Newton, MA (617) 559-0033
denibulin MediciNova Phase I
(MN-029) San Diego, CA (858) 373-1500
DMPEN Antisoma Phase I
Cambridge, MA (617) 225-0522
E6201 Eisai advanced solid tumors Phase I
Woodcliff Lake, NJ (888) 422-4743
E7050 Eisai Phase I
Woodcliff Lake, NJ (888) 422-4743
E7080 Eisai (see also other) Phase I/II
Woodcliff Lake, NJ (888) 422-4743
ENMD-2076 EntreMed refractory metastatic disease Phase I
Rockville, MD (see also multiple myeloma) (240) 864-2600
eniluracil Adherex Technologies (see also liver) Phase I
Durham, NC (919) 484-8484

74 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
SOLID TUMORS
Product Name Sponsor Indication Development Status
eribulin mesylate Eisai advanced solid tumors, solid tumors Phase I
(E7389) Woodcliff Lake, NJ (see also breast, head/neck, lung, (888) 422-4743
ovarian, prostate, sarcoma)
Exherin™ Adherex Technologies (see also skin) Phase II
(ADH-1) Durham, NC (919) 484-8484
EZN-2968 Enzon Pharmaceuticals (see also lymphoma) Phase I
Bridgewater, NJ (866) 792-5172
FP-1039 Five Prime Therapeutics Phase I
San Francisco, CA (415) 365-5600
Genasense® Genta brief, high-dose IV-infusion Phase I/II
oblimersen Berkeley Heights, NJ (see also breast, leukemia, lung, (908) 286-9800
lymphoma, skin)
--------------------------------------------------------------------------------------
intermittent therapy Phase I
(908) 286-9800
GMX-1777 Gemin X Biotechnologies (see also lymphoma, skin) Phase I
Montreal, Canada (514) 281-8989
HGS-1029 Human Genome Sciences Phase I
Rockville, MD (301) 309-8504
HMN-214 NS Pharma Phase I
Parsippany, NJ (973) 285-7010
IMC-3G3 Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
ImClone Systems (212) 645-1405
New York, NY
IMC-18F1 Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
ImClone Systems (212) 645-1405
New York, NY
IMC-A12 Eli Lilly solid tumors in adolescents and Phase I/II
Indianapolis, IN children (800) 545-5979
ImClone Systems (see also breast, colorectal, (212) 645-1405
New York, NY head/neck, liver, lung, pancreatic,
prostate, sarcoma)
--------------------------------------------------------------------------------------
solid tumor combination therapy, Phase I
other solid tumors (800) 545-5979
(212) 645-1405
IMGN-242 ImmunoGen (see also stomach) Phase I
Cambridge, MA (617) 995-2500
IMGN-388 ImmunoGen Phase I
Cambridge, MA (617) 679-5500
INNO-206 CytRx Phase I
Los Angeles, CA (310) 826-5648
INNO-305 CytRx (see also leukemia) Phase I
Los Angeles, CA (310) 826-5648

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 75
SOLID TUMORS
Product Name Sponsor Indication Development Status
IPI-493 Infinity Pharmaceuticals Phase I
Cambridge, MA (617) 453-1000
IPI-926 Infinity Pharmaceuticals Phase I
Cambridge, MA (617) 453-100
JI-101 Jubilant Innovation Phase I
Bedminster, NJ (215) 369-0965
JNJ-38877605 Johnson & Johnson Phase I
Pharmaceutical Research (800) 817-5286
& Development
Raritan, NJ
JX-594 Jennerex Biotherapeutics (see also liver) Phase I
San Francisco, CA (415) 281-8886
LE-DT NeoPharm Phase I
Lake Bluff, IL (847) 887-0800
lexatumumab Human Genome Sciences Phase I
Rockville, MD (301) 309-8504
L-MDAM BioNumerik Phase I
Pharmaceuticals (210) 614-1701
San Antonio, TX
LP-261 Locus Pharmaceuticals Phase I
Blue Bell, PA (215) 358-2000
LY2157299 Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
LY2181308 Eli Lilly (see also leukemia) Phase II
Indianapolis, IN (800) 545-5979
Isis Pharmaceuticals (760) 931-9200
Carlsbad, CA
LY2275796 Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
Isis Pharmaceuticals (760) 931-9200
Carlsbad, CA
LY2334737 Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
LY2603618 Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
M1685A Genentech Phase I
South San Francisco, CA (650) 224-1000
MDX-010 Bristol-Myers Squibb (see also skin) in clinical trials
(ipilimumab) Princeton, NJ (212) 546-4000
Medarex
Princeton, NJ
MDX-1105 Medarex Phase I
Princeton, NJ (609) 430-2880
MDX-1106 Medarex Phase I
Princeton, NJ (609) 430-2880

76 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
SOLID TUMORS
Product Name Sponsor Indication Development Status
MDX-1307 Medarex Phase I
Princeton, NJ (609) 430-2880
MEDI-575 MedImmune Phase I
Gaithersburg, MD (301) 398-0000
MetmAb Genentech Phase I
South San Francisco, CA (650) 225-1000
MGCD-265 MethylGene Phase I
Montreal, Canada (514) 337-3333
MGCD-0103 MethylGene combination therapy Phase I/II
Montreal, Canada (see also leukemia, lymphoma) (514) 337-3333
--------------------------------------------------------------------------------------
monotherapy Phase I
(514) 337-3333
MK-0731 Merck Phase I completed
Whitehouse Station, NJ (800) 672-6372
MK-1775 Merck Phase I
Whitehouse Station, NJ (800) 672-6372
MK-2206 Merck Phase I
Whitehouse Station, NJ (800) 672-6372
MK-5108 Merck refractory metastatic disease Phase I
Whitehouse Station, NJ (800) 672-6372
Vertex Pharmaceuticals
Cambridge, MA
MKC1106-PP MannKind Phase I
Valencia, CA (661) 775-5300
MLN4924 Millennium (see also leukemia) Phase I
Pharmaceuticals (800) 390-5663
Cambridge, MA
MLN8237 Millennium (see also brain, leukemia, Phase I
Pharmaceuticals lymphoma) (800) 390-5663
Cambridge, MA
MM-121 Merrimack Pharmaceuticals Phase I
Cambridge, MA (617) 441-1000
MN-201 Marillion advanced solid tumors Phase I
Pharmaceuticals (610) 644-5732
Malvern, PA
MORAb-004 Eisai Phase I
Woodcliff Lake, NJ (888) 422-4743
MP-470 SuperGen Phase I
Dublin, CA (925) 560-0100
MSX-122 Metastatix late-stage solid tumors Phase I
Tucker, GA (678) 367-0720
NB-1011 Kiadis Pharma Phase I/II
Amsterdam,
The Netherlands

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 77
SOLID TUMORS
Product Name Sponsor Indication Development Status
NKTR-105 Nektar Therapeutics Phase I
San Carlos, CA (650) 631-3100
NPI-0052 Nereus Pharmaceuticals (see also lymphoma, Phase I
San Diego, CA multiple myeloma) (858) 587-4090
oleandrin Ozelle Pharmaceuticals Phase I
(nerium oleander San Antonio, TX (309) 949-3745
extract)
OMP-21M18 GlaxoSmithKline Phase I
Rsch. Triangle Park, NC (888) 825-5249
OncoMed Pharmaceuticals (650) 995-8200
Redwood City, CA
omtriptolide Pharmagenesis Phase I
Palo Alto, CA (650) 813-1818
Pierre Fabre (973) 898-1042
Pharmaceuticals
Parsippany, NJ
ON-01910 Onconova Therapeutics (see also leukemia) Phase I
Princeton, NJ (609) 844-7735
Oncaspar® Enzon Pharmaceuticals combination therapy Phase I
pegaspargase Bridgewater, NJ (see also lymphoma) (866) 792-5172
OSI-906 OSI Pharmaceuticals Phase I
Melville, NY (631) 962-2000
OSI-930 OSI Pharmaceuticals Phase I
Melville, NY (631) 962-2000
PI3 kinase Genentech Phase I
inhibitor South San Francisco, CA (650) 224-1000
palifosfamide ZIOPHARM Oncology combination therapy Phase I
(ZIO-201) New York, NY (see also sarcoma) (212) 214-0700
PCI-24781 Pharmacyclics (see also leukemia) Phase I
Sunnyvale, CA (408) 774-0330
PDL-192 Facet Biotech Phase I
Redwood City, CA (650) 454-1000
PF-477736 Pfizer Phase I
New York, NY (860) 732-5156
PF-3814735 Pfizer Phase I
New York, NY (860) 732-5156
PF-4856882 Pfizer Phase I
(CovX045) New York, NY (860) 732-5156
PG-11047 Progen Pharmaceuticals Phase I
Redwood City, CA (650) 610-7800
PM-00104 PharmaMar USA (see also lymphoma) Phase I
Cambridge, MA (617) 868-3797
PM-02734 PharmaMar USA Phase I
Cambridge, MA (617) 868-3797
PRLX-93936 Prolexys Pharmaceuticals Phase I
Salt Lake City, UT (801) 303-1700

78 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
SOLID TUMORS
Product Name Sponsor Indication Development Status
PRX-321 Protox Therapeutics (see also brain) Phase I completed
Vancouver, Canada (604) 688-0199
PX-478 Oncothyreon (see also lymphoma) Phase I
Seattle, WA (206) 801-2100
PX-866 Oncothyreon Phase I
Seattle, WA (206) 801-2100
R547 Roche Phase I
Nutley, NJ (973) 235-5000
R763 EMD Serono Phase I
Rockland, MA (800) 283-8088
Rigel Pharmaceuticals (650) 624-1100
South San Francisco, CA
R1530 Roche Phase I
Nutley, NJ (973) 235-5000
R4733 Roche Phase I
Nutley, NJ (973) 235-5000
R7112 Roche (see also leukemia) Phase I
Nutley, NJ (973) 235-5000
R7167 Roche Phase I
Nutley, NJ (973) 235-5000
R7304 Roche Phase I
Nutley, NJ (973) 235-5000
R7347 Roche Phase I
Nutley, NJ (973) 235-5000
RH-1 Allos Therapeutics (see also lymphoma) Phase I
Westminster, CO (303) 426-6262
rinfabate Insmed Phase I completed
(rhIGFBP-3) Glen Allen, VA (804) 565-3000
RO-4987655 Roche Phase I
Nutley, NJ (973) 235-5000
RO-5083945 Roche Phase I
Nutley, NJ (973) 235-5000
sardomozide Novartis Pharmaceuticals (see also lymphoma) Phase I
East Hanover, NJ (888) 669-6682
SCH-900776 Schering-Plough (see also lymphoma) Phase I
Kenilworth, NJ (908) 298-4000
SF1126 Semafore Pharmaceuticals (see also mutliple myeloma) Phase I
Indianapolis, IN (317) 876-3075
simotaxel Taxolog Phase I
Fairfield, NJ (877) 829-6564
Wyeth Pharmaceuticals (800) 934-5556
Collegeville, PA
SN2310 OncoGenex Phase I
Pharmaceuticals (425) 686-1500
Bothell, WA

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 79
SOLID TUMORS
Product Name Sponsor Indication Development Status
SNS-032 Sunesis Pharmaceuticals (see also lymphoma) Phase I/II
South San Francisco, CA (650) 266-3500
SNS-314 Sunesis Pharmaceuticals Phase I
South San Francisco, CA (650) 266-3500
sonepcizumab Lpath Phase I
San Diego, CA (858) 678-0800
SPI-1620 Spectrum Pharmaceuticals adjunctive treatment Phase I
Irvine, CA (949) 788-6700
Sprycel™ Bristol-Myers Squibb (see also leukemia, prostate) in clinical trials
dasatinib Princeton, NJ (212) 546-4000
SSR97225 sanofi-aventis Phase I
Bridgewater, NJ (800) 633-1610
STA-9090 Synta Pharmaceuticals (see also leukemia) Phase I
Lexington, MA (781) 274-8200
TAK593 Millennium Phase I
Pharmaceuticals (800) 390-5663
Cambridge, MA
tanespimycin Bristol-Myers Squibb (see also multiple myeloma) Phase II
(Hsp90 inhibitor) Princeton, NJ (212) 546-4000
Tarvacin™ Peregrine Pharmaceuticals Phase I
bavituximab Tustin, CA (714) 508-6000
TGF beta inhibitor Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
TH-302 Threshold combination therapy Phase I/II
Pharmaceuticals (see also sarcoma) (650) 474-8200
Redwood City, CA --------------------------------------------------------------------------------------
monotherapy Phase I
(650) 474-8200
TLC388 Taiwan Liposome Phase I
Taipei, Taiwan
TRC-093 TRACON Pharmaceuticals Phase I
San Diego, CA (858) 550-0780
tricirbine VioQuest Pharmaceuticals (see also leukemia) Phase I/II
(VQD-002) Basking Ridge, NJ (908) 766-4400
TST-10088 Twinstrand Therapeutics Phase I
North Vancouver, Canada (604) 960-0857
UNBS-5162 Drais Pharmaceuticals (see also lymphoma) Phase I
Bridgewater, NJ (908) 895-1200
V935 Merck Phase III
Whitehouse Station, NJ (800) 672-6372
Velcade® Millennium (see also lung, lymphoma, Phase I/II
bortezomib Pharmaceuticals multiple myeloma) (800) 390-5663
Cambridge, MA
vinorelbine Hana Biosciences (see also lymphoma) Phase I
liposomal South San Francisco, CA (650) 588-6404

80 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
SOLID TUMORS
Product Name Sponsor Indication Development Status
VQD-001 VioQuest Pharmaceuticals Phase I/II
Basking Ridge, NJ (908) 766-4400
WX UK1 Wilex combination therapy Phase I
Munich, Germany www.wilex.com
XL-147 Exelixis Phase I
South San Francisco, CA (650) 837-7000
XL-281 Bristol-Myers Squibb Phase I
(RAF kinase Princeton, NJ (212) 546-4000
inhibitor) Exelixis
South San Francisco, CA
XL-518 Exelixis Phase I
(MEK inhibitor) South San Francisco, CA (650) 837-7000
Genentech
South San Francisco, CA
XL-765 Exelixis (see also brain) Phase I
South San Francisco, CA (650) 837-7000
XL-888 Exelixis Phase I
South San Francisco, CA (650) 837-7000
XMT-1001 Mersana Therapeutics refractory metastatic disease Phase I
Cambridge, MA (617) 498-0020
ZEN-012 AEterna Zentaris (see also lymphoma) Phase I
Warren, NJ (908) 626-5428
ZIO-301 ZIOPHARM Oncology combination therapy Phase I/II
(indibulin) New York, NY (646) 214-0700
--------------------------------------------------------------------------------------
monotherapy Phase I
(646) 214-0700

STOMACH CANCER
Product Name Sponsor Indication Development Status
Advexin® Introgen Therapeutics esophageal cancer Phase I/II
contusugene Austin, TX (see also bladder, brain, breast, (512) 708-9310
ladenovec head/neck, lung, ovarian, prostate)
AMG 102 Amgen gastric cancer Phase I/II
Thousand Oaks, CA (see also brain, colorectal, (805) 447-1000
kidney, lung)
AMG 386 Amgen gastrointestinal cancer Phase II
Thousand Oaks, CA (see also breast, kidney, ovarian, (805) 447-1000
other)
AV-951 AVEO Pharmaceuticals gastrointestinal cancer Phase I/II
Cambridge, MA (combination therapy) (617) 299-5000
(see also kidney, lung)

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 81
STOMACH CANCER
Product Name Sponsor Indication Development Status
Avastin® Genentech gastric cancer (combination Phase III
bevacizumab South San Francisco, CA therapy), gastrointestinal (650) 225-1000
stromal tumor (GIST)
(see also brain, colorectal,
head/neck, kidney, liver, lung,
lymphoma, multiple myeloma,
ovarian, pancreatic, prostate, other)
CNF-2024 Biogen Idec GIST Phase II
Cambridge, MA (see also breast, leukemia, (617) 679-2000
solid tumors)
Erbitux® Bristol-Myers Squibb esophageal cancer, gastric cancer Phase III
cetuximab Princeton, NJ (see also bladder, colorectal, (212) 546-4000
Eli Lilly head/neck, lung, prostate) (800) 545-5979
Indianapolis, IN (212) 645-1405
ImClone Systems
New York, NY
Herceptin® Genentech esophageal cancer, gastric cancer Phase III
trastuzumab South San Francisco, CA (see also colorectal, ovarian, (650) 225-1000
pancreatic, prostate, other)
Hycamtin® GlaxoSmithKline esophageal cancer, gastric cancer Phase II
topotecan Rsch. Triangle Park, NC (see also breast, colorectal, (888) 825-5249
head/neck, kidney, leukemia, lung,
lymphoma, multiple myeloma,
ovarian, pancreatic, prostate, other)
IMGN-242 ImmunoGen gastric cancer Phase II
Cambridge, MA (see also solid tumors) (617) 995-2500
Levulan® PD DUSA Pharmaceuticals gastrointestinal cancer in clinical trials
aminolevulinic acid Wilmington, MA (see also bladder, cervical, (978) 657-7500
colorectal, lung)
masitinib AB Science USA GIST Phase III
Short Hills, NJ (see also leukemia, pancreatic) (973) 218-2437
OncoGel™ Protherics esophageal cancer Phase II
Brentwood, TN (see also brain, pancreatic) (615) 327-1027
Oncophage® Antigenics (see also brain, colorectal, kidney, Phase I/II
vitespen New York, NY pancreatic, skin) (866) 805-8994
Opaxio™ Cell Therapeutics esophageal cancer, gastric cancer Phase I
paclitaxel Seattle, WA (see also lung, ovarian, other) (800) 215-2355
poliglumex Novartis Pharmaceuticals (888) 669-6682
East Hanover, NJ
PN401 Wellstat Therapeutics (see also colorectal, pancreatic) Phase II
Gaithersburg, MD (240) 631-2500
PX-12 Oncothyreon gastrointestinal cancer Phase I
Seattle, WA (see also pancreatic, other) (206) 801-2100
retaspimycin Infinity Pharmaceuticals GIST Phase III
(IPI 504) Cambridge, MA (see also breast, lung) (617) 453-1000
(Orphan Drug)

82 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
STOMACH CANCER
Product Name Sponsor Indication Development Status
Sutent® Pfizer gastric cancer (combination therapy) Phase II
sunitinib New York, NY (see also breast, colorectal, liver, (860) 732-5156
lung, pancreatic, prostate, sarcoma)
TAS-102 Taiho Pharma USA gastric cancer Phase II
Princeton, NJ (609) 750-5300
Tasigna® Novartis Pharmaceuticals GIST Phase III
nilotinib East Hanover, NJ (see also leukemia) (888) 669-6682
(Orphan Drug)
tesetaxel Genta second-line therapy Phase II
(Orphan Drug) Berkeley Heights, NJ (see also colorectal) (908) 286-9800
TheraCIM™ YM Biosciences esophageal cancer Phase II
nimotuzumab Wayne, PA (neoadjuvant therapy) (610) 560-0600
(see also brain, breast, prostate)
TNFerade™ GenVec esophageal cancer Phase II completed
Gaithersburg, MD (see also colorectal, head/neck, (240) 632-0740
pancreatic, skin)
Tykerb® GlaxoSmithKline gastric cancer (combination therapy) Phase III
lapatinib Rsch. Triangle Park, NC (see also brain, head/neck) (888) 825-5249
Xeloda® Roche esophageal cancer Phase II
capecitabine Nutley, NJ (see also colorectal) (973) 235-5000
XL-880 Exelixis gastric cancer Phase II
South San Francisco, CA (see also head/neck, kidney) (650) 837-7000
GlaxoSmithKline (888) 825-5249
Rsch. Triangle Park, NC

C A N C E R / C H E M O T H E R A P Y- R E L AT E D C O N D I T I O N S
Product Name Sponsor Indication Development Status
802-2 Adeona Pharmaceuticals graft-versus-host disease Phase I/II
Ann Arbor, MI (734) 332-7800
Acapodene® GTx complications from androgen application submitted
toremifene Memphis, TN deprivation therapy (901) 523-9700
(see also prostate)
acetylcysteine Adherex Technologies chemoprotection Phase I/II
Durham, NC (919) 484-8484
AKR-501 Eisai idiopathic thrombocytopenic Phase II
Woodcliff Lake, NJ purpura (888) 422-4743
Aredia® Novartis Pharmaceuticals cancer pain Phase III
pamidronic acid East Hanover, NJ (see also multiple myeloma) (888) 669-6682
Bexxar® GlaxoSmithKline myeloablation Phase II
tositumomab Rsch. Triangle Park, NC (see also leukemia, lymphoma) (888) 825-5249
CB-1400 Canopus BioPharma mucositis (prevention) Phase II
Studio City, CA (818) 980-5008
CJ-15161 Pfizer cancer pain Phase II
New York, NY (860) 732-5156

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 83
C A N C E R / C H E M O T H E R A P Y- R E L AT E D C O N D I T I O N S
Product Name Sponsor Indication Development Status
denosumab Amgen bone loss induced by hormone- Phase III
(AMG 162) Thousand Oaks, CA ablation therapy in breast or (805) 447-1000
prostate cancers, prevention of
cancer-related bone damage in
breast, prostate, or solid tumors
(see also multiple myeloma, other)
Elitek® sanofi-aventis chemotherapy-induced application submitted
rasburicase Bridgewater, NJ hyperuricemia in adults (800) 633-1610
Enbrel® Amgen graft-versus-host disease Phase II
etanercept Thousand Oaks, CA (805) 447-1000
Wyeth Pharmaceuticals (800) 934-5556
Collegeville, PA
fentanyl sublingual INSYS Therapeutics cancer pain Phase III
spray Phoenix, AZ (602) 910-2617
fentanyl sublingual Sosei R&D cancer pain Phase I
(SRSS-001) Tokyo, Japan
fentanyl transdermal Lavipharm cancer pain Phase III
patch East Windsor, NJ (609) 448-3001
Fosamax® Merck bone loss associated with androgen Phase II
alendronic acid Whitehouse Station, NJ deprivation therapy in prostate (800) 672-6372
cancer
golotimod SciClone Pharmaceuticals mucositis (prevention) Phase II
Foster City, CA (650) 358-3456
In-111-DAC Naviscan cancer diagnostic imaging Phase I
San Diego, CA (858) 587-3641
LGD-4665 GlaxoSmithKline treatment-induced Phase II
Rsch. Triangle Park, NC thrombocytopenia (888) 825-5249
morphine intranasal MDRNA cancer pain Phase II
Bothell, WA (425) 908-3600
MRX-1024 Molecular Therapeutics mucositis Phase I
Ann Arbor, MI (734) 259-4574
Nasalfent® Archimedes Pharma cancer pain Phase III
fentanyl intranasal Reading, United Kingdom
Neumega® Wyeth Pharmaceuticals chemotherapy-induced mucositis Phase II
oprelvekin Collegeville, PA (800) 934-5556
--------------------------------------------------------------------------------------
graft-versus-host disease Phase I/II
(800) 934-5556
Neuprex® XOMA graft-versus-host disease Phase I/II
opebacan Berkeley, CA in patients undergoing (510) 204-7200
allogeneic hematopoetic
stem cell transplantation
Nipent® Hospira graft-versus-host disease Phase II/III
pentostatin Lake Forest, IL (see also leukemia, lymphoma) (224) 212-2000
NP-2 Diamyd Medical cancer pain Phase I
gene therapy Pittsburgh, PA (412) 770-1310

84 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
C A N C E R / C H E M O T H E R A P Y- R E L AT E D C O N D I T I O N S
Product Name Sponsor Indication Development Status
Nplate™ Amgen chemotherapy-induced Phase II
romiplostim Thousand Oaks, CA thrombocytopenia (805) 447-1000
(see also leukemia)
ondansetron MonoSol Rx chemotherapy- and radiotherapy- Phase III
oral film Warren, NJ induced nausea and vomiting (219) 672-8112
Strativa Pharmaceuticals (201) 802-4206
Woodcliff Lake, NJ
ondansetron NovaDel Pharma chemotherapy- and radiotherapy- Phase III
oral spray Flemington, NJ induced nausea and vomiting (908) 782-3431
Strativa Pharmaceuticals (201) 802-4206
Woodcliff Lake, NJ
Onsolis™ BioDelivery Sciences cancer pain application submitted
fentanyl Morrisville, NC (919) 653-5160
transmucosal Meda Pharmaceuticals
Somerset, NJ
orBec® DOR BioPharma graft-versus-host disease application submitted
beclometasone Ewing, NJ (609) 538-8200
(Orphan Drug) Sigma-Tau Pharmaceuticals (800) 447-0169
Gaithersburg, MD --------------------------------------------------------------------------------------
graft-versus-host disease (prevention) Phase II
(609) 538-8200
(800) 447-0169
PF-4383119 Pfizer cancer pain Phase II
(tanezumab) New York, NY (860) 732-5156
PHY-906 PhytoCeutica chemoprotection Phase I/II
New Haven, CT (203) 777-3462
Phytosel® iBioPharma chemoprotection Phase I
Newark, DE (302) 355-0650
PMI-150 Javelin Pharmaceuticals cancer pain Phase III
(ketamine Cambridge, MA (617) 349-4500
intranasal)
Prochymal® Osiris Therapeutics graft-versus-host disease Phase III
human Columbia, MD (443) 545-1800
mesenchymal stem
cell therapy
(Orphan Drug)
Prograf® Astellas Pharma US graft-versus-host disease application submitted
tacrolimus Deerfield, IL (800) 727-7003
Rapamune® Wyeth Pharmaceuticals bone marrow transplant rejection Phase II
sirolimus Collegeville, PA (see also unspecified) (800) 934-5556
Rapinyl™ Orexo breakthrough cancer pain Phase III
fentanyl sublingual Uppsala, Sweden
(EN 3267) ProStrakan
Galashiels, United Kingdom

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 85
C A N C E R / C H E M O T H E R A P Y- R E L AT E D C O N D I T I O N S
Product Name Sponsor Indication Development Status
Reviroc™ Kiadais Pharma bone marrow transplant rejection Phase II
(Orphan Drug) St. Laurent, Canada (514) 336-4886
--------------------------------------------------------------------------------------
graft-versus-host disease Phase I/II
(514) 336-4886
Sativex® Otsuka America cancer pain Phase II/III
dronabinol/ Pharmaceutical (800) 562-3974
cannabidiol Rockville, MD
SCH-58500 Schering-Plough myeloablation Phase I
(p53 gene therapy) Kenilworth, NJ (see also bladder, head/neck, (908) 298-4000
liver, lung)
STS Adherex Technologies chemoprotection Phase III
Durham, NC (919) 484-8484
Tavocept™ BioNumerik chemoprotection Phase III
dimesna Pharmaceuticals (210) 614-1701
San Antonio, TX
Telintra® Telik chemotherapy-induced neutropenia Phase II
ezatiostat Palo Alto, CA (see also leukemia) (650) 845-7700
Titragesia™ ZARS Pharma cancer pain Phase III
fentanyl patch Salt Lake City, UT (801) 350-0202
totrombopag GlaxoSmithKline thrombocytopenia Phase I
Rsch. Triangle Park, NC (888) 825-5249
Urso Forte™ Axcan Pharma chemoprevention Phase II
ursodeoxycholic Birmingham, AL (see also colorectal) (205) 991-8085
acid
veltuzumab Immunomedics chemotherapy-induced immune Phase I/II
(IMMU-106) Morris Plains, NJ thrombocytopenic purpura (973) 605-8200
(see also lymphoma)
Voraxaze™ Protherics chemoprotection application submitted
glucarpidase Brentwood, TN (615) 327-1027
xaliproden sanofi-aventis chemotherapy-induced Phase III
Bridgewater, NJ neuropathies (800) 633-1610
ZRx101 ZelleRx graft-versus-host disease Phase I
Chicago, IL (see also kidney, (312) 243-5200
multiple myeloma, skin)

OTHER CANCERS
Product Name Sponsor Indication Development Status
3F8 mAb United Therapeutics central nervous system cancer Phase II
Silver Spring, MD (see also brain) (301) 608-9292
°
A6 Angstrom Pharmaceuticals advanced gynecological cancer Phase I
Solana Beach, CA (see also ovarian) (858) 314-2356

86 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
OTHER CANCERS
Product Name Sponsor Indication Development Status
aflibercept sanofi-aventis symptomatic malignant ascites Phase III
(VEGF-trap) Bridgewater, NJ (see also colorectal, lung, (800) 633-1610
Regeneron Pharmaceuticals pancreatic, prostate) (914) 345-7400
Tarrytown, NY
AMG 386 Amgen fallopian tube cancer, Phase II
Thousand Oaks, CA peritoneal cancer (805) 447-1000
(see also breast, kidney, ovarian,
stomach)
Armala™ GlaxoSmithKline fallopian tube cancer, Phase II
pazopanib Rsch. Triangle Park, NC peritoneal cancer (888) 825-5249
(see also brain, breast, cervical,
kidney, liver, lung, ovarian, sarcoma)
ARQ-501 ArQule leiomyoma Phase II
(beta lapachone) Woburn, MA (see also head/neck, pancreatic, (781) 994-0300
solid tumors)
ATI-BC-1 Algeta bone cancer (metastatic from Phase I
Oslo, Norway hormone-refractory prostate cancer) www.algeta.com
atiprimod Callisto Pharmaceuticals carcinoid tumor Phase II
New York, NY (212) 297-0010
Avastin® Genentech fallopian tube cancer, Phase III
bevacizumab South San Francisco, CA peritoneal cancer (650) 225-1000
(see also brain, colorectal,
head/neck, kidney, liver, lung,
lymphoma, multiple myeloma,
ovarian, pancreatic, prostate,
stomach)
axitinib Pfizer thyroid cancer Phase II
New York, NY (see also colorectal, kidney, lung, (860) 732-5156
solid tumors)
AZD6244 AstraZeneca thyroid cancer Phase II
Wilmington, DE (see also leukemia, liver, lung, (800) 236-9933
multiple myeloma, ovarian,
pancreatic, skin)
Azedra™ Molecular Insight neuroendocrine tumors Phase I/II
iodine-labeled Pharmaceuticals (see also brain) (617) 492-5554
metaiodobenzyl- Cambridge, MA
guanidine
(Orphan Drug)
Bonefos® Bayer HealthCare cancer metastases application submitted
clodronic acid Pharmaceuticals (888) 842-2937
Wayne, NJ
BSI-201 BiPar Sciences fallopian tube cancer, peritoneal Phase II
Brisbane, CA cancer, uterine cancer (650) 635-6050
(see also brain, breast, ovarian)
catumaxomab Fresenius Biotech malignant ascites Phase II
North America (see also ovarian) www.fresenius-biotech.com
Waltham, MA

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 87
OTHER CANCERS
Product Name Sponsor Indication Development Status
CDB-4124 Repros Therapeutics uterine leiomyoma Phase III
The Woodlands, TX (281) 719-3400
CS-7017 Daiichi Sankyo thyroid cancer Phase I
Parsippany, NJ (see also lung) (973) 359-2600
CX-4945 Cylene Pharmaceuticals giant lymph node hyperplasia Phase I
San Diego, CA (see also multiple myeloma, (858) 875-5100
solid tumors)
D4064A Genentech fallopian tube cancer, Phase I
South San Francisco, CA peritoneal cancer (650) 224-1000
(see also ovarian)
deforolimus ARIAD Pharmaceuticals endometrial cancer Phase II
(MK-8669) Cambridge, MA (see also breast, lung, prostate, (617) 494-0400
Merck sarcoma) (800) 672-6372
Whitehouse Station, NJ
denosumab Amgen prevention of bone metastases Phase III
(AMG 162) Thousand Oaks, CA (see also multiple myeloma, (805) 447-1000
cancer-related)
DM-CHOC-PEN Dekk-Tec central nervous system cancer Phase I
New Orleans, LA (504) 583-6135
E7080 Eisai thyroid cancer Phase II
Woodcliff Lake, NJ (see also solid tumors) (888) 422-4743
EC-20 Endocyte diagnosis of folate receptor- Phase II
West Lafayette, IN positive cancers (765) 463-7175
EC-145 Endocyte endometrial cancer Phase II
West Lafayette, IN (see also lung, ovarian) (765) 463-7175
everolimus Novartis Pharmaceuticals neuroendocrine tumors Phase III
East Hanover, NJ (see also kidney, pancreatic) (888) 669-6682
Herceptin® Genentech salivary gland cancer Phase II
trastuzumab South San Francisco, CA (see also colorectal, ovarian, (650) 225-1000
pancreatic, prostate, stomach)
Hycamtin® GlaxoSmithKline uterine cancer Phase II
topotecan Rsch. Triangle Park, NC (see also breast, colorectal, (888) 825-5249
head/neck, kidney, leukemia, lung,
lymphoma, multiple myeloma,
ovarian, pancreatic, prostate,
stomach)
idronoxil Marshall Edwards fallopian tube cancer Phase I/II
North Ryde, Australia (combination therapy)
(see also ovarian, prostate)
ING 1 Aduro BioTech adenocarcinoma Phase I
Berkeley, CA (510) 848-4400
MCS110 Novartis Pharmaceuticals bone cancer Phase I/II
East Hanover, NJ (see also prostate) (888) 669-6682
MER-101 Merrion Pharmaceuticals bone cancer Phase II
Wilmington, NC (910) 799-1847

88 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
OTHER CANCERS
Product Name Sponsor Indication Development Status
MK-0646 Merck neuroendocrine tumors Phase II
Whitehouse Station, NJ (see also breast, lung, pancreatic) (888) 669-6682
MK-0822 Merck bone cancer Phase III completed
Whitehouse Station, NJ (800) 672-6372
motesanib Amgen thyroid cancer Phase II
Thousand Oaks, CA (see also breast, colorectal, lung) (805) 447-1000
Millennium (800) 390-5663
Pharmaceuticals
Cambridge, MA
NBI-42902 Neurocrine Biosciences uterine leiomyoma Phase I
San Diego, CA (see also breast, prostate) (858) 617-7600
Norprolac® Ferring Pharmaceuticals prolactinoma Phase II
quinagolide Suffern, NY www.ferring.com
Opaxio™ Cell Therapeutics peritoneal cancer Phase II
paclitaxel Seattle, WA (see also lung, ovarian, stomach) (800) 215-2355
poliglumex Novartis Pharmaceuticals (888) 669-6682
East Hanover, NJ --------------------------------------------------------------------------------------
fallopian tube cancer Phase I/II
(800) 215-2355
(888) 669-6682
pasireotide Novartis Pharmaceuticals neuroendocrine tumors Phase I completed
East Hanover, NJ (888) 669-6682
PX-12 Oncothyreon metastatic disease Phase I
Seattle, WA (see also pancreatic, stomach) (206) 801-2100
Quadramet® Cytogen cancer metastases Phase III
samarium sm-153 Princeton, NJ (see also multiple myeloma, (800) 833-3533
lexidronam prostate, sarcoma)
injection
quarfloxin Cylene Pharmaceuticals neuroendocrine tumors Phase II
San Diego, CA (858) 875-5100
RAV-12 Raven Biotechnologies adenocarcinoma Phase I/II
South San Francisco, CA (see also pancreatic) (650) 624-2600
relacatib GlaxoSmithKline cancer metastases Phase II
(cathepsin Rsch. Triangle Park, NC (888) 825-5249
K inhibitor)
Revlimid® Celgene central nervous system cancer Phase II
lenalidomide Summit, NJ (see also leukemia, lymphoma, (908) 673-9000
multiple myeloma, prostate)
saracatinib AstraZeneca metastatic bone cancer Phase II
Wilmington, DE (800) 236-9933
seliciclib Cyclacel Pharmaceuticals nasopharyngeal cancer Phase II
Short Hills, NJ (see also lung) (973) 847-5955
Somatuline Tercica neuroendocrine tumors Phase III
Autogel® Brisbane, CA (650) 624-4900
lanreotide

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 89
OTHER CANCERS
Product Name Sponsor Indication Development Status
Tarceva® Genentech gynecological cancer Phase II
erlotinib South San Francisco, CA (combination therapy) (650) 224-1000
OSI Pharmaceuticals (see also bladder, brain, breast, (800) 572-1932
Melville, NY colorectal, head/neck, liver, lung)
Taxotere® sanofi-aventis pediatric cancer Phase III
docetaxel Bridgewater, NJ (800) 633-1610
V503 Merck vulvovaginal cancer prevention Phase III
Whitehouse Station, NJ (see also cervical) (800) 672-6372
XL-184 Bristol-Myers Squibb medullary thyroid cancer Phase III
Princeton, NJ (see also brain) (212) 546-4000
Exelixis
South San Francisco, CA
Yondelis® Johnson & Johnson endometrial cancer Phase II
trabectedin Pharmaceutical Research (see also breast, ovarian, (800) 817-5286
& Development prostate, sarcoma)
Raritan, NJ
Zactima® AstraZeneca medullary thyroid cancer Phase III
vandetanib Wilmington, DE (see also brain, breast, lung) (800) 236-9933
Zybrestat™ OXiGENE thyroid cancer (combination therapy) Phase II/III
fosbretabulin Waltham, MA (see also head/neck, lung, ovarian) (781) 547-5900
(Orphan Drug)

UNSPECIFIED CANCERS
(DRUGS THAT H AV E POTENTIAL FOR ONE OR MORE OF THE PREVIOUS CANCERS)
Product Name Sponsor Indication Development Status
1059615 GlaxoSmithKline Phase I
Rsch. Triangle Park, NC (888) 825-5249
1120212 GlaxoSmithKline Phase I
Rsch. Triangle Park, NC (888) 825-5249
AFX-9901 Afecta Pharmaceuticals in clinical trials
Irvine, CA (949) 253-4688
AG-24322 Pfizer Phase I
New York, NY (860) 732-5156
AGS-16M18 Agensys Phase I
Santa Monica, CA (310) 820-8029
Astellas Pharma US (800) 477-6472
Deerfield, IL
ALT-801 Altor BioScience Phase I/II
Miramar, FL (954) 443-8600
anti-HGF mAb Schering-Plough Phase I
Kenilworth, NJ (908) 298-4000
ANX-514 ADVENTRX Pharmaceuticals Phase I
(docetaxel San Diego, CA (858) 552-0866
emulsion)

90 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
UNSPECIFIED CANCERS
(DRUGS THAT H AV E POTENTIAL FOR ONE OR MORE OF THE PREVIOUS CANCERS)
Product Name Sponsor Indication Development Status
ARRY-300 Array BioPharma Phase I
Boulder, CO (303) 381-6600
ARRY-380 Array BioPharma Phase I
Boulder, CO (303) 381-6600
ARRY-614 Array BioPharma Phase I
Boulder, CO (303) 381-6600
AVR-118 Advanced Viral Research Phase II
Yonkers, NY (914) 376-7383
belotecan ALZA Phase I
Mountain View, CA (650) 564-5000
BIO-109 Evolve Oncology Phase II
New York, NY (646) 723-8941
BIO-113 Evolve Oncology Phase II
New York, NY (646) 723-8941
BIO-121 Evolve Oncology Phase I
New York, NY (646) 723-8941
BIO-128 Evolve Oncology Phase I
New York, NY (646) 723-8941
BLX-883 Biolex Phase I
Pittsboro, NC (919) 542-9901
carbendazim Arisyn Therapeutics Phase I
Frederick, MD (301) 644-3921
CLT-001 Cellerant Therapeutics Phase II
San Carlos, CA (650) 232-2122
CNDO-101 Coronado Biosciences Phase I
San Diego, CA (510) 396-5709
CPI-613 Cornerstone Phase I
Pharmaceuticals (609) 409-7050
Cranbury, NJ
EC-0225 Endocyte Phase I
West Lafayette, IN (765) 463-7175
ENMD-1198 EntreMed Phase I
Rockville, MD (240) 864-2600
EZN-2208 Enzon Pharmaceuticals Phase I
Bridgewater, NJ (866) 792-5172
F50035 Merck Phase II
Whitehouse Station, NJ (800) 672-6372
Pierre Fabre Medicament
Castres, France
Fibrovax™ Cytokine PharmaSciences Phase I
cancer vaccine King of Prussia, PA (610) 687-1776
GPX-150 Gem Pharmaceuticals Phase I/II
Birmingham, AL (205) 982-0320

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 91
UNSPECIFIED CANCERS
(DRUGS THAT H AV E POTENTIAL FOR ONE OR MORE OF THE PREVIOUS CANCERS)
Product Name Sponsor Indication Development Status
HuCAL fully Centocor Phase I
human antibody Horsham, PA (610) 651-6000
MorphoSys
Martinsried, Germany
IAP antagonist Genentech Phase I
South San Francisco, CA (650) 224-1000
IMC-18F1 ImClone Systems Phase I
New York, NY (212) 645-1405
Imprime PGG™ Biothera Phase I
Eagen, MN (651) 675-0300
JNJ-26483327 Johnson & Johnson in clinical trials
Pharmaceutical Research (800) 817-5286
& Development
Raritan, NJ
KX2-391 Kinex Pharmaceuticals Phase I
Buffalo, NY (716) 881-8984
LBY135 Novartis Pharmaceuticals Phase I
East Hanover, NJ (888) 669-6682
LOR-2501 Lorus Therapeutics Phase I
Toronto, Canada (416) 798-1200
LR-103 Genzyme Phase I
Cambridge, MA (617) 252-7500
LY2157299 Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
LY2603618 Eli Lilly Phase I
Indianapolis, IN (800) 545-5979
MK-2461 Merck Phase I/II
Whitehouse Station, NJ (800) 672-6372
MK-4101 Merck Phase I
Whitehouse Station, NJ (800) 672-6372
MK-8033 Merck Phase I
Whitehouse Station, NJ (800) 672-6372
MKI833 Wyeth Pharmaceuticals Phase 0
Collegeville, PA (800) 934-5556
NRX-4204 NuRx Pharmaceuticals Phase I
Irvine, CA (949) 336-7111
OSI-7904L OncoVista Phase II
San Antonio, TX (210) 677-6000
oxaliplatin Mebiopharm Phase I
liposomal Tokyo, Japan www.mebiopharm.com
PBI-05204 Phoenix Biotechnology Phase I
San Antonio, TX (877) 593-8945
PCI-27483 Pharmacyclics Phase I
Sunnyvale, CA (408) 774-0330

92 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
UNSPECIFIED CANCERS
(DRUGS THAT H AV E POTENTIAL FOR ONE OR MORE OF THE PREVIOUS CANCERS)
Product Name Sponsor Indication Development Status
PF-337210 Pfizer Phase I
New York, NY (860) 732-5156
PF-562271 Pfizer Phase I
New York, NY (860) 732-5156
PF-2341066 Pfizer Phase I
New York, NY (860) 732-5156
PF-3084014 Pfizer Phase I
New York, NY (860) 732-5156
PF-3446962 Pfizer Phase I
New York, NY (860) 732-5156
PF-3732010 Pfizer Phase I
New York, NY (860) 732-5156
PF-4217903 Pfizer Phase I
New York, NY (860) 732-5156
PF-4554878 Pfizer Phase I
New York, NY (860) 732-5156
PF-4856884 Pfizer Phase I
(CovX060) New York, NY (860) 732-5156
PF-4929113 Pfizer Phase I
New York, NY (860) 732-5156
PHA-848125 Nerviano Medical Sciences Phase I
Nerviano, Italy www.nervianoms.com
plasmid DNA Merck Phase I
cancer vaccine Whitehouse Station, NJ (800) 672-6372
Vical (858) 646-1100
San Diego, CA
QBI-139 Quintessence Biosciences Phase I
Madison, WI (608) 441-2950
R306465 Johnson & Johnson Phase I
Pharmaceutical (800) 817-5286
Research & Development
Raritan, NJ
Rapamune® Wyeth Pharmaceuticals (see also cancer-related) Phase I
sirolimus Collegeville, PA (800) 934-5556
RDEA-119 Ardea Biosciences Phase I/II
San Diego, CA (858) 652-6500
RDEA-436 Ardea Biosciences Phase 0
San Diego, CA (858) 652-6500
SJG-136 Ipsen Phase I
Milford, MA (508) 478-8900
SNX-5422 Serenex Phase I
Durham, NC (919) 281-6001
SRT-501 Sirtris Pharmaceuticals Phase II
Cambridge, MA (617) 252-6920

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 93
UNSPECIFIED CANCERS
(DRUGS THAT H AV E POTENTIAL FOR ONE OR MORE OF THE PREVIOUS CANCERS)
Product Name Sponsor Indication Development Status
TAK-285 Millennium Phase I
Pharmaceuticals (800) 390-5663
Cambridge, MA
taltobulin Wyeth Pharmaceuticals Phase I
Collegeville, PA (800) 934-5556
TRC-102 TRACON Pharmaceuticals Phase I
San Diego, CA (858) 550-0780
TRC-105 TRACON Pharmaceuticals Phase I
San Diego, CA (858) 550-0780
V930 Merck Phase I
(cancer vaccine) Whitehouse Station, NJ (800) 672-6372
Vical (858) 646-1100
San Diego, CA
VTX-2337 VentiRx Pharmaceuticals Phase I
San Diego, CA (858) 436-1530

The content of this report has been obtained through industry sources and the Adis “R&D Insight” database
based on the latest information. Report current as of March 23, 2009. The information may not be comprehensive.
For more specific information about a particular product, contact the individual company directly or go to
www.clinicaltrials.gov. The entire series of Medicines in Development is available on PhRMA’s web site.
A publication of PhRMA’s Communications & Public Affairs Department. (202) 835-3460
www.phrma.org | www.innovation.org | www.pparx.org | www.buysafedrugs.info | www.sharingmiracles.com
Provided as a Public Service by PhRMA. Founded in 1958 as the Pharmaceutical Manufacturers Association.
Copyright © 2009 by the Pharmaceutical Research and Manufacturers of America. Permission to reprint is awarded if
proper credit is given.

94 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
GLOSSARY
actinic keratoses—Roughness and occur, and the average incidence is phomas, AIDS-related malignancies,
thickening of the skin caused by over- 1 case per 100,000 people per year. multiple myeloma, myelodysplasia
exposure to the sun’s ultraviolet rays. and myeloproliferative disorders.
cutaneous—Pertaining to the skin.
It can degenerate into a skin cancer
hepatocellular cancer/carcinoma—
called squamous cell carcinoma. dysplasia—Abnormal tissue develop-
A cancer that begins in the liver cells.
ment.
adenocarcinoma—Malignant tumor
hyperuricemia—An abnormally high
derived from a gland or glandular gastric—Of or relating to the stomach.
uric acid level in the blood.
tissue.
GISTs—Gastrointestinal stromal
adjunctive treatment—An auxiliary tumors are uncommon tumors of the imaging agent—A substance used to
treatment that is secondary to the GI tract. Not all GISTs are cancerous; enhance x-ray images of organs and
main treatment. some are benign. Although these spaces in the body.
cancers can arise anywhere in the intraepithelial neoplasia, anal (AIN)
adjuvant—A substance or drug that GI tract, they occur most often in & cervical (CIN)— AIN is a conse-
aids another substance in its action. the stomach (60% to 70%) and less quence of chronic human papillo-
allogeneic—Refers to having cell commonly in the small intestine mavirus infection in the anal canal
types that are distinct and cause (20% to 30%). The rest are found in and appears to be driven by high
reactions in the immune system. the esophagus, large intestine, rectum, viral loads of human papillomavirus.
and anus. About 80% of people diag- What is known of its natural history
application submitted—An applica- nosed with GIST are older than 50. resembles that of cervical intraep-
tion for marketing has been submitted It is slightly more common in men. ithelial neoplasia. Dysplasia and cer-
by the company to the Food and Blacks are more likely to develop vical intraepithelial neoplasia (CIN)
Drug Administration (FDA). GISTs than whites. are different terms or names for the
ascites—Excess fluid in the space glioblastoma—A fast growing and same condition—it is a precursor to
between the tissues lining the highly malignant type of brain tumor cervical cancer. CIN may be mild,
abdomen and abdominal organs (the arising from glial (supporting) cells moderate or severe.
peritoneal cavity). within the brain. There are about Kaposi’s sarcoma—A rare, malignant
basal cell cancer—Cancer of the five to 10 new cases per million skin tumor that occurs in some AIDS
lower layers of the skin. population per year in the United patients. It can be accompanied by
States, and the cause is unknown. fever, enlarged lymph nodes and
B-cell—A class of white blood cells gastrointestinal problems.
important to the body’s immune glioma—A type of brain tumor arising
system. from the supporting glial cells within leiomyoma—A benign neoplasm
the brain. Gliomas make up about derived from smooth muscle.
biliary—Relating to bile. 60 percent of all primary brain tumors
and are frequently malignant. leukemia—A form of cancer in which
carcinoma—A malignant tumor that abnormally growing white blood cells
arises from epithelial tissues, such graft-versus-host disease are scattered throughout the body and
as skin. (GVHD)—A complication in bone bone marrow. They can take over the
marrow transplants where immune marrow and prevent it from making
cervical—Relating to the neck of
system cells attack the transplant enough normal blood cells (white,
the uterus.
recipient’s tissues. red and platelets), leaving the patient
chemoprotection—A therapeutic highly susceptible to serious infec-
head and neck cancer—The term
technique in which bone marrow tions, anemia and bleeding episodes.
given to a variety of malignant tumors
cells are removed from an individual The cells can also spill into the blood,
that develop in the mouth, throat,
with cancer and are genetically mod- infiltrating and interfering with the
paranasal sinuses, nasal cavity, larynx,
ified to withstand higher doses of function of other organs. The four
and salivary glands. Many authori-
chemotherapy before being returned main types of leukemia are: acute
ties also include skin tumors of the
to the donor. lymphoblastic leukemia (ALL), acute
face and neck and tumors of the cer-
cholangiocarcinoma—A malignancy vical lymph nodes. There are more myeloid leukemia (AML), chronic
of the biliary duct system that may than half a million survivors of oral, lymphocytic leukemia (CLL), and
originate in the liver and extrahepatic head, and neck cancer living in the chronic myeloid leukemia (CML).
bile ducts. More than 90 percent are United States today. The acute types have a rapid onset,
adenocarcinomas, and the remainder and overwhelming infection or blood
hematological malignancies— loss can cause death. The chronic
are squamous cell tumors. Cholangio-
Cancers of the blood or blood- forms progress much more slowly.
carcinomas tend to grow slowly and
forming tissues, such as leukemia,
to infiltrate the walls of the ducts. Each lung cancer—The leading cause
Hodgkin’s and non-Hodgkin’s lym-
year, approximately 2,500 cases of cancer deaths in both men and

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 95
GLOSSARY
women. There are several types of can occur anywhere along the diges- Phase 0—First-in-human trials con-
lung cancer, the most common being tive tract from the mouth to the anus. ducted in accordance with FDA’s
squamous cell carcinoma, small (oat) It can be a very troublesome and 2006 guidance on exploratory
cell carcinoma, adenocarcinoma and painful side effect of chemotherapy. Investigational New Drug (IND) stud-
large cell carcinoma. Each has a dif- ies designed to speed up development
multiple myeloma—A malignant
ferent growth pattern and response to of promising drugs by establishing
condition of middle to old age,
treatment. The squamous cell, small very early on whether the agent
characterized by the uncontrolled
cell and large cell types are all strongly behaves in human subjects as was
proliferation and disordered function
associated with tobacco abuse. anticipated from preclinical studies.
of plasma cells in the bone marrow.
lymphoma—Cancers in which the The condition, which makes the Phase I—Safety testing and pharma-
cells of lymphoid tissue, found mainly patient particularly prone to infection, cological profiling of new drugs in
in the lymph nodes and spleen, mul- is rare, with about three new cases small numbers of humans.
tiply unchecked. Lymphomas fall into annually per 100,000 population.
two categories: Hodgkin disease, Phase II—Effectiveness testing and
myeloablation—A severe form of identification of side effects of new
characterized by a particular kind
myelosuppression, a condition in drugs in humans.
of abnormal cell, and non-Hodgkin
which bone marrow activity is
lymphomas, which vary in their Phase III—Extensive clinical trials
decreased, resulting in fewer red
malignancy according to the nature in humans to verify effectiveness and
blood cells, white blood cells, and
and activity of the abnormal cells. monitor adverse reactions of new drugs.
platelets. It is a side effect of some
Mantle cell lymphoma is a type of
cancer treatments. prolactinoma—A noncancerous
non-Hodgkin lymphoma.
pituitary tumor that produces a hor-
macroglobulinemia—A disorder in myelodysplastic syndromes (MDS)—
mone called prolactin, which results
which plasma cells produce an Blood disorders that ultimately are
in too much prolactin in the blood.
excessive quantity of macroglobulins fatal. Patients usually succumb to
(large antibodies) that accumulate in infections or bleeding. The term refractory—Resistant to treatment or
the blood. It results from a group of “preleukemia” has been used to cure.
abnormal, cancerous lymphocytes describe these disorders.
sarcoma—A malignant tumor that
and plasma cells. Men are affected neoadjuvant therapy—Chemo- arises from deep body tissues, such
more often than women, and the therapy, radiation therapy, or hor- as muscle, bone or fibrous tissue.
average age at onset is 65. mone therapy given before the
primary or main treatment. Neo- T-cell—One of two main classes of
mastocytosis—A condition charac- white blood cells called lymphocytes,
terized by infiltration of mast cells adjuvant therapy, like chemotherapy
and radiation therapy, is often given which are important to the body’s
into the tissues of the body. Mast disease-fighting immune system.
cells are connective tissue cells before surgery to reduce the size of
which release chemicals including a tumor or to make surgery less thrombocytopenia—A reduction in
histamine that are very irritating and complicated. the number of platelet cells in the
cause itching, swelling, and fluid neuroblastoma—A tumor of the blood, which causes a tendency to
leakage from cells. adrenal glands or sympathetic nerv- bleed, especially from the smaller
ous system (the part of the nervous blood vessels.
medullary—Relating to the medulla
(any soft marrow-like structure, espe- system responsible for certain auto- thymoma—Although rare, thymomas
cially the innermost part) or marrow. matic body functions, such as the are the most common tumor of the
control of heart rate). Neuroblastomas thymus, a small organ located in the
melanoma—A cancer made up of are the most common extracranial upper chest just below the neck that
pigmented (usually brown-colored) (outside the skull) solid tumors of produces certain types of white blood
skin cells anywhere in the body. childhood. cells (lymphocytes) before birth and
mesothelioma—A tumor of the lining of during childhood. Thymomas arise
osteosarcoma—Cancer of the bone from thymic epithelial cells, which
the lung and chest cavity (the pleura). that occurs predominantly in adoles- make up the covering of the thymus.
metastases/metastatic—Areas of cents and young adults. It accounts Up to 40 percent of thymomas are
secondary cancer that have spread for 5 percent of cancer in children invasive. They affect men and women
from the primary or original cancer peritoneal—Relating to the peri- equally and are usually diagnosed
site. toneum, the membrane that lines the between the ages of 40 and 60.
mucositis—The swelling, irritation, abdominal cavity and covers most of Thymomas are uncommon in children.
and ulceration of the mucosal cells the abdominal organs. unresectable—Unable to be
that line the digestive tract. Mucositis removed (resected) by surgery.

96 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
SELECTED FACTS ABOUT CANCER IN THE
UNITED STATES
Overview1
• In 2008, more than 1.4 million new cancer cases are expected to be diagnosed. The National Cancer Institute estimates
that approximately 10.1 million Americans with a history of cancer were alive in January 2002. The 5-year relative
survival rate for all cancers diagnosed between 1996 and 2003 is 66 percent, up from 50 percent in the mid-70s.
• Men have a little less than a 1 in 2 lifetime risk of developing cancer, and for women, the risk is a little more than
1 in 3. About 77 percent of all cancers are diagnosed in people ages 55 and older.
• Scientific evidence suggests that about one-third of the cancer deaths expected this year will be related to overweight
or obesity, physical inactivity, and nutrition, and thus could be prevented.
• Cancer is the second leading cause of death by disease—1 of every 4 deaths—in the United States, exceeded only
by heart disease. This year, an estimated 565,650 are expected to die of cancer, more than 1,500 people a day.
Costs1
• The National Institutes of Health estimate overall costs for cancer in 2007 at $219.2 billion: $89 billion for
direct medical costs (total of all health expenditures); $18.2 billion for indirect morbidity costs (e.g., cost of lost
productivity due to illness); and $112 billion for indirect mortality costs (cost of lost productivity due to
premature death).

Bladder (Urinary) Cancer1


• Nearly 69,000 new cases of bladder cancer are expected in 2008. The incidence rate is nearly four times higher in
men than in women and almost two times higher in whites than in African Americans.
• Bladder cancer will cause more than 14,000 deaths in 2008. Mortality rates have continued to decrease since
the late ‘70s, although the rate of decrease slowed in the most recent time period (0.2 percent a year from
1987-2004 compared with 2.1 percent a year from 1977-1987).

Breast Cancer1
• After continuously increasing for more than two decades, female breast cancer incidence rates decreased by 3.5
percent per year from 2001-2004. From 1992-2004, incidence rates decreased among American Indians/Alaska
Natives (1.5 percent per year) and did not change significantly among Asian Americans/Pacific Islanders or
Hispanics/Latinas.
• Death rates from breast cancer have steadily decreased in women since 1990, with larger decreases in women
younger than age 50 (a decrease of 3.3 percent per year) than in those age 50 and older (2 percent per year).
From 1995-2004, female breast cancer death rates declined by 2.4 percent per year in whites and Hispanics/Latinas,
1.6 percent per year in African Americans, and remained unchanged among Asian Americans/Pacific Islanders
and American Indians/Alaska Natives. The decrease in breast cancer death rates represents progress in both
earlier detection and improved treatment.

Cervical Cancer/Uterine (Endometrial) Cancer1


• An estimated 11,070 cases of invasive cervical cancer are expected to be diagnosed in 2008. Incidence rates have
decreased steadily over the past several decades in both white and African-American women. Mortality rates have
also declined steadily; an estimated 3,870 cervical cancer deaths are expected in 2008.
• More than 40,000 cases of cancer of the uterine corpus (body of the uterus), usually of the endometrium or lining
of the uterus, are expected to be diagnosed in 2008.

Colorectal Cancer1
• An estimated 108,070 colon and 40,740 rectal cancer cases are expected to occur in 2008. Colorectal cancer is
the third most common cancer in men and women. More than 90 percent of colorectal cancer cases are diagnosed
in people over age 50.

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 97
SELECTED FACTS ABOUT CANCER IN THE
UNITED STATES
Colorectal Cancer1 (continued)
• Nearly 50,000 deaths from colorectal cancer are expected to occur this year, accounting for 9 percent of all
cancer deaths. Mortality rates from colorectal cancer have declined in both men and women over the past two
decades with a steeper decline in the most recent time period (1.8 percent per year from 1985-2002 compared
to 4.7 percent from 2002-2004). That decrease reflects declining incidence rates and improvements in early
detection and treatment.

Leukemia1
• An estimated 44,270 new leukemia cases are expected in 2008, with slightly more cases of chronic (19,940) than
acute (18,720) forms of the disease.
• Although often thought of as primarily a childhood disease, leukemia is diagnosed 10 times more often in adults
than in children. Acute lymphocytic leukemia accounts for approximately 72 percent of the leukemia cases
among children. In adults, the most common types are acute myeloid leukemia (about 13,290 cases) and
chronic lymphocytic leukemia (about 15,110 cases).

Lung Cancer1
• The estimated 215,020 new cases of lung cancer expected in 2008 will account for about 15 percent of cancer
diagnoses. The incidence rate is declining significantly in men, from a high of 102 cases per 100,000 in 1984 to
73.6 in 2004. In women, the rate is approaching a plateau after a long period of increase.
• Lung cancer is the leading cause of cancer death in men and women. The estimated 161,840 deaths expected
this year will account for about 29 percent of all cancer deaths. Death rates declined significantly in men from
1991 to 2002 by about 1.9 percent per year. Since 1987, more women have died each year from lung cancer
than from breast cancer. Female lung cancer death rates are approaching a plateau after continuously increasing
for several decades, reflecting the decrease in smoking rates over the past 30 years.
Lymphoma1
• Of the estimated 74,340 new cases of lymphoma this year, 8,220 will be Hodgkin’s lymphoma and 66,120 will be
non-Hodgkin’s lymphoma (NHL).
• Since the early 1970s, incidence rates for NHL have nearly doubled. Although some of this increase is due to AIDS-
related NHL, for the most part, the rise is unexplained. Since 1991, increasing NHL incidence has been confined to
women.
• Over the past 30 years, incidence rates for Hodgkin’s lymphoma have decreased in men (0.7 percent per year)
while they slightly increased in women (0.4 percent per year).

Ovarian Cancer1
• The estimated 21,650 new cases of ovarian cancer expected this year would account for about 3 percent of all
cancers among women. It ranks second among gynecologic cancers, following cancer of the uterine corpus.
• Ovarian cancer causes more deaths than any other cancer of the female reproductive system—15,520 deaths are
expected in 2008.

Pain
• Most patients with cancer fear pain as their worst symptom. Indications are that 30 percent of those with newly
diagnosed cancer and 80 percent with previously diagnosed cancer have complaints of pain.2
• Studies have shown that 90 percent of patients with advanced cancer experience severe pain and that pain occurs
in 30 percent of all cancer patients, regardless of the stage of the disease. As many as 50 percent of patients may
be undertreated for cancer pain, yet not all cancer patients feel pain, and pain is rarely a sign of early cancer. Pain
usually increases as cancer progresses.3

98 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009
SELECTED FACTS ABOUT CANCER IN THE
UNITED STATES
Pain (continued)
• The most common cancer pain is from tumors that metastasize to the bone—as many as 60 percent to 80 percent of
cancer patients with bone metastasis experience pain. The second most common cancer pain is caused by tumors
infiltrating the nerve and hollow viscus. Tumors near neural structures may cause the most severe pain. The third
most common pain associated with cancer occurs as a result of chemotherapy, radiation, or surgery. Cancer pain
also may occur in different parts of the body. In one study, more than 80 percent of patients experienced two
distinct pains, and more than 30 percent experienced three distinct pains.3
• Fewer than half of cancer patients who experience pain receive adequate treatment for their pain. More than half of
all hospitalized patients experienced pain in the last days of their lives, and although therapies are present to
alleviate most pain for those dying of cancer, research shows that 50 percent to 75 percent of patients die in
moderate to severe pain.4
• African Americans and Hispanics are affected by racial profiling for diversion and under-treatment for pain by some
physicians. This is compounded by a lack of research on pain across racial and ethnic differences as well as
cultural attitudes toward pain care. One study found that more than 80 percent of African-American patients and
80 percent of Hispanic patients waited until their pain severity was a 10 on a 10-point scale before calling their
healthcare provider or oncology clinic for assistance with pain management.4
• Chronic pain has been said to be the most costly health problem in America. Estimated annual costs, including
direct medical expenses, lost income, lost productivity, compensation payments, and legal charges, are about
$90 billion.5

Pancreatic Cancer1
• Nearly 38,000 new cases of pancreatic cancer are expected to occur in the United States in 2008. Incidence rates
of pancreatic cancer have been stable in men since 1993 and in women since 1983.
• More than 34,000 deaths from pancreatic cancer are expected this year. The death rate has continued to decline
since 1975 in men, while it has leveled off in women after increasing from 1975-1984.
Prostate Cancer1
• Prostate cancer is the most frequently diagnosed cancer in men—more than 186,000 new cases will be diagnosed
in 2008. Incidence rates are significantly higher in African-American men than in white men. Rates peaked in white
men in 1992 (237.8 per 100,000 men) and in African-American men in 1993 (343.1 per 100,000 men).
• Prostate cancer is a leading cause of cancer death in men, and an estimated 28,660 are expected to die this
year. Although death rates have decreased more rapidly among African-American men than among white men
since the early 1990s, rates in African-American men still remain more than twice as high as those in white men.

Skin Cancer1
• The most serious form of skin cancer is melanoma, which is expected to be diagnosed in more than 62,000 people
in 2008. During the 1970s, the incidence rate for melanoma increased rapidly by about 6 percent annually. From
1981-2000, the rate of increase slowed to 3 percent per year, and since 2000, melanoma incidence has been
stable. Melanoma is primarily a disease of whites—rates are more than 10 times higher in whites than in African
Americans.
• Skin cancer will cause more than 11,000 deaths in 2008—8,420 from melanoma and 2,780 from other
nonepithelial skin cancers. The death rate for melanoma has been decreasing rapidly in whites younger than age
50, by 3 percent a year since 1991 in men and by 2.3 percent a year since 1985 in women. In those older than
age 50, rates have been stable since 1998 in men and since 1990 in women.

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 99
SELECTED FACTS ABOUT CANCER IN THE
UNITED STATES
New Cancer Cases/Deaths 1
Cancer Type Estimated 2008 New Cases Estimated 2008 Deaths
All Sites 1,437,180 565,650
Male 745,180 294,120
Female 692,000 271,530
Acute Lymphocytic Leukemia 5,430 1,460
Male 3,220 800
Female 2,210 660
Acute Myeloid Leukemia 13,290 8,820
Male 7,200 5,100
Female 6,090 3,720
Bladder Cancer 68,810 14,100
Male 51,230 9,950
Female 17,580 4,150
Bone Cancer (and joints) 2,380 1,470
Male 1,270 820
Female 1,110 650
Brain Cancer (and other nervous system) 21,810 13,070
Male 11,780 7,420
Female 10,030 5,650
Breast Cancer 184,450 40,930
Male 1,990 450
Female 182,460 40,480
Cervical Cancer/Uterine Cancer 51,170 11,340
Male — —
Female 51,170 11,340
Chronic Lymphocytic Leukemia 15,110 4,390
Male 8,750 2,600
Female 6,360 1,790
Chronic Myeloid Leukemia 4,830 450
Male 2,800 200
Female 2,030 250
Colorectal Cancer 148,810 49,960
Male 77,250 24,260
Female 71,560 25,700
Esophageal Cancer 16,470 14,280
Male 12,970 11,250
Female 3,500 3,030

100 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009


SELECTED FACTS ABOUT CANCER IN THE
UNITED STATES
New Cancer Cases/Deaths 1 (continued)
Cancer Type Estimated 2008 New Cases Estimated 2008 Deaths
Kidney Cancer (and renal pelvis) 54,390 13,010
Male 33,130 8,100
Female 21,260 4,910
Leukemia (all types) 44,270 21,710
Male 25,180 12,460
Female 19,090 9,250
Liver Cancer 21,370 18,410
Male 15,190 12,570
Female 6,180 5,840
Lung Cancer (and bronchus) 215,020 161,840
Male 114,690 90,810
Female 100,330 71,030
Lymphoma (all types) 74,340 20,510
Male 39,850 10,490
Female 34,490 10,020
Lymphoma (non-Hodgkin’s) 66,120 19,160
Male 35,450 9,790
Female 30,670 9,370
Melanoma-Skin Cancer 62,480 8,420
Male 34,950 5,400
Female 27,530 3,020
Multiple Myeloma 19,920 10,690
Male 11,190 5,640
Female 8,730 5,050
Ovarian Cancer 21,650 15,520
Male — —
Female 21,650 15,520
Pancreatic Cancer 37,680 34,290
Male 18,770 17,500
Female 18,910 16,790
Prostate Cancer 186,320 28,660
Male 186,320 28,660
Female — —
Stomach Cancer 21,500 10,880
Male 13,190 6,450
Female 8,310 4,430

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 101


SELECTED FACTS ABOUT CANCER IN THE
UNITED STATES
Sources:
1. Cancer Facts & Figures 2008, American Cancer Society (www.cancer.org)
2. Journal of the American Osteopathic Association (www.jaoa.org)
3. Oncology Channel® (www.oncologychannel.com)
4. American Pain Foundation (www. painfoundation.org)
5. Oregon Health and Science University (www.ohsu.edu)

102 M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009


T H E D R U G D I S C O V E RY, D E V E L O P M E N T AND APPROVAL PROCESS
It takes 10-15 years on average for an experimental drug to travel from the lab to U.S. patients. Only five in 5,000
compounds that enter preclinical testing make it to human testing. One of these five tested in people is approved.

Clinical Trials
Discovery/ Phase Phase Phase Phase
Preclinical Testing I II III FDA IV

Years 6.5 1.5 2 3.5 1.5

20 to 100 100 to 500 1,000 to 5,000

File NDA/BLA at FDA


Test Laboratory and healthy patient patient

File IND at FDA


Population animal studies volunteers volunteers volunteers Review Additional
process/ post-
Assess safety, Determine Evaluate Confirm effectiveness, approval marketing
Purpose biological safety effectiveness, monitor adverse testing
activity and and look for reactions from required
formulations dosage side effects long-term use by FDA

Success 5,000 5 1
Rate compounds evaluated enter trials approved

THE DRUG DEVELOPMENT AND APPROVAL PROCESS


Clinical Trials, Phase I. These tests involve about 20
T he U.S. system of new drug approvals is perhaps
the most rigorous in the world. to 100 normal, healthy volunteers. The tests study a
drug’s safety profile, including the safe dosage range.
It takes 10-15 years, on average, for an experimental
drug to travel from lab to U.S. patients, according to The studies also determine how a drug is absorbed,
the Tufts Center for the Study of Drug Development, distributed, metabolized, and excreted as well as the
based on drugs approved from 1994 through 1998. duration of its action.
Only five in 5,000 compounds that enter preclinical Clinical Trials, Phase II. In this phase, controlled
testing make it to human testing. And only one of those trials of approximately 100 to 500 volunteer patients
five is approved for sale. (people with the disease) assess a drug’s effectiveness.
On average, it costs a company $1.3 billion to get Clinical Trials, Phase III. This phase usually involves
one new medicine from the laboratory to U.S. patients, 1,000 to 5,000 patients in clinics and hospitals.
according to a 2007 study by the Tufts Center for the Physicians monitor patients closely to confirm efficacy
Study of Drug Development. and identify adverse events.
Once a new compound has been identified in the New Drug Application (NDA)/Biologic License
laboratory, medicines are developed as follows: Application (BLA). Following the completion of all
Preclinical Testing. A pharmaceutical company con- three phases of clinical trials, a company analyzes all
ducts laboratory and animal studies to show biological of the data and files an NDA or BLA with FDA if the
activity of the compound against the targeted disease, data successfully demonstrate both safety and effec-
and the compound is evaluated for safety. tiveness. The applications contain all of the scientific
information that the company has gathered.
Investigational New Drug Application (IND). After Applications typically run 100,000 pages or more.
completing preclinical testing, a company files an IND The average review time for the 24 new therapeutics
with the U.S. Food and Drug Administration (FDA) to approved by the FDA in 2008 was 17.8 months.
begin to test the drug in people. The IND becomes
effective if FDA does not disapprove it within 30 days. Approval. Once FDA approves an NDA or BLA, the
The IND shows results of previous experiments; how, new medicine becomes available for physicians to
where and by whom the new studies will be conducted; prescribe. A company must continue to submit periodic
the chemical structure of the compound; how it is reports to FDA, including any cases of adverse reactions
thought to work in the body; any toxic effects found and appropriate quality-control records. For some
in the animal studies; and how the compound is man- medicines, FDA requires additional trials (Phase IV) to
ufactured. All clinical trials must be reviewed and evaluate long-term effects.
approved by the Institutional Review Board (IRB) Discovering and developing safe and effective new
where the trials will be conducted. Progress reports medicines is a long, difficult, and expensive process.
on clinical trials must be submitted at least annually Pharmaceutical companies invested an estimated
to FDA and the IRB. $65.2 billion in research and development in 2008.

M E D I C I N E S I N D E V E L O P M E N T F O R Cancer 2009 103


Medicines in Development for Cancer is presented by PhRMA in cooperation with the following
organizations:

American Brain Tumor Association


American Nurses Association
Association of Community Cancer Centers
Burger King Cancer Caring Center
Chemotherapy Foundation
Oncology Nursing Society
PAACT (Patient Advocates for Advanced
Cancer Treatments)

Being listed in this report in no way implies that the above-mentioned organizations endorse or recommend
the use of any of the products in development contained in this publication. For further information, patients
should consult their physicians or health care providers.

New Medicines. New Hope.®

Pharmaceutical Research and Manufacturers of America


950 F Street, NW
Washington, DC 20004

www.phrma.org | www.innovation.org | www.pparx.org | www.buysafedrugs.info | www.sharingmiracles.com 4/09